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ABSTRACT 
 
Applications of nanotechnology in medicine, also known as nanomedicine, is a 
rapidly growing field as it holds great potential in the development of novel therapeutics 
toward treatment of various diseases.  Shell crosslinked knedel-like nanoparticles 
(SCKs) that are self assembled from amphiphilic block copolymers into polymeric 
micelles followed by crosslinking selectively throughout the shell domain have been 
investigated as theranostic agents for the delivery of nucleic acids and incorporation of 
imaging probes.  The main focus of this dissertation is to design and develop unique 
multifunctional bio-synthetic hybrid nanoparticles that can carry agents for 
radiolabeling, moieties for inducing stealth properties to minimize protein adsorption in 
vivo, ligands for site-specific targeting, therapeutic payloads, and are optimized for 
efficient delivery of cargoes intracellularly and to the target sites toward constructing 
novel nanoscopic objects for therapy and diagnosis.   
Alteration of polymeric building blocks of the nanoparticles provides 
opportunities for precise control over the sizes, shapes, compositions, structures and 
properties of the nanoparticles.  To ensure ideal performance of nanoparticles as 
theranostic agents, it is critical to ensure high intracellular bioavailability of the 
therapeutic payload conjugated to nanoparticles.  Special efforts were made by 
employing well-defined multi-step polymerization and polymer modification reactions 
that involved conjugation of peptide nucleic acids (PNAs) to chain terminus of 
poly(ethylene glycol) (PEG) chain grafts such that they were presented at the outermost 
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surface of SCKs.  Additionally, chemical modification reactions were performed on the 
polymer backbone to integrate positive charges onto the shell of the nanoparticles to 
afford cationic SCKs (cSCKs) for facilitating cellular entry and electrostatic interactions 
with negatively charged nucleic acids.  Covalent conjugation of F3, a tumor homing 
peptide, post-assembly of the nanoparticles enhanced cellular uptake and knockdown of 
nucleolin (a shuttling protein overexpressed at the sites of angiogenesis) and thus 
inhibiting tumor cell growth.  Furthermore, these polymer precursors of the cSCKs were 
modified with partial to full incorporation of histamines to facilitate their endosomal 
escape for efficient delivery into the cytosol.  The cSCKs were further templated onto 
high aspect ratio anionic cylinders to form hierarchically-assembled nanostructures that 
bring together individual components with unique functions, such as one carrying a 
therapeutic payload and the other with sites for radiolabeling.  These higher order 
nanoobjects enhance circulation in vivo, have capabilities to package nucleic acids 
electrostatically and contain sites for radiolabeling, providing an overall advantage over 
the individual components, which could each facilitate only one or the other of the 
combined functions.  Hierarchically-assembled nanostructures were investigated for 
their cellular uptake, transfection behavior and radiolabeling efficiency, as the next 
generation ?f ?heranostic ?gents.  
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CHAPTER I 
INTRODUCTION 
  
Nature has continued to awe and inspire scientists with its intricate designs 
integrated to form highly sophisticated systems with superior functions and complexities 
which are yet to be paralleled by their synthetic analogues.1-3  Ubiquitous examples of 
such systems surround us in our daily lives where Nature has made alteration in 
compositions, structures and properties at a molecular level to provide attributes for 
enhanced performance.  Proteins, such as histones exhibit efficient packaging and 
ordering of DNA to form structural units called nucleosomes that play a role in gene 
regulation.  Furthermore, viruses are ultimate examples of highly efficient delivery 
vehicles for nucleic acids, as they are equipped with essential functionalities for binding 
to cells and consist of sophisticated structures facilitating cellular internalization while 
protecting the viral DNA.4  Although Nature has seemingly effortless ways to create 
intricate systems with high levels of precision, duplicating such sophistication artificially 
is extremely challenging.  Detailed comprehension of existing natural system requires 
synergy between multiple disciplines such as Biology, Chemistry and Physics, to bring 
together tools for understanding phenomenon at macroscopic and even more 
importantly, at nanoscopic levels, opening avenues toward development of new 
innovative technologies.   
In 1959, an American physicist Richard Feyman, gave a talk at the American 
Physical Society titled “There’s plenty of room at the bottom” which introduced the 
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concept of nanotechnology to the world.5  It was his futuristic vision and imagination 
that currently allows us to manipulate matter at an atomic scale enabling us to create 
materials, devices and other structures sizing from 1 to 100 nm.  The applications of 
nanotechnology are countless, ranging from their use to harness energy, develop 
advanced materials and groundbreaking discoveries in designing novel therapeutics.  In 
the recent years, employment of nanotechnology in medicine, also known as 
nanomedicine, is one of the fastest growing areas in nanotechnology creating state-of-
the-art efficient diagnostic and therapeutic tools for detection and treatment of various 
diseases.6-9   
Over the past two decades nanoparticle based therapeutics have been introduced 
for the treatment of cancer, diabetes, inflammation, and neurodegenerative diseases.10,11  
Nanoparticles can be constructed from various materials (e.g. polymers, lipids, metals) 
and can host a wide range of active components such as chemotherapeutics, moieties for 
radiolabeling and ligands to impart stealth characteristics, nucleic acids, which promote 
their biomedical applications.4,7,8,12-17  In particular, polymer based nanoparticles have 
received much attention due to their immense versatility in shapes, sizes, morphologies, 
ease in making chemical modification, providing internal volume for encapsulation of 
drugs, external surface area for conjugation of biologically active agents and 
multivalency.9,14,18-21   
The most profound development nanomedicine has been underpinned by recent 
advances and collaboration between organic and polymer chemists, biologists and 
clinicians to provide functional materials along with chemical and biological techniques 
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for extensive analysis.6,7,22  Progress made in polymerization techniques, mostly 
controlled radical polymerization techniques have dramatically improved the preparation 
of well-defined polymeric materials with control over their structures, functionalities and 
three dimensional architectures, thereby expanding the prospects of the types of 
nanoscopic assemblies that can be designed, developed and applied for various 
biomedical applications.23   
Covalent interactions along with and supramolecular assembly has been 
exploited by Nature to fabricate functional macromolecular building blocks.  
Additionally, programmed assembly of block copolymers with structural and 
compositional variation by physical and chemical manipulation have enabled preparation 
of a myriad of morphologies like spheres, cylinders, toroids, vesicles and helices.24-29  
Our group has long standing interest in development of macromolecular functional 
nanoscopic objects from supramolecular assembly of amphiphilic block copolymer 
followed by chemical modification to afford well-defined core-shell nanoparticles 
known as shell crosslinked knedel-like (SCK) nanoparticles.7,21,30-32  These nanoparticles 
have evolved as theranostic agents for imaging, diagnosis and delivery of therapeutic 
cargo such as chemotherapeutic and nucleic acids, thereby demonstrating great potential 
in biomedical applications toward treatment of various diseases.14,33-37   
This dissertation is focuses on the design and development of multifunctional 
SCKs of various compositions, shapes, sizes and charges that have been tailored for their 
optimum performance for employment as nanoscopic objects for theranostic 
applications.  Well-defined SCKs for these studies were prepared from self assembly of 
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amphiphilic block copolymers that were obtained by controlled radical polymerization 
techniques (RAFT and ATRP) followed by crosslinking selectively in the hydrophilic 
segment to provide stability in aqueous solution.  Tuning the lengths and in turn the ratio 
of the hydrophilic and hydrophobic segments followed by altering the self assembly 
conditions dictated the sizes and shapes of the nanoparticles.  Furthermore, selection of 
monomeric building blocks of the polymers allowed alteration in polymer composition 
which in turn affected the properties of nanoparticles.  These nanoparticles were also 
optimized for circulation in vivo for a programmed period of time to increase their 
accumulation at the target sites.   
In addition to the having precise control over structures and compositions, these 
nanoparticles can covalently or electrostatically carry therapeutic cargoes such as nuclei 
acids allowing it to mimic natural delivery systems (e.g.; viruses).  Although nucleic 
acids exhibit great potential as therapeutics for treatment of various diseases, they face a 
series of hurdles, both extra- and intracellularly before reaching the cytosol of the 
cells38,39 owing to their inherent negative charge, rapid enzymatic degradation and 
localization in endocytic vesicles during cellular uptake compromising their therapeutic 
potential.  Employment of nanoparticles for complexation nucleic acids (PNAs and 
siRNAs) provides a great advantage as the positively charged nanocomplexes are 
partially protected against enzymatic degradation and enhances cellular uptake.  Special 
efforts have been made in this dissertation to make optimization of nanoparticles for 
efficient delivery of nucleic acids into cells for superior transfection.   
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In Chapter 2, dual peptide nucleic acid- and peptide-functionalized nanoparticles 
were developed for their potential utility in the recognition and inhibition of mRNA 
sequences for inducible nitric oxide synthase (iNOS), which are overexpressed at the 
sites of inflammation, such as in cases of acute lung injury.  Multifunctional 
nanoparticles with moieties to aid in radiolabeling, imparting stealth characteristics 
along with chemical functionalities for covalent conjugation of peptide nucleic acids and 
cell penetrating peptides were prepared and characterized.  Special attention was 
provided to ensure that the biologically active ligands were available on the surface for 
interaction with mRNA, by conjugating the peptides to the chain end terminus of PEG 
after assembly of nanoparticles.  These biosynthetic hybrid nanostructures were 
evaluated for their binding affinity to mRNAs by performing in vitro competition 
binding experiments which demonstrated that the Kd values of the PNAs were ca. an 
order of magnitude greater than the free PNAs, while the mismatched PNA showed no 
significant binding.  This study was the preliminary step, where nanoparticles with 
optical and radio-labeling sites along with reactive functional handles for conjugation of 
ligands were prepared within well-defined nanoscopic domains toward the development 
of hierarchical nanostructures that hold great promise as antisense imaging agents and 
therapeutics.  The ability to tune the particle composition allows tuning the PNA-RNA 
molecular recognition events while balancing the electrostatic binding and repulsions.  
However, the negative charge on the surface of the nanoparticles might induce repulsion 
with the cellular bilayer, hindering efficient uptake of these nanoparticles.  Hence, this 
study was further extended with cationic nanoparticles carrying positive charge on the 
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shell that facilitates cellular internalization and enhancing transfection of genetic 
materials into the cells.   
Building upon the extensive understanding of PAA based negatively charged 
nanoparticles investigated in Chapter 2 and integrating characteristics that enables 
efficient transport of nucleic acids into cells offered opportunities to broaden the 
prospect of these nanoparticles for treatment of various diseases.  Chapter 3, reports the 
facile synthesis of cationic SCKs conjugated with fluorophore and tumor-homing F3 
peptide for delivery of siRNA to brain tumor cells.  Similar to the anionic SCKs 
prepared in the earlier studies, these cationic nanoparticles were prepared from self 
assembly of amphiphilic block copolymers followed by crosslinking selectively in the 
hydrophilic region to afford cSCKs.  The alteration in charge was obtained by making 
compositional changes in the block copolymers which are the building blocks of the 
nanostructures.  Cationic units were introduced via amidation reaction onto the 
amphiphilic block copolymer that allowed the nanoparticles to carry a positive charge at 
physiological pH which assisted in electrostatic interaction of negatively charged nucleic 
acids.  Furthermore, F3 peptide that targets nucleolins overexpressed at the sites of 
angiogenesis, was covalently conjugated to the cSCKs and investigated for the cellular 
entry.  These samples show similar physicochemical characterizations before and after 
conjugation to peptide as confirmed by DLS and TEM.  In vitro studies demonstrated 
higher uptake of F3-targeted cSCKs into U87 glioma cells compared to control (cSCKs 
with scrambled peptides) samples.  Additionally, confocal experiments of cSCKs 
complexed with nucleolin-siRNA, showed higher knockdown of nucleolin in U87 
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glioma cells.  With the high levels of sophistication that are possible via simple iterations 
of controlled polymer chemistries, several functions can be incorporated for optimization 
of the biological performances for these bio-synthetic hybrid nanostructures.   
Nanoparticles complexed with nucleic acids have to overcome several intra- and 
extra cellular barriers to reach their final destination in vivo hence continuous efforts 
have been ongoing for efficient delivery of nucleic acids into the cells.  One of the ways 
of cellular uptake of nanoaparticles complexed with nucleic acids is by endocytosis, 
where the complexes are taken into cell by formation of vesicular structures known as 
endosomes formed by pinching off the bilayer.  Materials entering the cells can be 
trapped into the endosomes and hence hindering effective delivery into the cells.  The 
endosomal compartments have a unique pH environment that can be utilized to disrupt 
endosome to release the materials into the cytosol.  Chapter 4 entails modification of 
cSCKs to incorporate various amounts of histamines and primary amines (as low- and 
high-pKa functionalities) into their shells to achieve enhanced cell transfection with 
reduced toxicity, by absorbing protons at pH values between the physiological and 
endosomal pH range, resulting in disruption of endosomal membranes.  These cSCKs 
were electrostatically complexed with siRNA and investigated for their cellular uptake, 
cytotoxicity, immunogenicity and endosomal escape in RAW 264.7 mouse macrophages 
and OVCAR-3 cells.  In vitro studies demonstrated that increase in histamine content 
decreased the cytotoxicities of the nanoparticles.  Incorporation of 15% histamine into 
the SCKs seemed to be optimum in this study to maintain its binding affinity with 
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siRNA while also being able to escape from the endosome into the cytosol for effective 
delivery of siRNA.   
In the last part of this dissertation, we have extended the study of nucleic acid 
delivery from mere spherical cationic nanoparticles to hierarchically-assembled 
nanoparticles with cationic spheres template onto anionic cylinders.  With the recent 
advances in nanotechnologies and a high level of interest in creating nanodevices that 
can bring together multiple desired components for coincident therapeutics and 
diagnostics toward developing candidates for nanomedicine, these hierarchically-
assembled theranostic supramolecular structures act as a platform that allows for 
merging individual components with independent domains, such as sites for 
radiolabeling and functionalities for carrying payload to optimize them as a theranostic 
agents.  In Chapter 6, we demonstrate the preparation of hierarchically-assembled 
theranostic (HAT) nanostructures from two different components-one carrying 
therapeutic payload and the other carrying sites for radiolabels, achieved by templating 
cationic SCKs (cSCKs) that can electrostatically bind siRNA, onto anionic shell 
crosslinked rods (SCRs) that provides sites for radiolabeling.  These sophisticated 
nanostructures when investigated for their radiolabeling efficiency demonstrated 
superior radiolabeling compared to the negative-control sample.  Evaluation of siRNA 
binding efficiencies along with their cytotoxicities and cellular uptake in vitro showed 
that the siRNA binding property of cationic SCKs were translated into the hierarchical 
assemblies.  This simple procedure exhibits great potential as the next generation of 
theranostic agents by allowing a facile iterative process to bring together unique 
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individual components to form a higher order nanostructure that are optimized for their 
performance in vivo and provide an overall advantage to their individual units.   
Nanoscopic objects serve as scaffolds for a combination of imaging, diagnostics 
and therapeutics.  The ability to manipulate their sizes, shapes, morphologies and 
compositions by making alteration at a molecular level to optimize them for 
radiolabeling, increase loading capacities of drugs, impart stealth characteristics, tether 
interesting biological ligands allows the nanoobjects achieve therapeutic potential to 
treat different diseases.  Furthermore, the ability to bring together multiple independent 
components together and integrate their properties into a hierarchical structure provides 
additional advantages and novel ways to mimic three dimensional structures present in 
Nature.  The wide arrays of nanoparticles for numerous biomedical applications are 
discussed in the following chapters.   
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CHAPTER II 
DUAL PEPTIDE NUCLEIC ACID-AND PEPTIDE-FUNCTIONALIZED SHELL 
CROSSLINKED NANOPARTICLES DESIGNED TO TARGET MRNA TOWARD 
THE DIAGNOSIS AND TREATMENT OF ACUTE LUNG INJURY* 
 
2.1 Introduction 
The mortality associated with acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS) remains high in the U.S. and around the world,40 establishing 
the need for improved treatment and prevention strategies.  ALI is an inflammatory 
process in the airspaces and lung parenchyma that is characterized by fluid accumulation 
(pulmonary edema) and it can progress to an acute stage that presents necrosis of the 
lung tissue.41  One of the major indications of ALI is the overexpression of inducible 
nitric oxide synthase (iNOS), an enzyme that is found predominantly in the cells of 
epithelial origin.  The production of iNOS is caused by the activation of 
proinflammatory cytokines such as interleukin-lβ (IL-lβ) and tumor necrosis factor-α 
(TNF-α), which are signaling molecules that are released as a part of the immune 
response due to the presence of bacterial products (e.g., lipopolysaccharides (LPS)).42  
The upregulation of iNOS results in the production of nitric oxide (NO), which when  
 
 
 
____________ 
*Reprinted with permission from “Dual peptide nucleic acid- and peptide-functionalized 
shell cross-linked nanoparticles designed to target mRNA toward the diagnosis and 
treatment of acute lung injury” by Ritu Shrestha, Yuefei Shen, Kevin A. Pollack, John-
Stephen A. Taylor, Karen L. Wooley, Bioconjugate Chem. 2012, 23, 574-585.  
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present in regulated amount can act as a mediator of vital biological functions in the 
lung.43  However, the overexpression of this enzyme leads to the production of high 
concentrations of NO in an unregulated fashion, causing harm to cells and resulting in  
of NO and improves the symptoms of ALI.44,45   
Because inducible nitric oxide synthase is both a biomarker and an exacerbating 
agent for ALI, there is great interest in the development of diagnostic agents and 
inhibitors for iNOS.  Most of the work in this area has focused on imaging agents46-48 
and inhibitors for the iNOS protein49 as well as imaging agents for detecting the 
formation of the nitric oxide that iNOS catalyzes.50-52  An alternative strategy would be 
to target the mRNA encoding the iNOS protein with antisense agents that could have a 
dual function of both detecting iNOS mRNA expression level and inhibiting translation 
of the mRNA to the protein.  One ideal class of antisense agents for this purpose are 
peptide nucleic acids (PNAs), which are synthetic analogs of DNA, in which the sugar 
phosphate backbone is replaced with an uncharged pseudopeptide backbone composed 
of N-(2-amino-ethyl) glycine units to which the nucleobases are linked through 
methylene carbonyl linkers.53,54  Their attractiveness stems from their stability to 
degradation in vivo, high affinity for mRNA, and ability to block translation.55-57  
Additionally, PNAs are able to invade regions of secondary structure in the target 
mRNA, and the resulting PNA∙RNA complexes are resistant to the action of RNase H 
which would otherwise degrade the mRNA and result in a loss of signal.  While there are 
several reports on the use of PNAs to both inhibit 57 and image gene expression,58-62 
application of PNAs as regulators and imaging agents of gene expression in vivo has 
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been hampered by their poor cellular uptake and rapid clearance.53,63,64  To overcome the 
permeability problems, PNAs have been conjugated to a variety of cell penetrating 
peptides and other ligands, which have been shown to improve their uptake in cell 
culture through endocytosis though they often remain trapped in endosomes.65,66  In 
addition, simple cell penetrating PNA conjugates suffer from rapid clearance in vivo due 
to their small size.  One way to circumvent these problems is to conjoin PNAs with 
nanoparticles having optimal cell penetrating, endosomal escape, pharmacokinetic, and 
biodistribution properties.   
In our group, we have had long standing interest in developing novel polymeric 
systems and chemistries for the preparation of shell crosslinked knedel-like (SCK) 
nanoparticles 67-71 and fine tuning of existing nanostructures 20,25-28,72 for a diverse set of 
applications in biomedical research.14,21,35,73-78  SCKs are composed of block copolymers 
with hydrophilic and hydrophobic segments, making them amphiphilic and prone to self 
assembly in selective solvents.  Due to crosslinking between adjacent groups present in 
the shell, SCKs possess structural stability.  Moreover, their tunable size, shape and 
ability to perform chemical modifications within selective sub-particle regions 16,79, 
allows for the conjugation of biologically active ligands, 74,76,80,81 such as PNAs,82 to 
their surfaces, making them a versatile agent for gene delivery and 
transfection.33,36,81,83,84  In the past, we have employed PNAs conjugated to SCKs to 
direct their assembly into higher order structures via selective and tunable binding 
interactions,82 and for intracellular delivery of PNA through a bioreductively-cleavable 
linker.33  The versatility of SCKs also allows for fine tuning of the core properties, 
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resulting in shape adaptable nanoparticles 85-88 that might enhance multi-valent binding 
recognition events.  Herein, we report the design and synthesis of hierarchically-
assembled, multi-functional SCKs that are conjugated with PNAs specific for iNOS 
mRNA to promote recognition and inhibit iNOS expression.  These SCKs were also 
conjugated to the protein transduction domain of human immunodeficiency virus type 1 
TAT protein to facilitate cellular entry, and to a fluorescent probe or DOTA for labeling 
with the PET imaging radionuclide 64Cu for imaging purposes.  The PNA-SCK 
conjugates were shown to sequence-specifically bind to iNOS mRNA with high affinity 
by comparing the binding of matched and mismatched PNA-SCK conjugates.   
2.2 Materials and Methods 
Polymerizations were performed on a double manifold with glassware and 
syringes that were dried in an oven (100 °C) for at least 1 h, and with syringes that were 
washed with N2 (3 ×), prior to use.  tert-Butyl acrylate (t-BA, 99%) was received from 
Sigma-Aldrich Company (St. Louis, MO), distilled over calcium hydride, and stored 
under N2 prior to use.  Octadecyl acrylate, decyl alcohol, trifluoroacetic acid (TFA, 95%; 
Aldrich), 2,2′-(ethylenedioxy)-bis(ethylamine) (97%, Aldrich), 1-(3′-
dimethylaminopropyl)-3-ethylcarbodiimide methiodide (EDCI, 98%, Aldrich), 
hydroxybenzotriazole (HOBT, Aldrich), 2–(1H–benzotriazol–1–yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU, Aldrich), Boc-NH-PEG3kDa-NH2 
(Rapp Polymere, Tübingen, Germany), MeO-PEG2kDa-NH2 (Rapp Polymere, Tübingen, 
Germany), hydroxyl amine hydrochloride (98%, Aldrich), Sephadex G50 (Medium, GE 
Healthcare, Piscataway, NJ), N-succinimidyl-S-acetylthiopropionate (SATP) (Pierce, 
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Rockford, IL), and 4-maleimido butyric acid (Aldrich), N,N-diisopropylethylamine (DIPEA) 
(Aldrich), diethyl ether (anhydrous) (Aldrich), Alexa Fluor 633 hydrazide (Invitrogen) 
and O-(7-Azabenzo-triazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HATU) were used as received.  Fmoc-XAL PEG-PS resin was purchased from 
PerSeptive Biosystems (Ramsey, MN).  GGYGRKKRRQRRR-maleimide was 
purchased from Chengdu Kaijie Bio-pharmaceuticals Co.,Ltd (Chengdu, China).  PNA 
monomers (Fmoc-A-(Bhoc)-OH, Fmoc-C-(Bhoc)-OH, Fmoc-G-(Bhoc)-OH and Fmoc-
T-OH) were obtained from Panagene (Daejeon, Korea).  (S-1-dodecyl-S΄-(α,α´-
dimethyl-α´´-acetic acid)trithiocarbonate) (DDMAT) and Boc-protected DOTA-lysine (a 
lysine derivative of1, 4, 7, 10-tetraazocyclododecane-N, N’, N’’, N’’’-tetraacetic acid 
(DOTA)) were synthesized as reported previously 14,21,35,89.  All other reagents were 
obtained from Sigma-Aldrich and used as received.  Ellman’s reagent kit (Pierce) was 
used for Ellman’s assay, with the calibration curve constructed using cysteine 
monohydrate in aqueous buffer (100 mM PBS, 0.1 M NaCl, 10 mM EDTA, pH 7.4) at 
412 nm.  Spectra/Por membrane tubes were purchased from Spectrum Medical 
Industries, Inc., and were used for dialysis.  Nanopure water (18 MΩ•cm) was acquired 
by means of a Barnstead Nanopure ultrapure water purification system (Thermo 
Scientific, Asheville, NC).   
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1H NMR and 13C NMR spectra were recorded on an Inova 300 or Mercury 300 
spectrometer interfaced to a UNIX computer using VnmrJ software.  Samples were 
prepared as solutions in CDCl3, CD2Cl2, or DMF-d7 and solvent protons were used as 
internal standard.  IR spectra were recorded on an IR Prestige 21 system (Shimadzu 
Corp., Japan).  A small amount of sample was placed to cover the ATR crystal for IR 
measurements.  Data were analyzed using IRsolution software.  UV-vis absorption 
measurements were made using a UV-2550 system (Shimadzu Corp., Japan) using 
PMMA cuvettes.  Spectra were analyzed with UV-Probe 2.33 software.   
Gel permeation chromatography was conducted on a system equipped with a 
Waters Chromatography, Inc. (Milford, MA) model 1515 isocratic pump and a model 
2414 differential refractometer with a three-column set of Polymer Laboratories, Inc. 
(Amherst, MA) Styragel columns (PLgel 5µm Mixed C, 500 Å, and 10
4 Å, 300 x 7.5 mm 
columns) and a guard column (PLgel 5µm, 50 x 7.5 mm).  
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The system was equilibrated at 40 °C in tetrahydrofuran (THF), which served as 
the polymer solvent and eluent (flow rate set to 1.00 mL/min).  The differential 
refractometer was calibrated with Polymer Laboratories, Inc. polystyrene standards (300 
to 467,000 Da).  Polymer solutions were prepared at a concentration of ca. 3 mg/mL 
with 0.05% vol toluene as flow rate marker and an injection volume of 200 µL was used.  
Data were analyzed using Empower Pro software from Waters Chromatography Inc.   
Differential scanning calorimetry studies were performed on a Mettler Toledo 
DSC822 calibrated according to the standard procedures using Indium.  The heating 
rates were 10 °C min-1 and cooling rates were 5 °C min-1 with a temperature range of -
120–150 °C.  The crystalline melting point (Tm) and crystallization temperature (Tc) 
were determined during the second heating or cooling cycles, respectively.  
Thermogravimetric analysis was performed under Ar atmosphere using a Mettler Toledo 
model TGA/DSC1 with a heating rate of 10 °C/min.  Measurements were analyzed using 
Mettler Toledo STARe software v.10.00.   
Samples for TEM were prepared by depositing 5 μL of sample to glow 
discharged carbon coated copper grids.  Excess sample was wicked off using filter paper 
and the grids were allowed to dry in air for 1 minute.  The grids were then stained with 5 
μL of 2% uranyl acetate and excess stain was wicked off using filter paper.  Specimens 
were observed on a JEOL 1200EX transmission electron microscope operating at 100 
kV and micrographs were recorded at calibrated magnifications using an SIA-15C CCD 
camera.  The final pixel size was 0.42 nm/pixel.  The number-average particle diameters 
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(Dav) and standard deviations were generated from the analysis of particles from at least 
two different micrographs.   
Dynamic light scattering (DLS) measurements were conducted using Delsa Nano 
C from Beckman Coulter, Inc. (Fullerton, CA) equipped with a laser diode operating at 
658 nm.  Size measurements were made in water (n = 1.3329,  = 0.890 cP at 25 ± 1 °C; 
n = 1.3293,  = 0.547 cP at 50 ± 1 °C; n = 1.3255,  = 0.404 cP at 70 ± 1 °C).  Scattered 
light was detected at 165° angle and analyzed using a log correlator over 70 
accumulations for a 0.5 mL of sample in a glass sizing cell (0.9 mL capacity).  The 
photomultiplier aperture and the attenuator were automatically adjusted to obtain a 
photon counting rate of ca. 10 kcps.  The calculations of the particle size distribution and 
distribution averages were performed using CONTIN particle size distribution analysis 
routines.  Prior to analysis, the samples were filtered through a 0.45 μm Whatman Nylon 
membrane filter (Whatman, Inc.).  The samples in the glass sizing cell were equilibrated 
at the desired temperature for 5 min before measurements were made.  The peak average 
of histograms from intensity, volume or number distributions out of 70 accumulations 
was reported as the average diameter of the particles.   
PNA synthesis was carried out on an automated ABI 8909 synthesizer (Applied 
Biosystems, Carlsbad, CA) with a PNA option.  High-pressure liquid chromatography 
(HPLC) of PNAs was carried out on Beckman Coulter System Gold 126 HPLC system.  
Matrix-assisted laser desorption ionization (MALDI) mass spectra of PNA conjugates 
were measured on a PerSeptive Voyager RP MALDI-time of flight (TOF) mass 
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spectrometer using CHCA as a matrix and calibrated versus insulin (average [M + H] = 
5734.5) which was present as an internal standard.   
DNA was 5’-labeled by [γ-32P]-ATP with T4 polynucleotide kinase.  DNA, T4 
polynucleotide kinase buffer, H2O, [γ-
32P]-ATP and T4 polynucleotide kinase were 
mixed together and incubated for 1 h at 37 °C, followed by boiling for 20 min to 
inactivate the kinase.  Radiolabeled DNA bands with corrected sizes were purified from 
polyacrylamide gel and taken forward for further experiments.   
Synthesis of poly(tert-butyl acrylate) (PtBA140) (1) 
             To a 100 mL Schlenk flask equipped with a stir bar, DDMAT (284 mg, 0.779 
mmol) was added as a chain transfer agent followed by AIBN (6.40 mg, 39.0 µmol) and 
2-butanone (11.2 g, 156 mmol).  Monomer tBA (20.0 g, 156 mmol) was added and the 
Schlenk flask was then sealed with a rubber septum.  The reaction mixture was allowed 
to stir at room temperature to ensure homogeneity.  After performing four freeze-pump-
thaw cycles, the reaction mixture was allowed to equilibrate to room temperature before 
being inserted into a preheated oil bath at 60 °C.  The kinetics of polymerization were 
monitored by analyzing aliquots at predetermined times via 1H NMR spectroscopy.  
After 2 h, the desired conversion was achieved and the reaction was quenched by 
immersing the Schlenk flask into liquid N2.  A minimum amount of THF was used to 
dissolve the reaction mixture which was precipitated three times into a mixture of 
methanol and ice to afford the homopolymer of PtBA.  The polymer was dissolved in 
dichloromethane and dried over magnesium sulfate.  Finally, the solvent was removed 
under vacuum to yield (13.0 g, 68 % yield, based upon 80% conversion) of poly(tert-
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butyl acrylate) as a bright yellow powder.  (Mn)NMR = 18.3 kDa.  (Mn)GPC = 23.6 kDa.  
(Mw)GPC = 26.4 kDa.  PDI = 1.12.  IR:  2920, 2830, 1716, 1443, 1364, 1285, 1125, 813, 
745 cm-1.  1H NMR (CD2Cl2) δ:  0.85 (t, J = 7.0 Hz, CH3CH2-), 1.20-1.85 (br, -CHCH2- 
of the polymer backbone, alkyl chain initiator and HOOCC(CH3)2-), 2.20 (br, -CHCH2- 
of the polymer backbone), 3.20 (t, J = 7.0 Hz, -SCSCH2-), 4.6-4.7 (br, -CH2CHS-) ppm.  
13C NMR (CD2Cl2) δ:  12.5, 22.7, 27.9, 29.5, 36.1, 37.3, 41.9-42.4, 80.2, 173.9-174.1 
ppm.  DSC:  (Tg) = 48 °C.  TGA:  Tonset = 186 °C, Tdecomposition:  (186-228 °C) 37.5 % 
mass loss; (228-307 °C) 7.5% mass loss; (307-472 °C) 27% mass loss; 28% mass 
remaining.   
Synthesis of poly(tert-butyl acrylate)140-b-poly(octadecyl acrylate16-co-decyl 
acrylate43) (PtBA140-b-P(ODA16-co-DA43) (2) 
To a 50 mL flame–dried Schlenk flask equipped with a stir bar, ODA (1.67 g, 
5.14 mmol) was added followed by DA (2.95 g, 13.9 mmol), PtBA (3.50 g, 0.190 mmol) 
and a stock solution of AIBN (1.56 mg, 9.50 µmol) prepared in toluene.  The monomers 
and macrochain transfer agent were allowed to dissolve in toluene (3.50 g, 38.0 mmol).  
The reaction mixture was degassed by three freeze pump thaw cycles and allowed to 
warm to room temperature.  Polymerization was facilitated by immersing the Schlenk 
flask into a preheated oil bath at 70 °C.  Progress of polymerization was monitored by 1H 
NMR spectroscopy of aliquots at pre-determined times.  Upon attaining the desired 
degree of polymerization, after 1.5 h, the reaction was quenched by immersing the 
reaction flask into liquid N2.  The reaction mixture was dissolved in a minimum amount 
of THF (6.00 mL) and three consecutive precipitations were performed in methanol in 
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an ice bath.  After the final precipitation, a yellow powder (3.35 g, 70% yield, based on 
60% conversion) was obtained after removal of solvent and subsequent drying in vacuo.  
(Mn)NMR = 32.6 kDa.  (Mn)GPC = 26.8 kDa.  (Mw)GPC =29.7 kDa.  PDI = 1.10.  IR:  2920, 
2830, 1716, 1443, 1364, 1285, 1125, 813, 745 cm-1.  1H NMR (CD2Cl2) δ:  0.88 (t, J = 
6.9 Hz, -CH3CH2- of ODA, DA and chain transfer agent), 1.35-1.76 and 1.70-1.98 (br, -
CH2CH-backbone of PODA, PDA, CTA and HOOCC(CH3)2-), (2.05-2.40 (br, -CH2CH-
), 4.00 (br, -OCH2CH2-, PODA, PDA) ppm.  
13C NMR (CD2Cl2) δ:  13.8, 22.7, 25.9, 
27.7-27.8, 28.7, 29.4, 29.6, 31.9, 34.5-37.5, 41.4-41.9, 64.6, 80.2, 173.8-174.1 ppm.  
DSC:  (Tg) = 41 °C.  (Tm) = -2.2 and 9.1 °C.  (Tc) = -6.8 and 3.4 °C.  TGA:  Tonset = 209 
°C, Tdecomposition:  (209-250 °C) 11 % mass loss; (250-485 °C) 70% mass loss; 20% mass 
remaining.   
Synthesis of poly(acrylic acid)140-b-poly(octadecyl acrylate16-co-decyl acrylate43) 
(PAA140-b-P(ODA16-co-DA43)) (3) 
A round bottom flask equipped with stir bar was charged with 2 (1.00 g, 30.7 
µmol).  Dichloromethane (10 mL) was added followed by dropwise addition of TFA (10 
mL) and the reaction mixture was allowed to stir for 24 h at RT.  The solvent was 
removed under vacuum and the polymer was allowed to dissolve in a minimum amount 
of THF.  Upon extensive dialysis against nanopure water and lyophilization, a pale white 
fluffy solid of PAA140-b-P(ODA16-co-DA43) (3) (0.74 g, 98%) was obtained.  (Mn)NMR = 
24.7 kDa.  IR:  3600-2350, 1716, 1443, 1250, 1159, 830, 750 cm-1.  1H NMR (DMF-d7) 
δ:  0.86 (t, J = 6.6 Hz, -CH3CH2-  of ODA, DA and chain transfer agent), 1.15-1.4 (br, -
CH2-alkyl chain of PODA, PDA, CTA and HOOCC(CH3)2-), 1.95-2.1 (br, -CH2CH- 
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backbone of PODA, PDA and CTA), 2.05-2.20 (br, -CH2CH- backbone of PODA, PDA 
and CTA), 4.00 (br, -OCH2CH2-, PODA, PDA) ppm.  
13C NMR (DMF-d7) δ:  14.5, 
23.5, 27.0, 29.5, 30.5, 31.0, 33.0, 35.1-37.5, 41.5-43.0, 65.0, 174.1-175.1, 175.9 ppm.  
DSC:  (Tg) = 129.5 °C.  (Tm) = 6.3 °C, (Tc) = 3.1 °C.  TGA:  Tonset = 190°C, Tdecomposition: 
(190-294 °C) 18 % mass loss; (294-495 °C) 68% mass loss; 14% mass remaining.   
Synthesis of poly(acrylic acid137)-g-DOTA3-b-poly(octadecyl acrylate16-co-decyl 
acrylate43) (PAA137-g-(CONH-lysine-DOTA-Boc)3-b-P(ODA16-co-DA43)) (4) 
General procedure for amidation, involving the attachment of DOTA:  A 50 mL 
flame-dried RB flask equipped with a stir bar was charged with 3 (350 mg, 14.1 µmol) 
and DMF (5.00 g).  Stock solutions of HOBT, HBTU and CONH-lysine-DOTA-Boc 
were prepared in dry DMF.  After the polymer was allowed to dissolve completely, 
HBTU (56.1 mg, 0.148 mmol), HOBt (19.9 mg, 0.148 mmol) and DIPEA (6.19 mg, 
0.148 mmol) were added at intervals of 30 min.  DOTA-lysine (51.7 mg, 73.8 µmol) was 
added and the solution was stirred for 24 h at RT.  The reaction mixture was then 
transferred to dialysis tubing (MWCO ca.6000-8000 Da) presoaked in nanopure water.  
Extensive dialysis against nanopure water followed by lyophilization afforded a white 
powder of 3 (235 mg, 89.0%, 3 DOTA-lysine per chain, 60% coupling efficiency).  
Mn=26.7 kDa.  IR:  3400-2570, 1715, 1580, 1477, 1250, 1160, 978, 830, 750 cm
-1.  1H 
NMR (DMF-d7) δ:  0.86 (t, J = 6.6 Hz, -CH3CH2- of ODA, DA and chain transfer agent, 
CH3- tert-butyl groups of DOTA), 1.15-1.4 (br, -CH2-alkyl chain of PODA, PDA, CTA 
and HOOCC(CH3)2-), 1.95-2.1 (br, -CH2CH- backbone of PODA, PDA and CTA) 2.05-
2.20 (br, -CH2CH- backbone of PODA, PDA and CTA), 2.3-2.4 (br, DOTA), 2.95-3.10 
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(br, DOTA), 4.00 (br, -OCH2CH2-, PODA, PDA) ppm.  
13C NMR (DMF-d7) δ:  14.5, 
23.5, 27.0, 29.5, 30.5, 31.0, 33.0, 35.1-37.5, 41.5-43.0, 53.0, 56.0, 65.0, 82.0, 174.1-
175.1, 177.6 ppm.  DSC:  (Tg) = 131.8 °C.  (Tm) = 1.0 °C, (Tc) = -3.0 °C.  TGA:  Tonset = 
112 °C, Tdecomposition:  (112-190°C) 9 % mass loss; (190-247 °C) 7% mass loss; (264-278 
°C) 7% mass loss; (278-395 °C) 38% mass loss; (395-500 °C) 19% mass loss; 20% mass 
remaining.   
Synthesis of poly(acrylic acid)131-g-(PEG3 kDa-Boc)3-g-(mPEG2 kDa)3-g-(CONH-
lysine-DOTA-Boc)3-b-poly(octadecyl acrylate16-co-decyl acrylate43) (PAA131-g-
(PEG3 kDa-Boc)3-g-(mPEG2 kDa)3-g-(CONH-lysine-DOTA-Boc)3-b-P(ODA16-co-
DA43)) (5) 
A reaction mixture of 4 (97.0 mg, 3.63 µmol), HBTU (19.4 mg, 51.1 µmol), 
HOBt (12.1 mg, 51.1 µmol), DIPEA (6.58 mg, 51.1 µmol), 2 kDa mPEG-NH2 (25.8 mg, 
12.8 µmol), and 3 kDa Boc-NH-PEG-NH2 (82.3 mg, 12.8 µmol) in DMF was allowed to 
undergo reaction under the general procedure outlined for amidation above to yield an 
amorphous white solid of 5, PAA131-g-(PEG3 kDa-Boc)3-g-(mPEG2 kDa)3-g-(CONH-
lysine-DOTA-Boc)3-b-P(ODA16-co-DA43) (133 mg, 88%), having ca. 3 of each type of 
PEG per chain, 75 % coupling efficiency.  (Mn)NMR = 41.6 kDa.  IR:  3600-2580, 1715, 
1543, 1455, 1250, 1160, 1114, 966, 807, 760 cm-1.  1H NMR (DMF-d7) δ:  0.86 (t, J = 
6.6 Hz, -CH3CH2-  of ODA, DA and chain transfer agent, CH3- tert-butyl groups of 
DOTA), 1.15-1.4 (br, CH2-alkyl chain of PODA, PDA, CTA and HOOCC(CH3)2-), 
1.95-2.10 (br, -CH2CH- backbone of PODA, PDA and CTA) 2.05-2.20 (br, 3 H, -
CH2CH- backbone of PODA, PDA and CTA), 2.30-2.4 (br, DOTA), 2.95-3.10 (br, 
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DOTA), 3.20 (s, -OCH3,
 PEG), 3.50 (-CH2-,br, PEG), 4.00 (br, -OCH2CH2-, PODA, 
PDA) ppm.  13C NMR (DMF-d7) δ:  14.5, 23.5, 27.0, 29.5, 30.5, 31.0, 33.0, 35.1-37.5, 
41.5-43.0, 52.0, 56.0, 58.6, 65.0, 70.8, 82.0, 174.6, 176.8 ppm.  DSC:  (Tm) = -43.8 °C, 
(Tm) (ODA-co-DA) = 8.2 °C, (Tm) (PEO) = 33.6 °C, (Tc) = -44.3 and 3.8 °C.  TGA:  Tonset = 
150 °C, Tdecomposition:  (150-438 °C) 68% mass loss; (438-500 °C) 6% mass loss; 26% 
mass remaining.   
Synthesis of poly(acrylic acid)131-g-(PEG3 kDa-NH2)3-g-(mPEG2 kDa)3-g-(CONH-
lysine-DOTA-COOH)3-b-poly(octadecyl acrylate16-co-decyl acrylate43) (PAA131-g-
(PEG3 kDa-NH2)3-g-(mPEG2 kDa)3-g-(CONH-lysine-DOTA-COOH)3-b-P(ODA16-co-
DA43)) (6)  
In a round bottom flask was placed 5 (90.0 mg, 2.16 µmol) and TFA (6.00 mL) 
was added dropwise.  The reaction mixture was allowed to stir for 24 h at RT.  The TFA 
was then removed under a flow of N2, the polymer was dissolved in THF, the solution 
was then dialyzed against nanopure water, and the polymer was isolated by 
lyophilization to obtain 6 as a fluffy white powder (55 mg, 65%).  (Mn) NMR = 41.0 kDa.  
IR:  3600-2600, 1715, 1590, 1430, 1250, 1135, 945, 820, 760 cm-1.  1H NMR (DMF-d7) 
δ:  0.86 (t, J = 6.6 Hz, -CH3CH2-  of ODA, DA and chain transfer agent), 1.15-1.4 (br, 
CH2- alkyl chain of PODA, PDA, CTA and HOOCC(CH3)2-), 1.95-2.1 (br, -CH2CH- 
backbone of PODA, PDA and CTA), 2.05-2.20 (br, -CH2CH- backbone of PODA, PDA 
and CTA ), 2.3-2.4 (br, DOTA), 2.95-3.10 (br, DOTA), 3.20 (s, -OCH3, 
 PEG), 3.50 (-
CH2-,br, PEG), 4.00 (br, 4 H, -OCH2CH2-, PODA, PDA) ppm.  
13C NMR (DMF-d7) δ:  
14.5, 23.5, 27.0, 29.5, 30.5, 31.0, 33.0, 35.1-37.5, 41.5-43.0, 52.0, 58.0, 58.6, 65.0, 70.5, 
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174.1-175.1, 176.8 ppm.  DSC:  (Tm) = -43.5 °C, (Tm)(ODA-co-DA) = 10.8 °C, (Tm)(PEO) = 
29.8 °C, (Tc) = -35.2 and 3.9 °C.  TGA:  Tonset = 150 °C, Tdecomposition:  (150-438 °C) 68% 
mass loss; (438-500 °C) 6% mass loss; 26% mass remaining.   
Synthesis of poly(acrylic acid)131-g-(PEG3 kDa- NHCO-C2H4-SCOCH3)3-g-(mPEG2 
kDa)3-g-(CONH-lysine-DOTA-COOH)3-b-poly(octadecyl acrylate16-co-decyl 
acrylate46) (PAA131-g-(PEG3 kDa-NHCO-C2H4-SCOCH3)3–g-(mPEG2 kDa)3-(CONH-
lysine-DOTA-COOH)3-b-P(ODA16-co-DA43)) (7) 
In a round bottom flask, 6 (30 mg, 0.68 μmol) was dissolved in dry DMF (4.00 
mL), SATP (4.74 mg, 20.5 μmol), DIPEA (20 μL, 0.1 μmol) was added and the reaction 
mixture was stirred at RT.  The reaction mixture was then transferred into presoaked 
dialysis tubing (MWCO ca. 6000-8000 Da) to remove small molecule impurities.  After 
extensive dialysis and lyophilization 7 was obtained (25 mg, 82%).  (Mn) NMR = 41.7 
kDa.  IR:  3600-2600, 1715, 1590, 1415, 1250, 1120, 920, 820, 730 cm-1.  1H NMR 
(DMF-d7) δ:  0.86 (t, J = 6.6 Hz, -CH3CH2 of ODA, DA and chain transfer agent), 1.15-
1.40 (br, CH2- alkyl chain of PODA, PDA, CTA and HOOCC(CH3)2), 1.95-2.10 (br, -
CH2CH- backbone of PODA, PDA and CTA), 2.05-2.20 (br, -CH2CH- backbone of 
PODA, PDA and CTA ), 2.30-2.40 (br, DOTA), 2.71-2.75 (br, -CH2S-), 2.95-3.10 (br, 
DOTA), 3.50 (-OCH2-CH2O-,br, PEG) 4.00 ( br, -OCH2CH2-, PODA, PDA) ppm.  
13C 
NMR (DMF-d7) δ:  14.5, 23.5, 27.0, 29.5, 30.5-31.5, 33.0, 35.1-37.5, 41.5-43.0, 55.8, 
57.5, 65.0, 70.5, 174.1-175.1, 176.5 ppm.  DSC:  (Tm) = -44.3 °C, (Tm)(ODA-co-DA) = 11.3 
°C, (Tm)(PEO) = 27.8 °C, (Tc) = -36.4 and 6.1 °C.  TGA:  Tonset = 170 °C, Tdecomposition: 
(170-283 °C) 4% mass loss; (283-460 °C) 87.3% mass loss; 8.7% mass remaining.   
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Procedure for the preparation of micelles (8) 
To 7 in DMF (8.0 mg, 1.0 mgmL-1) was added an equal volume of nanopure 
water dropwise via a syringe pump over the course of 3 h.  The mixture was allowed to 
stir for 16 h at RT and was then transferred to presoaked dialysis tubing (MWCO ca. 
6000-8000 Da) and dialyzed against nanopure water for ca. 4 d to remove the organic 
solvent and give a final polymer concentration of 0.32 mgmL-1.  (Dh)n (DLS) = 43 ± 8 
nm; (Dh)vol (DLS) = 63 ± 6 nm; (Dh)int (DLS) = 124 ± 20 nm; Dav (TEM) = 36 ± 4 nm.   
Procedure for the preparation of SCKs (9) 
To a solution of micelles (8) (15 mL, 0.32 mgmL-1) was added 2, 2`-
(ethylenedioxy)bis(ethylamine) (0.63 mg, 4.3 μmol, to achieve nominally crosslinking 
through 20% of the COOH groups) from a stock solution via a syringe pump over 30 
min.  The reaction mixture was allowed to stir at RT for 30 min and EDCI (1.17 mg, 
3.93 μmol) was added as a solution in water via syringe pump over 15 min.  The reaction 
mixture was allowed to stir at RT for 24 h and was then transferred to presoaked dialysis 
tubing (MWCO ca. 6000-8000 Da) and dialyzed for ca. 4 d to afford the SCK solution 
with a final concentration of 0.29 mgmL-1.  (Dh)n (DLS) = 48 ± 7 nm; (Dh)vol (DLS) = 79 
± 10 nm; (Dh)int (DLS) = 123 ± 9 nm; Dav (TEM) = 41 ± 4 nm.   
Conjugation of Alexa Fluor 633 hydrazide to SCKs (10)  
To a SCK solution (8.0 mL, 0.29 mgmL-1) at 0 °C was added a stock aqueous 
solution of EDCI (2.41 mg, 8.10 μmol) over a period of 3 min, and the mixture was 
allowed to stir for 20 min.  Sulfo-NHS (1.78 mg, 8.10 μmol) was added from a stock 
solution prepared in nanopure water and the reaction was stirred for 2 h.  The pH of the 
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solution was adjusted to 7.2 using PBS buffer (pH 8.86, 0.2 M) and Alexa Fluor 633 
hydrazide (72.0 μg, 0.064 μmol) was added to the reaction mixture from a stock solution 
in DMSO.  The reaction mixture was allowed to stir for 24 h in the dark and was then 
transferred to presoaked dialysis tubing (MWCO ca. 6000-8000 Da) and dialyzed 
against NP water for 5 d in an Al-foil-wrapped beaker.  The concentration of dye was 
found to be 12.0 μM from UV-vis spectroscopy.  (Dh)n (DLS) = 60 ± 16 nm; (Dh)vol 
(DLS) = 79 ± 30 nm; (Dh)int (DLS) = 125 ± 53 nm; Dav (TEM) = 40 ± 4 nm.   
Deprotection of masked thiols of Alexa Fluor 633 hydrazide labeled SCKs (11) 
Hydroxyl amine hydrochloride (75.0 μL, 0.5 M) in aqueous buffer (100 mM, 150 
mM NaCl) was added to a stirred solution of SCK 10 (5.0 mL) suspended in buffer (100 
mM, 150 mM NaCl) and the reaction mixture was allowed to stir for 3 h at RT.  The 
solution was assayed by Ellman’s assay and the thiol content was determined to be 33 ± 
4 μM.  The solution was immediately used for conjugation with maleimide-
functionalized PNAs and CPPs.   
Synthesis of maleimide-PNA conjugates (12)   
PNAs were synthesized continuously on universal support XAL-PEG-PS resin at 
a 2 µmol scale with standard solid phase Fmoc chemistry on an Expedite 8909 
Synthesizer.  After completion of automated synthesis, PNAs were cleaved from the 
solid support and the bases were deprotected using trifluoroacetic acid: m-cresol (4:1, 
v/v) for 3 h and then precipitated with diethyl ether.  The crude products were purified 
by HPLC and characterized by MALDI-TOF.  PNAs were then dissolved in NMP: 
dimethylsulfoxide (DMSO) (7:3, v/v) with 15 min vigorous stirring. Maleimide 
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dissolved in NMP was added to the PNA solution followed by addition of DIEA (16 µL) 
and the reaction mixture was maintained at room temperature for 2.5 h with gentle 
shaking.  Excess cold diethyl ether (anhydrous) was added to precipitate the PNA-
maleimide conjugates.  The PNA-maleimide conjugates were dried under nitrogen and 
characterized by MALDI-TOF mass spectrometry.   
General procedure for conjugation of SCKs with iNOS PNAs with and without 
TAT (13) 
To a SCK solution (750 μL, 0.29 mgmL-1) suspended in buffer (100 mM PBS, 
150 mM NaCl, pH 7.2), citric acid buffer (pH 5.12) was used to adjust the pH to 6.5.  A 
concentrated solution of iNOS PNA (Maleimide-TTTCCTTTTCCTCTTTCA or 
Maleimide-TGTCCTCCTTTTCTTTCA) (5.0 nmoles in DMF) in (100 mM PBS, 150 
mM NaCl, pH 7.4) was added to the SCK solution to prepare SCKs with mismatch or 
match PNAs.  Additionally, TAT (Maleimide-GGYGRKKRRQRRR) (6.7 nmoles from 
a stock solution in DMF) was added to the reaction mixture of SCKs with either match 
or mismatch PNA sequences to prepare PNA-SCK-TAT conjugates.  The reaction 
mixture was stirred at room temperature for 6 h and remaining thiols were capped by 
addition of 4-maleimido-butyric acid (1 mg suspended in 100 mM PBS, 150 mM NaCl, 
pH 7.4).  The reaction was stirred for 16 h before being purified by Sephadex®G-50 gel 
column.  Dav (TEM) = 28 ± 5 nm. 
Preparation of biotinylated iNOS mRNA (14) 
Image CloneID 4978648 containing the iNOS mRNA sequence (Gene Bank 
BC062378, ATCC cloning NO. 10470196) was obtained from ATCC.  The plasmid 
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DNA was purified and linearized at the unique XbaI site before transcription.  
Transcription reactions were carried out using the Promega RiboMAX Large Scale RNA 
production system utilizing the SP6 promoter (Promega).  Transcription proceeded with 
SP6 RNA polymerase, NTPs and Bio-UTP (Roche) for 4 h at 37 °C, and followed by 
DNase I treatment, phenol:chloroform: isoamylalcohol (25:24:1) extraction and ethanol 
precipitation.  The final purified iNOS RNA was quite homogeneous and corresponded 
in size to the expected 4 Kb transcript.  
Binding affinity of ODNs to iNOS mRNA by a Dynabead-based binding assay  
The radiolabeled ODN (100 pM) was incubated with biotinylated mRNA (0.01, 
0.1, 1, 10, 100 nM) and 1 µL of RNase inhibitor for 4h at 37°C in a total volume of 100 
μL.  Streptavidin coated Dynabeads were added and mixed for 30 min.  The beads were 
then separated by a magnet, washed twice and resuspended in 100 μL of hybridization 
buffer (5m M Tris-HCl, pH 7.0, 1 mM EDTA, 0.1 M NaCl). Solutions were then 
counted by liquid scintillation to give bound fractions directly.   
The dissociation constants were determined by non-linear fitting of the fraction bound 
versus RNA concentration data to the analytical expression shown below for a two state 
binding equilibrium using the Kaleidagraph program.   
   (1) 
where FB is the experimentally determined fraction of bound ODN, NSB is the fraction 
of ODN that is nonspecifically bound, SB is the fraction of ODN that can be specifically 
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bound and was set equal to (1-NSB), [L] is total ODN concentration, Kd is dissociation 
constant of the ODN and [RNA] is total RNA concentration.   
Binding affinity of iNOS PNA-SCK-TAT for iNOS mRNA by a competition assay  
Biotinylated mRNA (10 pM) was incubated with 1000 pM radiolabeled ODN 
and 1 µL of RNase inhibitor for 4 h at 37 °C, to which unlabeled competitor PNAs (0, 
0.001, 0.01, 0.1, 1, 10 nM) or iNOS PNA-SCK-TAT (0, 0.01, 0.1, 1, 10, 100 and 1000 
nM, concentration calculated based on PNA concentration) were added.  The 
streptavidin coated Dynabeads were added and mixed for another 30 min at 37 °C.  
Following incubation, the reaction mixture was separated by a magnetic field, washed 
twice and resuspended in hybridization buffer (5 mM Tris-HCl, pH 7.0, 1 mM EDTA, 
0.1 M NaCl).  The solution containing bound ODNs was counted by liquid scintillation.  
Additionally, SCK-TAT alone served as a control group.   
The fraction of antisense ODN bound to the RNA (B) was then plotted against 
the competitor PNA concentration ([PNA]), and an IC50 value is determined (the 
concentration of competitor PNA that reduces binding of the ODN by 50%) by fitting 
the data according to a standard equation.  Once the IC50 values are obtained, the Kds for 
the PNAs can be determined using a simple relationship involving the IC50 and the Kd 
for the antisense ODN.   
 
     (2) 
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       (3) 
2.3 Result? and Discussion 
Design of the PNA nanoparticles 
The PNA nanoparticles were designed to meet a number of criteria for future 
applications as imaging and knock down agents for iNOS expression.  The first was that 
the nanoparticle be able to enter cells efficiently so as to be able to engage the iNOS 
mRNA in the cytoplasm.  The second was that the attached PNAs would be able to 
freely interact with the mRNA.  The third was that the nanoparticle would be capable of 
being detected by both fluorescent and PET imaging modalities.  The fourth was that the 
nanoparticles avoid detection by the mononuclear phagocytic system (MPS), also 
referred to as the reticuloendothelial system (RES), which would otherwise result in their 
rapid clearance from the blood.  To meet these criteria, a PEGylated shell crosslinked 
nanoparticle was chosen in which the PNAs and the TAT peptide would be attached to 
the ends of the PEG chains, while the imaging agents would be conjugated to the 
polyacrylate shell.  PEGylation has been previously shown to impart stealth character to 
SCKs and prolong their retention in the blood 14,21, presumably by shielding the 
polyacrylate core from components of the MPS.  The TAT peptide was chosen to 
facilitate endocytosis of the SCKs 90,91, and to enable TAT to interact with the cell 
surface, it was attached to the ends of the PEG chains, using a thiol coupling strategy 16.  
Likewise, the PNAs were designed to also be attached to the ends of the PEG chains to 
enable them to interact with the mRNA in the cytoplasm.  The imaging agents were 
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designed to be attached to the polyacrylate shell to minimize their exposure to the MPS.  
The polyacrylate shell was also expected to serve additional functions to serve as a 
robust network for maintaining the nanoparticle structure and to, potentially, facilitate 
rupture of the endosome upon lowering of the pH during endosomal acidification 92.   
Synthesis of the SCK nanoparticles 
 
 
 
 
Figure 2.1.  Schematic representation of synthesis of amphiphilic functional block graft copolymer, 7. 
 
 
 
The block copolymer precursor used in this study was prepared by a two-step 
reversible addition-fragmentation chain transfer (RAFT) polymerization process, 
followed by deprotection (Fig. 2.1), as described in previous work by our group 85.  S-1-
dodecyl-S’-(α, α’-dimethyl-α’’-acetic acid) trithiocarbonate (DDMAT) was used as a 
chain transfer agent to synthesize an initial PtBA140 1 homopolymer, which served as a 
macrochain transfer agent.  This macrochain transfer agent was then employed during 
the copolymerization of octadecyl acrylate and decyl acrylate to afford PtBA140-b-
P(ODA16-co-DA43), 2, having a narrow molecular weight distribution (PDI < 1.10) (Fig 
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2.2).  The tert-butyl protecting groups were removed via acidolysis with TFA in CH2Cl2 
to yield the amphiphilic block copolymer of PAA140-b-P(ODA16-co-DA43), 3.  The 
PAA140-b-P(ODA16-co-DA43) polymer was further functionalized with chelators and 
PEO grafts to provide for terminal coupling sites for attachment of the biologically-
active ligands (PNA and TAT) and to allow for direct, future translation to in vivo 
studies.  The block copolymer was first functionalized with Boc-protected DOTA-lysine 
via amidation of acrylic acid repeat units of the polymer to afford 4 with ca. 3 DOTA-
lysines per polymer backbone.  DOTA serves as a chelator for 64Cu which will allow the 
resulting nanoparticles to be used for PET imaging in vivo.14,21,35,93  Furthermore, 
different lengths of PEO grafts (2 kDa and 3 kDa) were appended to the polymer 
backbone to obtain 5, using similar amidation chemistry to yield ca. 3 of each type of 
PEO per polymer chain.  The 2 kDa PEO grafts provide stealth properties for the 
nanoparticles, while the 3 kDa PEO chains, after chain terminus deprotection and 
modification, additionally, provide reactive sites.  The Boc-protecting groups from 
DOTA and 3 kDa PEOs were removed using TFA in a global deprotection step 
revealing amines at their termini.  In the last step, methyl ester protected sulfohydryl 
groups were introduced at the NH2- termini of the 3 kDa PEOs by reaction with SATP to 
yield functional block graft copolymers, 7 (Table 2.1).  After each chemical 
transformation of the amphiphilic block copolymers, purification was performed via 
extensive dialysis against nanopure water and the polymers were isolated by 
lyophilization.   
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Figure 2.2.  GPC traces for PtBA 1 and PtBA-b-P(ODA-co-DA) 2. 
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Table 2.1. Summary of polymers prepared. 
 Polymer DOTA PEG SCOCH3 
Mn [Da] 
1H NMR 
Mn [Da] 
GPC 
Mw [Da] 
GPC 
PDI 
GPC 
1 PtBA140 - - - 18,300 12,000 13,200 1.1 
2 PtBA140-b-P(ODA16-co-DA43) - - - 32,600 20,800 25,500 1.2 
3 PAA140-b-P(ODA16-co-DA43) - - - 24,700 - - - 
4 PAA137-g-(CONH-lysine-DOTA-Boc)3-b-P(ODA16-co-
DA43) 
3 - - 26,700 - - - 
5 PAA131-g-(PEG3 kDa-Boc)3-g-(mPEG2 kDa)3-g-(CONH-lysine-
DOTA-Boc)3-b-P(ODA16-co-DA43) 
3 3 - 41,600 - - - 
6 PAA131-g-(PEG3 kDa-NH2)3-g-(mPEG2 kDa)3-g-(CONH-lysine-
DOTA-COOH)3-b-P(ODA16-co-DA43) 
3 3 - 41,000 - - - 
7 PAA131-g-(PEG3 kDa-NHCO-C2H4-SCOCH3)3–g-(mPEG2 
kDa)3-(CONH-lysine-DOTA-COOH)3-b-P(ODA16-co-DA43) 
3 3 3 41,700 - - - 
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Preparation of functionalized and labeled nanoparticles 
 
Figure 2.3  Schematic representation of self assembly of the multi-functional block graft copolymer 7 into 
micelle 8, crosslinking into SCK 9, conjugation of Alexa Fluor 633 hydrazide 10, and functionalization 
with PNAs and TAT to give the final bio-synthetic hybrid nanostructure 13.   
 
 
 
SCKs were prepared by the solution-state assembly of the amphiphilic block 
graft copolymers in water followed by crosslinking reactions selectively throughout the 
hydrophilic shell layer (Fig. 2.3).  After dissolving 7 in DMF at a concentration of 1 
mg∙mL-1, self assembly was induced by gradual addition of an equal amount of water 
over a period of 3 h.  The aqueous micelle solution was allowed to stir overnight and 
was then transferred to dialysis tubing (MWCO 6-8 kDa) and dialyzed against nanopure 
water for 4 d to remove organic solvent.  The SCKs were obtained by crosslinking 
approximately 20% of the acrylic acid segments by amidation with the amine groups of 
the crosslinker (2, 2’-ethylenedioxy)bis(ethylamine), in the presence of EDCI, followed 
by extensive dialysis to remove unreacted small molecule starting materials and reaction 
by products.   
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Alexa Fluor 633 hydrazide was attached to the SCKs, to serve as a fluorescent 
probe, by performing post-assembly conjugation of the hydrazide group of the dye to 
EDCI-activated acrylic acids in the shell of the SCKs at 0 °C.  The reaction was carried 
out for 24 h in the dark and the fluorescently-labeled SCKs were purified by extensive 
dialysis for 5 d against nanopure water to remove unconjugated dye molecules.  
Bioconjugation of TAT and PNAs to the SCK nanoparticles 
By introducing a masked thiol on to the end of the 3 kDa PEO terminus, a 
surface functional nanoparticle was designed and prepared that could undergo 
conjugation with biomacromolecules, e.g., proteins,16 peptides and nucleic acid 
sequences, through efficient reactions, such as thiol-maleimide, thiol-haloacetyl or 
disulfide couplings.  The acetyl protecting groups of the masked thiols were removed by 
reaction with the addition of a 0.1 M hydroxylamine solution for 4 h (Fig. 2.3).   
  
 37 
 
The thiol content of the nanoparticles was then evaluated using Ellman’s assay 
and was determined to be 33 ± 4 μM.  Ellman’s assay of SCKs before reacting with 
hydroxylamine showed undetectable concentration of –SH.  The resulting reactive –SH 
sites were expected to be presented on the surface of the SCK nanostructures, allowing 
for surface availability of biologically-active ligands, and were therefore, utilized for 
conjugation of the PNAs as mRNA recognition elements and TAT CPPs for cell entry.  
These SCKs were subjected to reaction, coincidentally, with PNAs and TAT that were 
functionalized with maleimide, at pH 6.5 for 6 h at 0 °C.  Two anti-iNOS PNAs, 
PNA240 and PNA480, and mismatch controls were selected for conjugation to the SCKs 
(Table 2.2), from a set of PNAs previously shown to have similar affinity for iNOS 
mRNA, but differing abilities to inhibit iNOS expression 94.  In each case, the unreacted 
thiols were capped using 4-maleimido butyric acid.  The nanoparticle conjugates were 
purified with Sephadex G-50 columns and the amounts of PNAs incorporated into the 
SCK samples were calculated by UV-vis spectroscopy (Figures 2.4 A and B) using the 
inherent wavelength of 260 nm for PNAs.   
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Figure 2.4.  (A) UV-vis spectra of iNOS PNA-SCK conjugates, (B).UV-vis spectroscopy of iNOS PNA-
SCK-TAT conjugates. 
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Table 2.2. ODN and PNA sequences used.   
 
Sequence ID Sequence (5’-3’ or amino-carboxy) 
240 5'- TGT CCT TTT CCT CTT TCA -3' 
240 (mm) 5’- TGT CCT CCT TTT CTT TCA -3’ 
480 5'- TGA AAT CCG ATG TGG CCT-3' 
480(mm) 5’-TAG AAT CCA GTG GTG CCT- 3’ 
 
Characterization of nanoparticles 
The size and shape of the SCKs were determined using DLS and TEM.  DLS 
analysis showed that the hydrodynamic diameters of the SCKs were slightly larger than 
were the diameter values determined by TEM, due to the hydration of the hydrophilic 
shell in aqueous conditions.  The micelles and SCKs were 48 ± 7 nm by DLS and 41 ± 4 
nm by TEM (Fig. 2.5).  The average core diameter of the nanoparticles after conjugation 
with PNAs and TAT were determined using TEM and were found to be ca. 28 ± 5 nm 
(S1).   
 
 
 
 
 
Figure 2.5. TEM image of SCKs 9. 
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Binding affinity of the PNA and PNA-SCK conjugates for iNOS mRNA 
The binding affinities of the PNA and PNA-SCK conjugates were determined by 
a competition assay against radiolabeled ODNs targeting the same site on the mRNA.  
To carry out this assay, we first determined the binding affinity of the ODNs targeting 
the same site as the PNA using a Dynabead assay that we had previously developed for 
this purpose.95  The target mRNA was produced by transcription from an iNOS cDNA 
clone in vitro with Bio-dUTP to incorporate biotin groups into the RNA to enable it to 
be retrieved with streptavidin coated magnetic beads.  The 5’-radiolabeled antisense 
ODNs were then incubated with the iNOS RNA and allowed to equilibrate for 4 h, after 
which the Dynabeads were added to bind to the mRNA, which could then be 
immobilized with a magnetic field.  The solution containing the free ODNs was removed 
from the reaction tube and both the free and bound fractions were quantified by liquid 
scintillation counting.  The ratio of bound to free ODN vs concentration was then fit to a 
standard equation (Equation 1), from which the dissociation constant (Kd) could be 
determined.  As can be seen in Table 2.3, ODNs designed on the basis of binding sites 
identified by the RT-ROL mapping assay (iNOS240, iNOS480) 94 showed very high 
affinity with dissociation constants (Kd’s) of 7.3 ± 1.2 and 5.2 ± 2.5 nM (Table 2.3).   
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Table 2.3. Binding affinities of ODNs, PNAs, PNA-SCK and iNOS PNA-SCK-TAT 
conjugates.   
 
Sequence 
ID 
ODN (nM) PNA (nM) 
PNA-SCK 
(nM) 
PNA-SCK-TAT 
(nM) 
240 7.3 ± 1.2 0.10 ± 0.052 3.2 ± 2.0 1.4 ± 0.5 
240mm - >10000 >1000 >1000 
480 5.2 ± 2.5 0.086 ± 0.026 1.1 ± 0.3 1.7 ± 1.0 
480mm 
 
- 
>10000 >1000 >1000 
No PNA - - >1000 >1000 
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Figure 2.6.  Dynabead competition assay to determine iNOS mRNA binding affinity of SCK-PNA 
conjugates.  A) Biotinylated iNOS mRNA (10 pM) bound to streptavidin coated Dynabeads were 
incubated with 1 nM 5’-radiolabeled 240 or 480 antisense ODN and increasing concentrations of the 
corresponding SCK-PNA conjugate.  After incubation for 4 h, the bound versus free fractions were 
separated by a magnet and the radioactivity in each fraction was quantified by liquid scintillation counting.  
B) Plots of the average fraction of mRNA bound by radioactively labeled ODN vs. the SCK-PNA 
conjugates from three experiments fit to the analytical expression 2) described in the experimental section 
from which the IC50 was extracted.  The data in Table 3 was obtained from averaging fits to each 
independent experiment (See supporting information).   
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Once the binding affinity of the ODNs was established, the binding affinity of 
PNAs and PNA-SCK conjugates to iNOS mRNA could be determined by a competition 
assay in which the concentration of ODN was held constant and the concentration of the 
PNA or PNA-SCK was varied (Fig. 2.6-2.11).  The Kd could then be calculated from the 
IC50.  As can be seen in Table 2.3, the two PNAs, PNA-240 and PNA-480 showed 
similar Kd’s of 101 ± 52 and 86 ± 26 pM, while the mismatched PNAs had Kd’s of > 10 
nM.  When conjugated to the SCKs, the binding affinity of the PNAs appeared to 
decrease about 30 to 10-fold, respectively, to 3.2 ± 2.0 and 1.1 ±0.3 nM, while the 
mismatched PNAs showed no significant affinity.  The decrease in affinity of the PNAs 
upon conjugation could be due to a number of factors, such as electrostatic repulsion 
between the SCK and the RNA, or steric interference by a bound RNA molecule.  The 
binding affinity of the iNOS PNA-SCK-TAT conjugates, which could have been 
expected to be higher due to the positive charge of the TAT peptide, was not 
significantly different from the conjugates lacking the TAT peptide.   
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2.4 Conclusions 
SCKs covalently conjugated with iNOS PNAs and CPPs have been prepared and 
their binding affinities with complementary mRNAs post-conjugation were evaluated.  
Specific effort was made to have these biologically-active units presented from the outer 
most surface of the SCKs, by employing well-defined multi-step polymerization and 
polymer modification reactions that involved combinations of stealthy PEG chain grafts.  
The binding affinity measurements demonstrated that the PNAs retain molecular 
recognition selectivity even after undergoing coupling onto the nanoscopic SCK objects.  
The shapes and sizes of SCKs remained almost the same in the resulting nanoconjugates.  
By partitioning various optical and radiolabeling sites and reactive functionalities for 
conjugation of biological ligands within a size-, shape- and flexibility-controlled 
nanoscopic framework, these bio-synthetic hybrid materials provide preliminary steps 
towards the development of hierarchical nanostructures that hold great promise as 
antisense imaging agents and therapeutics.  The availability of particles with tunable 
compositions and properties will allow us to fine-tune the PNA-RNA molecular 
recognition events, while balancing the electrostatic binding and repulsion.36,83  With the 
high levels of sophistication that are possible via simple iterations of controlled polymer 
chemistries, there are several functions whose biological performances are yet to be 
evaluated.  Extended in vitro and in vivo studies are underway. 
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Figure 2.7. TEM images of iNOS PNA-SCK conjugates with and without TAT.   
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Figure 2.8.  Determination of ODN 240 and 480 binding affinity for iNOS mRNA.  Fits of fraction ODN 
bound to the iNOS mRNA from a Dynabead binding assay to equation 1) as described in the experimental 
section.  The concentration of ODN was 100 pM. 
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Figure 2.9.  Determination of PNA 240 and 480 binding affinity for iNOS mRNA through a Dynabead 
competition assay as described in the experimental section.  The fraction of mRNA (10 pM) bound to 5’-
radiolabeled ODN (1 nM) as a function of PNA concentration (nM) was fit to equation 2) to determine the 
IC50.  The Kd for PNA binding was then determined from the Kd for the ODN and the IC50 for the PNA 
according to equation 3).   
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Figure 2.10.  Determination of SCK-PNA 240 and 480 binding affinity for iNOS mRNA through a 
Dynabead competition assay as described in the experimental section.  The fraction of mRNA (10 pM) 
bound to 5’-radiolabeled ODN (1 nM) as a function of SCK-PNA concentration (nM) was fit to equation 
2) to determine the IC50.  The Kd for SCK-PNA binding was then determined from the Kd for the ODN and 
the IC50 for the SCK-PNA according to equation 3).   
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Figure 2.11.  Determination of TAT-SCK-PNA 240 and 480 binding affinity for iNOS mRNA through a 
Dynabead competition assay as described in the experimental section.  The fraction of mRNA (10 pM) 
bound to 5’-radiolabeled ODN (1 nM) as a function of TAT-SCK-PNA concentration (nM) was fit to 
equation 2) to determine the IC50.  The Kd for TAT-SCK-PNA binding was then determined from the Kd 
for the ODN and the IC50 for the TAT-SCK-PNA according to equation 3).   
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CHAPTER III 
ENHANCED CELLULAR UPTAKE OF F3 PEPTIDE- AND FLUOROPHORE-
TETHERED CATIONIC SHELL CROSSLINKED NANOPARTICLES FOR 
TARGETING NUCLEOLIN AND SELECTIVE DELIVERY OF SMALL 
INTERFERING RNA TOWARD THE TREATMENT OF PEDIATRIC BRAIN 
TUMORS 
 
3.1 Introduction 
The fatalities associated with adult and pediatric brain tumors remain high in the 
United States, establishing a need for an improved and effective alternative treatment 
strategy.55  Brain tumor occurs due to the unlimited proliferation of cells.96  
Approximately 66,290 new cases of brain and central nervous system tumors are 
expected to be diagnosed in 2012, among which 4,200 are projected to be pediatric 
incidences.55  Despite modern advances in chemo- and radiotherapy, methods of 
treatment, in general, are non-selective and have many adverse effects.97  Therefore, 
there is a need for alternative strategies for more effective and targeted therapy toward 
the treatment of brain tumors.   
In recent years, RNA interference (RNAi) has received much attention due to its 
potential in the treatment of various diseases.38  RNAi is a gene silencing mechanism 
where small interfering RNA (siRNA) downregulates the expression of a specific gene 
providing this technology with a high level of selectivity and efficiency, and hence, 
offering it a great advantage over other forms of therapeutics.98  However, employing 
siRNAs for clinical applications imposes a limitation, owing to their large size and 
inherent negative charge resulting in low cellular uptake.38,99,100  Additionally, the rapid 
enzymatic degradation of siRNA by extra- and intracellular nucleases compromises its 
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therapeutic potential.  One way to circumvent this challenge is to complex the 
negatively-charged siRNA with positively-charged lipids/polymers, where the 
electrostatic interactions between siRNA and cationic lipids/polymers result in the 
formation of positively-charged nanocomplexes, which partially protects the siRNA 
against degradation and enhances cellular uptake.   
Recent advances made with synthetic chemistry provide opportunities for the 
construction of well-defined, sophisticated materials having precise control over charges, 
sizes and three dimensional structures, resembling nanoscopic objects as formed in 
Nature22 and extending significantly the types of materials that are available for nucleic 
acid packaging, protection and delivery strategies, among other nanomedicine 
applications.  The design and development of nanomaterials have extended beyond mere 
fundamental investigations, to potentially translatable, medically-relevant 
nanotechnologies for the detection, diagnosis and treatment of cancer and other 
diseases.20,31,101  Several platforms, such as liposomes,102 magnetic nanoparticles,103 and 
quantum dots104,105 have been explored, however, our group has a long standing interest 
in developing novel polymeric systems and chemistries for the preparation of shell 
crosslinked knedel-like (SCK) nanoparticles,30,106 and fine tuning of existing 
nanostructures for a diverse set of applications in biomedical research.7,9,14,93,107,108  
SCKs are core-shell morphology nanoparticles composed of block copolymers that 
consist of a hydrophilic and a hydrophobic segment, making them amphiphilic and prone 
to self assembly in selective solvents.  Furthermore, selective crosslinking throughout 
the adjacent chains in the hydrophilic shell layer allows SCKs to possess structural and 
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kinetic stabilities.  These nanomaterials have emerged as a powerful tool for providing 
novel non-viral vectors for effective delivery of therapeutics.33,109   
Extending the application of nanotechnology for the delivery of siRNA 
therapeutics, specifically, includes several challenges that the SCK nanoparticle platform 
has the potential to address, including effective packaging of the nucleic acids, 
protection against enzymatic degradation and allowing the targeted delivery of siRNA to 
the tumor site as well as intracellularly into the cytoplasm of cancer cells toward the 
treatment of brain tumors.  Here, we take advantage of our ability to exploit the 
properties of nanoparticles by performing manipulations at early stages of their design, 
to incorporate positive charges along the hydrophilic segment of the block copolymer 
precursor to yield cationic SCKs (cSCKs).  cSCKs have been engineered33,110,111 with 
positive charges in the shell domain of the nanoconstructs to impart cationic character 
and enhance cellular uptake, while allowing also for electrostatic attractive interactions 
for binding siRNA to conduct RNAi.  Moreover, efficient and effective RNAi can occur 
by directing the siRNA not to the entire cell population but to selected target cells.  This 
process requires engineering a platform that provides dual advantage such that it carries 
positive charges on the surface and additionally, is tethered with ligands allowing it to 
identify specific cell types.   
With our current interest in developing multifunctional nanoparticles capable of 
delivery of diagnostic and therapeutic agents to tumors, we have focused on the highly 
promising F3 peptide ligand, which can bind to overexpressed nucleolin as an 
angiogenesis marker, and has been shown to effectively traffick nanoparticles to brain 
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tumors in vivo.112  F3 peptide is a 31-amino acid peptide that has demonstrated to have 
cell penetrating properties and is a promising candidate for drug-targeting and gene-
therapy applications.113-115  Covalent conjugation of F3 peptide onto nanoparticles allows 
for enhanced cellular uptake116,117 of the nanostructures and targeted delivery of 
therapeutics, resulting in an increased efficacy, reduced side effects and, hence, 
improved overall efficiency of delivery.  Herein, cSCKs conjugated with fluorophore 
and decorated with F3 peptide were prepared as bio-synthetic hybrids that were mixed 
with negatively-charged nucleolin-siRNA and investigated for their differential cellular 
uptake and knockdown of nucleolin expression in U87 glioma cells in vitro.   
3.2 Materials and Methods 
Synthesis of poly(tert-butyl acrylate)160 (PtBA160) (1) 
Bulk polymerization of tert-butyl acrylate by atom transfer radical 
polymerization:  To a flame dried 100 mL Schlenk flask, tert-butyl acrylate (56.6 g, 44.2 
mmol) was added along with copper (I) bromide (0.41 g, 2.86 mmol). The reaction 
mixture was sealed and three freeze pump thaw cycles were performed to ensure the 
removal of air.  N,N,N’,N’,N’’-pentamethyldiethylenetriamine (0.49 g, 2.87 mmol) and 
2-ethylbromo propionate (0.40 g, 2.21 mmol) were added to the reaction mixture via a 
syringe and the reaction mixture was allowed to undergo two more freeze pump cycles.  
The reaction mixture was brought to room temperature and stirred to ensure 
homogeneity.  Following this, the Schlenk flask was immersed into a preheated oil bath 
at 50 °C.  Aliquots were taken at predetermined time interval and conversion was 
monitored via NMR and GPC.  After the expected conversion was reached, the 
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polymerization was quenched by immersing the reaction flask into liquid nitrogen.  The 
reaction mixture was passed through a short alumina plug to remove copper and three 
consecutive precipitations were performed in methanol and ice (80:20).  After the final 
precipitation, a white gooey polymer (18.0 g, 50% yield) was obtained after removal of 
solvent and subsequent drying under vacuo.  (Mn)NMR = 21.2 kDa.  (Mn)GPC = 14.9 kDa.  
(Mw)GPC = 17.7 kDa.  PDI= 1.18.  IR: 3000, 2920, 1710, 1500, 1370, 1220, 1150, 880, 
810 cm-1.  1H-NMR (CD2Cl2): δ 1.5 (s, (CH3)3COC-), 1.8, (br, -CHCH2-), 2.2 ((br, -
CHCH2-), 4.1 (CH3CH2OCO-) ppm.  
13C NMR (CD2Cl2): δ: 26.7, 31.6 – 38.0, 80.2, 
174.6 ppm.  DSC: (Tg) = 58 °C.  Tonset = 118 °C, Tdecomposition:  [(118 - 248 °C) 31 % mass 
loss; (248 - 457 °C) 43% mass loss; 26% mass remaining].   
Synthesis of poly(tert-butyl acrylate)160-b-poly(styrene)30 (PtBA160-b-PS30) (2) 
Amphiphilic block copolymer of poly(tert-butyl acrylate)160-b-poly(styrene)30 
(PtBA160-b-PS30) was prepared using atom transfer radical polymerization.  To a flame 
dried 25 mL Schlenk flask, PtBA164 (8.00 g, 0.37 mmol) was added along with copper 
(I) bromide (108 mg, 0.75 mmol), styrene (1.96 g, 18.9 mmol) and anisole (8.00 g).  The 
reaction mixture was sealed and three freeze pump thaw cycles were performed to 
ensure the removal of air.  N, N, N’, N’, N’’-pentamethyldiethylenetriamine (130 mg, 
0.75 mmol) was added to the reaction mixture via a syringe and the reaction mixture was 
allowed to undergo two more freeze pump thaw cycles.  The reaction mixture was 
brought to room temperature and stirred to ensure homogeneity.  Following this, the 
Schlenk flask was immersed into a preheated oil bath at 82 °C.  Aliquots were taken at 
predetermined time interval and conversions were monitored via 1H - NMR and GPC.  
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After the expected conversion was reached, the polymerization was quenched by 
immersing the reaction flask into liquid nitrogen.  The reaction mixture was passed 
through a short alumina plug to remove copper and three consecutive precipitations were 
performed in methanol and ice (80:20).  After the final precipitation, a white powder 
(6.08 g, 97% yield) was obtained after the removal of solvent and subsequent drying 
under vacuo.  (Mn)NMR = 24.4 kDa.  (Mn)GPC = 23.4 kDa.  (Mw)GPC = 25.9 kDa.  PDI= 
1.11.  IR: 3000, 2945, 1730, 1460, 1380, 1280, 1150, 870, 770 cm-1.  1H-NMR (CD2Cl2): 
δ 1.5 (s, (CH3)3COC-), 1.8, (br, -CHCH2-), 2.2 ((br, -CHCH2-), 4.1 (CH3CH2OCO-), 
6.2-7.3 (br, ArH) ppm.  13C NMR (CD2Cl2): δ: 26.7, 31.6 – 38.0, 80.2, 126.4 – 128.1, 
174.6 ppm.  DSC: (Tg) = 51 °C.  Tonset = 136 °C, Tdecomposition:  [(136 - 245 °C) 36 % mass 
loss; (245-464 °C) 43% mass loss; 21% mass remaining].   
Synthesis of poly(acrylic acid)160-b-poly(styrene)30 (PAA160-b-PS30) (3) 
Block copolymer 2 (2.10 g, 0.09 mmol) was dissolved in trifluoroacetic acid 
(70.0g, 0.61 mol) and stirred at room temperature for 16 h.  The next day, TFA was 
evaporated and polymer was dissolved in THF and transferred to a presoaked dialysis 
bag (MWCO 6-8000 Da).  The mixture was extensively dialyzed for 4 days against 
nanopure water followed by lyophilization to obtain white fluffy polymer of PAA164-b-
PS31 (1.02 g, yield = 78.0%).  (Mn)NMR = 15.2 kDa.  IR: 3700-2400, 1720, 1488, 1280, 
1205, 860 cm-1.  1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer backbone), 2.2 (br, -
CHCH2-), 4.1 (CH3CH2OCO-), 6.2 - 7.3 (br, ArH), 12.2 (br, COOH) ppm.  
13C NMR 
(DMSO-d6) δ: 31.6 – 38.0, 126.4 – 128.1, 175.6 ppm.  DSC: (Tg) = 49 °C, 127 °C.  Tonset 
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= 154 °C, Tdecomposition:  [(154 - 289 °C) 6 % mass loss; (289-482 °C) 40% mass loss; 
40% mass remaining].   
Synthesis of poly(acrylamidoethylamine-boc)160-b-poly(styrene)30 (PAEA-boc160-b-
PS30) (4) 
General procedure for conjugation of N-boc-ethylenediamine: Lyophilized 
polymer, 3 (150 mg, 9.86 µmol) was allowed to dissolve in DMF (7.50 mL) for 30 mins 
prior to the addition of HOBT (324 mg, 2.39 mmol) and HBTU (912 mg, 2.39 mmol) in 
a DMF solution.  The reaction was stirred for 30 mins and diisopropylethylamine (180 
mg, 1.34 mmol) was added along with N-boc-ethylenediamine (389 mg, 2.39 mmol).  
The reaction was stirred overnight at room temperature for 24 h and dialyzed against 150 
mM NaCl solution for 2 days, then against nanopure water for 5 days.  After dialysis the 
solution was filtered to obtain a white powder (380 mg, 95.0% yield).  (Mn)NMR = 38.7 
kDa.  (Mn)GPC = 47.0 kDa.  (Mw)GPC = 60.1 kDa.  PDI= 1.27.  IR: 3630-3120, 2960, 
2910, 1650, 1620, 1540, 1450, 1380, 1260, 1180, 1030, 890, 830 cm-1.  1H-NMR 
(DMSO-d6) δ: 1.0 - 2.0 (br, polymer backbone, boc), 2.2 ((br,-CHCH2-), 2.8 - 3.4 (br,-
NCH2CH2N-) 6.2 - 7.3 (br, ArH) ppm.  
13C NMR (DMSO-d6) δ: 26.7, 31.6 – 41.0, 56.5, 
80.2, 126.4 – 128.1, 145.5, 175.3 ppm.  DSC: (Tg) = 28 °C, 106 °C.  Tonset = 132 °C, 
Tdecomposition:  [(132 - 239 °C) 29 % mass loss; (239-475 °C) 47% mass loss; 24% mass 
remaining].   
Synthesis of poly(acrylamidoethylamine)160-b-poly(styrene)30 (PAEA160-b-PS30) (5) 
General procedure for the removal of Boc groups: A white powder of 4, (153 mg, 
3.54 µmol) was dissolved in TFA (7.00 g, 61.4 mmol) and stirred at room temperature 
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overnight.  The next day, TFA was the removed under vacuo.  The polymer was then 
dissolved in DMSO and dialyzed against nanopure water followed by lyophilization to 
obtain the deprotected polymer.  (Mn)NMR = 22.1 kDa.  IR: 4000-2360, 1670, 1560, 1470, 
1190, 1130, 855, 810, 750 cm-1.  1H-NMR (DMSO-d6): δ 1.0-2.0 (br, polymer 
backbone), 2.2 (br,-CHCH2-), 2.8- 3.4 (br,-NCH2CH2N-) 6.2-7.3 (br, ArH), 7.2 - 8.4 (br, 
NH) ppm.  13C-NMR (DMSO-d6): δ: 26.7, 31.6 – 38.0, 40.5, 126.4 – 128.1, 145.5, 175.0 
ppm.  DSC: (Tg) = 29 °C, 109 °C.  Tonset = 173 °C, Tdecomposition:  [(173 - 296 °C) 14 % 
mass loss; (296-484 °C) 48% mass loss; 38% mass remaining].   
Preparation of micelles (6) 
To 5 (5.05 mg), DMSO (3.40 mL) was added and the reaction was stirred for 1 h.  
The solution was then transferred into a presoaked dialysis tubing (MWCO ca. 6000-
8000 Da) and dialyzed against nanopure water for 4 d to remove residual solvent and 
impurities to afford clear micellar solution at a concentration of 530 µgmL-1.  (Dh)num 
(DLS) = 168 ± 163 nm; (Dh)vol (DLS) = 29 ± 19 nm; (Dh)int (DLS) = 19 ± 5 nm.  Zeta 
potential = 50 ± 2 mV (pH 5.5).   
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Preparation of cSCKs (7) 
To 6 (6.00 mL), sodium carbonate (20 µL of 1.0 M solution) was added to adjust 
the pH to ca. 8.0.  A diacid crosslinker (2.0 mg) was activated with HOBT (1.7 mg, 2.2 
equiv. per COOH) and HBTU (4.8 mg, 2.2 equiv. per COOH) in 300 µL of DMF for 30 
min.  The activated crosslinker solution was slowly added to the micellar solution to 
crosslink ca. 5 % of the amines.  The reaction mixture was stirred overnight, and then 
transferred to a dialysis tube (MWCO ca. 6000-8000 Da) and dialyzed against nanopure 
water for 3 days to obtain clear cSCK solution at 520 µg/mL.  (Dh)num (DLS) = 252 ± 
221 nm; (Dh)vol (DLS) = 45 ± 31 nm; (Dh)int (DLS) = 29 ± 8 nm.  Zeta potential = 35 ± 2 
mV (pH 5.5).   
Conjugation of Cy3 – NHS to cSCKs (8) 
To 7 (4.00 mL), sodium carbonate (20 µL of 1.0 M solution) was added to adjust 
the pH to ca. 8.0.  Cy3–NHS (0.3 µL) was added from a stock solution (200 mM) in 
DMSO to tether ca. 1 dye per polymer chain.  The reaction mixture turned magenta as 
soon as the dye was added.  The reaction was stirred overnight, and then transferred to a 
dialysis tube (MWCO ca. 6000-8000 Da) and dialyzed against 10 mM PBS buffer in 
dark for 3 days to obtain magenta solution of cSCK solution with a concentration of 580 
µgmL-1.  Dye concentration was quantified by UV-vis spectrophotometer and found to 
be 3.35 µM.  (Dh)num (DLS) = 515 ± 594 nm; (Dh)vol (DLS) = 28 ± 21 nm; (Dh)int (DLS) 
= 20 ± 5 nm.  Zeta potential = 35 ± 2 mV (pH 5.5).   
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Modification of F3 peptide to bear maleimide units (9) 
F3 peptide (FITC-Ahx-KDEPQRRSARLSAKPAPPKPEPKPRKAPAKK) and 
scrambled sequence (FITC-Ahx-KDEARALPSQRSRKPAPPKPEPKPKKAPAKK) 
labeled with FITC were modified to append maleimide onto the lysine units of the 
peptide backbone.  To each peptide (10.0 mg, 2.54 µmol) in 10 mM PBS buffer (500 
µL), succinimidyl-N-maleimidoethyl carboxylate (7.10 mg, 26.7 µmol) was added from 
a stock solution in DMF along with DIPEA (4 µL).  After 2h, the reaction was 
transferred to a Zeba desalting column that was washed and equilibrated with 10 mM 
PBS buffer to remove small molecule impurities. 
Conjugation of F3 peptides to Cy3 – cSCKs (10) 
To 8 (1.50 mL), sodium carbonate (20 µL of 1.0 M solution) was added to adjust 
the pH to ca. 8.0 followed by the addition of 9 (FITC-F3-maleimide) (250 µL of stock 
solution).  The reaction was stirred for 24 h followed by purification using Sephadex G-
75 to remove unreacted F3 – peptide affording dark pink solution of Cy3 – cSCK – F3 – 
FITC conjugate.  The reaction was analyzed by UV-vis spectrophotometer to confirm 
the presence of Cy3 on the cSCKs and FITC on the peptide.  (Dh)num (DLS) = 194 ± 207 
nm; (Dh)vol (DLS) = 26 ± 17 nm; (Dh)int (DLS) = 17 ± 5 nm.  Zeta potential = 81 ± 14 
mV (pH 5.5).   
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3.3 Results and Discussion 
Dual F3 peptide- and Cy3-labeled cSCKs were prepared from amphiphilic block 
copolymers in a stepwise process, allowing for an increasing level of complexity at each 
stage of modification that enhanced the structural function of the resulting 
nanostructures.  As illustrated throughout Figures 3.1, 3.2, 3.3 and 3.5, controlled radical 
polymerization, post-polymerization chemical modification reactions, supramolecular 
assembly in water, and intramicellar crosslinking reactions afforded cSCKs, which then 
underwent conjugation reactions of fluorescent labels and biologically-active targeting 
ligands with reactive sites in the shells of the cSCKs to produce bio-synthetic hybrid 
nanoparticles.   
 
 
 
 
Figure 3.1.  Schematic representation of preparation of cationic amphiphilic block copolymer in a 
stepwise process by sequential atom transfer radical polymerization of tert-butyl acrylate and styrene 
followed by deprotection, amidation of N-boc ethylene. 
 
 
 
The amphiphilic block copolymer precursor to the cSCK was prepared by a 
sequential atom transfer radical polymerization of tert-butyl acrylate and styrene 
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followed by a sequence of selective acidolysis and amidation reactions.  The PtBA160 (1) 
macroinitiator was afforded through the bulk polymerization of tBA at 50 °C for 4 h 
using ethyl 2-bromopropionate as the initiator and CuBr/PMDETA catalytic system (Fig. 
3.1).  The homopolymer was chain extended to afford the block copolymer PtBA160-b-
PS30 (2), employing 1 and styrene in the presence of CuBr/PMDETA in anisole.  By 
allowing the reaction to proceed under conditions of high dilution and low conversion, 
the polymer was prepared with narrow molecular weight distribution (PDI<1.10) (Fig. 
3.2).  Furthermore, the tert-butyl protecting groups were removed via acidolysis with 
TFA in CH2Cl2 to yield the amphiphilic block copolymer of PAA160-b-PS30
 (3).  The 
acrylic acid repeat units were then converted to acrylamides, each carrying a protected 
amino group, by using an excess of N-Boc ethylene diamine in the presence of HOBT, 
HBTU and DIPEA in DMF, yielding P(AEA-Boc)160-b-PS30 (4).  In the final step, the 
Boc protecting groups were removed by direct dissolution of 4 in TFA overnight, 
followed by removal of the TFA under a N2 stream, to afford the block graft copolymer 
PAEA160-b-PS30 (5).   
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Figure 3.2.  Gel permeation chromatograms of PtBA160-b-PS30 (2) and P(AEA-Boc)160-b-PS30 (4). 
 
 
 
 
Figure 3.3  Schematic representation of self assembly of amphiphilic block graft copolymer PAEA160-b-
PS30 (5) on transitioning from organic solvent to water, followed by crosslinking selectively of the 
hydrophilic shell to afford cationic SCK (7). 
 
 
 
cSCKs were prepared by the solution-state assembly of the amphiphilic block 
copolymers 5 in water followed by crosslinking reactions selectively throughout the 
hydrophilic shell layer.  After dissolving 5 in DMSO at a concentration of 2 mgmL-1, 
self assembly was induced by direct dialysis of the polymer solution in DMSO against 
molecular biology grade water, using a dialysis membrane (MWCO 6-8 kDa), where 
gradual exchange of DMSO by water occurred (Fig. 3.3).  Due to the nanoscopic size of 
the assemblies, the micelle solution remained clear at 0.70 mg mL-1.  The cSCKs were 
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obtained by crosslinking approximately 5% of the amino groups along the hydrophilic 
segments by amidation with activated carboxylic acids (activated using 2.2 equiv. of 
both HOBT and HBTU relative to the COOH groups in the crosslinker in DMF) of the 
diacid crosslinker (4,15-dioxo-8,11-dioxa-5,14-diazaoctadecane-1,18-dioic acid) at pH 
ca. 8 (adjusted using 1.0 M Na2CO3(aq.)).  The crosslinking reaction was allowed to 
proceed overnight, followed by extensive dialysis to remove unreacted small molecule 
starting materials and reaction by-products.   
 
 
 
 
Figure 3.4  Schematic representation of preparation of Cy3-labeled cSCK by covalent conjugation of 
Cy3-NHS with amines along the hydrophilic segments within the shells of cSCKs at pH 8.0. 
 
 
 
Cy3-NHS was attached to the cSCKs, to serve as a fluorescent probe, by 
performing post-assembly conjugation of the activated ester of the dye to amines in the 
shells of the cSCKs at pH ca. 8.0 (adjusted using 1.0 M Na2CO3(aq)) (Fig. 3.4).  The 
reaction was carried out for 24 h in the dark, followed by purification by extensive 
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dialysis against 150 mM NaCl for 1 d and nanopure water for additional 3 d to remove 
unconjugated dye and small molecule by-products, and afford the fluorescently-labeled 
cSCKs having ~0.2 dye molecules per polymer chain comprising the cSCKs, as 
determined by UV-vis spectroscopy with observation at the Cy3 max.  
FITC-labeled, tumor-homing F3 peptide, which has demonstrated cell 
penetrating properties, was conjugated to the cSCKs in this study to target nucleolin, 
overexpressed at tumor cell surfaces and tumor vasculature, and facilitate enhanced 
cellular uptake.  FITC-F3 was modified to bear maleimide functionalities on the peptide 
backbone (Fig. 3.5), to provide a functional handle for conjugation of the peptide to the 
cSCKs (Scheme 3.6).   
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Figure 3.5  Schematic representation of modification of FITC-F3 peptide using succinimidyl-N-
maleimidoethyl carboxylate as a bifunctional coupling agent to install maleimide groups for attachment to 
the cSCKs.  Although the maleimide connection is shown only on one lysine, several maleimides groups 
could be present.   
 
 
 
FITC-F3 underwent reaction with a 10-fold excess of bi-functional coupling 
agent (succinimidyl-N-maleimidoethyl carboxylate) with a NHS ester on one end and 
maleimide on the other terminus.  F3 peptide (FITC-Ahx-
KDEPQRRSARLSAKPAPPKPEPKPRKAPAKK) has several lysine units that can 
undergo reaction with the activated ester of the bifunctional reagent to install maleimide 
groups along the peptide backbone.  The reaction was purified by spin column to remove 
unreacted small molecules and byproducts to obtain a bright fluorescent solution of 
modified FITC-F3 peptide.   
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Figure 3.6  Schematic representation of (A) Preparation of F3 peptide-tethered cSCK by conjugating 
maleimide-modified FITC-F3 onto Cy3-cSCK.  (B) Purification of Cy3-cSCK-F3-FITC conjugates (pink 
band) using Sephadex G-75 to remove unconjugated F3 peptide (yellow-green band).   
 
 
 
The objective of tethering F3 peptide onto the Cy3-labeled cSCKs was to create 
surface functional nanoparticles for their use as targeting entities for tissue-specific 
targeting and delivery.  Maleimide-functionalized F3 peptides, and their scrambled 
analogs, were subjected to undergo reactions with amine functionalized cSCK at pH ca. 
8.0 overnight (Fig. 3.6A) to afford the targeted and non-targeted (control) cSCK 
samples, respectively.  The nanoparticle conjugates were purified with Sephadex G-75 
columns that allowed for visualization of the unconjugated peptide as a bright yellow-
green band on the column (Fig. 3.6B).  The amounts of F3 peptide incorporated into the 
cSCK samples were calculated by UV-vis spectroscopy (Fig. 3.7 A and B) using the 
inherent wavelength of 488 nm for FITC on the F3 peptide.  Scrambled F3 peptide was 
employed, as a control sequence, to investigate the differential uptake of the 
nanoparticles in the presence of the peptide.  From UV-vis measurements, ca. 0.2 dye 
molecules and 0.3 peptides were conjugated per polymer chain.   
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Figure 3.7  (A)  UV-vis spectra of FITC-labeled F3 peptide, Cy3-labeled cSCK, Cy3- and F3 peptide-
conjugated cSCKs, and Cy3- and scrambled F3 peptide-conjugated cSCKs.  (B) Fluorescence emission 
spectra (excitation at 546 nm) of Cy3-labeled cSCK, Cy3- and F3 peptide-conjugated cSCKs, and Cy3- 
and scrambled F3 peptide-conjugated cSCKs.  All samples were analyzed as solutions in molecular 
biology grade water.   
 
 
 
 
Figure 3.8  Dynamic light scattering of (A) micelles, (B) cSCKs, (C) Cy3- and F3-tethered cSCKs and 
(D) Cy3- and scrambled F3-tethered cSCKs. 
 
 
 
The sizes and charges of the cSCKs were determined using dynamic light 
scattering  (Fig. 3.8) and zeta potential measurements.  The micelles and cSCKs were ca. 
21 nm as measured by DLS prior to conjugation of the peptides and ca. 25 nm post-
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peptide conjugation.  The sizes of the particles remained the same ca. 21-25 nm, within 
the experimental error, across the series of conjugations of the Cy3 and the F3 peptide.  
The zeta potential values of the micelles and cSCKs, ca. 30 mV (at pH 5.5, in nanopure 
water), confirmed the positive surface charge density.  After covalent conjugation to 
peptides, the zeta potential values were found to be ca. 43 mV (at pH 5.5, in nanopure 
water), perhaps due to incorporation of several lysine units present on the peptide 
backbone that contributed to the increase in cationic character of the peptide-cSCK 
conjugates.   
 
 
Figure 3.9.  (A) Absorbance levels from U87MG glioma cell viability studies using the MTT assay of 
cSCKs at various concentrations (µgmL-1).  (B) Absorbance levels from cell viability studies using the 
MTT assay of cSCKs at 2 µgmL-1 loaded with nucleolin targeting siRNA to illustrate significant 
inhibition of U87MG glioma cell growth for the F3-targeted cSCKs.   
 
 
 
The Cy3-labeled F3-cSCK conjugates, 9 and 10, were used to perform in vitro 
studies to investigate their cellular uptake behavior in U87MG glioma cells.  Previously, 
we found that compared to normal human astrocytes, human glioma tumor cells 
(U87MG) showed significant amounts of nucleolin expression.  Additionally, F3 
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peptide-based protein HMGN2 sequence has demonstrated significant binding to human 
malignant tumors including human glioma cells.  We, therefore, hypothesized that 
conjugation of F3 peptide onto cSCK nanoparticles would enhance cellular uptake of F3 
peptide-conjugated cSCKs into U87MG cells compared to scrambled F3-peptide 
conjugated cSCKs.  The cytotoxicity profiles of unconjugated cSCKs on U87MG glioma 
cell lines were first examined to determine the non-toxic concentration levels.  At a 
concentration of 4 µgmL-1, cSCK nanoparticles exhibited slightly lower cell viability 
compared to the control sample, as determined by MTT assay (Fig. 3.9A).  However, at 
a higher concentration (40 µgmL-1), the cSCKs showed much lower cell viability and, 
therefore, a concentration of 2 µgmL-1 was selected to treat U87MG cells for 
investigation of cellular uptake of F3 peptide- and scrambled F3 peptide-conjugated 
cSCKs using confocal microscopy.  As shown in Fig. 3.10, remarkable cellular uptake 
was observed for F3 peptide-conjugated cSCK nanoparticles, 9, compared to scrambled 
F3 peptide-conjugated cSCKs, 10.  As expected, cells treated with unconjugated, 8, or 
10 also showed moderate amounts of uptake.   
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Figure 3.10  Confocal fluorescence microscopy images of U87MG cells, incubated with 9 or 10, and 
observed with filters that allow for visualization of DAPI nuclear stain, Cy3 and FITC, indicating 
enhanced cellular uptake of F3 peptide-conjugated cSCKs, 9, in U87MG glioma cells, compared to 
scrambled peptide conjugated cSCKs, 10.   
 
Figure 3.11  Enhanced cellular uptake of F3 peptide conjugated cSCKs and nucleolin-siRNA in U87MG 
glioma cells.   
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Figure 3.12  Cellular uptake of F3-labeled cSCK-siRNA for knockdown of overexpressed nucleolin in 
U87MG glioma cells.   
 
 
 
Nucleolin is a shuttling protein that plays an important role in tumor cell 
proliferation.  Previously, we have shown that knocking down nucleolin expression in 
U87MG glioma cells by lentivirus infection approach significantly inhibits tumor cell 
growth both in vitro and in vivo cSCK nanoparticles have the potential to deliver siRNA 
successfully into tumor cells by electrostatic complexation of positively-charged cSCKs 
with negatively-charged siRNA.  We, therefore, mixed a pool of synthesized siRNA 
molecules specifically against nucleolin with either F3 peptide-conjugated cSCKs or 
scrambled F3 peptide-conjugated cSCKs, 9 or 10, and treated U87MG cells in vitro.  
Within 72 h, there was a dramatic knock down of nucleolin expression among those cells 
treated with nucleolin siRNA-loaded F3-targeted cSCKs, both by immunofluorescence 
staining (Fig. 3.11 and 3.12) and by immunoblot assay (data not shown).  Most 
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importantly, consistent with our previous observation, cells treated with nucleolin 
siRNA-loaded and F3-targeted cSCKs (F3-cSCK-Nu-siRNA mixtures) also showed 
significant decrease of tumor cell survival by MTT assay (Fig. 3.9B), due to their 
senescent phenotypic changes (Fig. 3.12).  At higher magnification, those cells with 
robust uptake of F3-cSCK-Nu-siRNA mixtures were flat and remarkably enlarged 
compared to those less targeted populations, consistent with their bona fide 
morphological changes caused by senescence upon knock-down molecules into glioma-
bearing mice will provide us a very useful therapeutic modality of nucleolin protein.  
Here, by integrating a tumor specific peptide into a cationic nanoparticle system we were 
able to successfully deliver nucleolin siRNA molecules into human glioma cells that 
subsequently showed attenuated tumor growth in vitro.  Future investigation of this 
system in vivo in terms of their biodistribution and efficacy of delivering siRNA are 
underway.  
3.4 Conclusions 
Well-defined cSCKs dually labeled with Cy3 and F3 peptides and loaded with 
nucleolin siRNA have been prepared and their differential uptake and knock down of 
overexpressed nucleolin in U87MG glioma cells were evaluated.  In vitro studies 
demonstrated an enhanced uptake of cSCKs tethered to F3 peptide compared to the 
scrambled peptide control nanoparticle sample.  Additionally, cSCKs showed effective 
binding to plasmid DNA and were delivered into the cells for efficient knockdown of 
nucleolin as demonstrated by immunoblot assays.  Specific efforts are being made 
currently to have these biologically-active units presented from the outer most surface of 
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the SCKs, by employing well-defined multi-step polymerization and polymer 
modification reactions that involve combinations of stealthy PEG chain grafts.16  This 
work is the first step to develop cationic SCKs tethered with targeting ligands for tissue-
selective cellular delivery and uptake.  With the high levels of sophistication that are 
possible via simple iterations of controlled polymer chemistries, there are several 
functions that are yet to be incorporated and biological performances to be evaluated.  
Extended in vitro and in vivo studies toward employing these materials for gene and 
nucleic acids toward treatment of acute lung injury are also currently underway.   
3.5 Acknowledgements 
  This material is based upon work supported by the National Heart Lung and 
Blood Institute of the National Institutes of Health as a Program of Excellence in 
Nanotechnology (HHSN268201000046C).  The Welch Foundation is gratefully 
acknowledged for support through the W. T. Doherty-Welch Chair in Chemistry, 
Grant No. A-0001.  The authors would like to thank Dr. Mahmoud Elsabahy and Dr. 
Lily Yun Lin for helpful discussions and support, Ms. Adriana Pavia for creating the 
Autodesk 3ds Max images, and Mr. Kevin Pollack for assistance with thermal 
analysis.   
 
 
 
 
 74 
 
CHAPTER IV 
ENHANCED ENDOSOMAL ESCAPE AND EFFICIENT SIRNA DELIVERY BY 
OPTIMIZATION OF CATIONIC SHELL CROSSLINKED KNEDEL-LIKE 
NANOPARTICLES WITH TUNABLE BUFFERING CAPACITIES 
 
4.1. Introduction 
In recent years, the use of small interfering RNAs (siRNAs) has gained much 
attention as therapeutics for the treatment of various diseases, due to their ability to 
selectively target and cleave complementary mRNA sequences for efficient gene 
silencing.38,118-120  siRNA is composed of double-stranded RNA molecules that are ca. 
20-25 nucleotides long with inherent negative charge and macromolecular size.  The 
success of siRNA-based therapeutics is largely dependent on the efficient delivery of 
siRNA into the cytoplasm of the target cells while inducing minimal toxicity.  Examples 
of the hurdles towards the proficient delivery of siRNA include extracellular and 
intracellular enzymatic degradation, limited cellular uptake, entrapment into endocytic 
vesicles that form upon the endocytosis of the siRNA, and limited release into the 
cytoplasm of the transfected cells.38,39,121  Internalization of siRNA via endocytic 
pathways usually ends into acidified endosomes and later into lysosomes, where 
enzymatic degradation can occur, in addition to hindering the siRNA from reaching their 
target sites into the cytoplasm.1,7  One way to circumvent these challenges is to complex 
the negatively-charged siRNA with positively-charged lipids/polymers, where 
electrostatic interactions between siRNA and cationic carriers result in the formation of 
positively-charged nanocomplexes, which partially protect the siRNA against 
degradation and enhance cellular uptake.122-125  In addition, several types of membrane 
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disruptive polymers and imidazole-containing polymers have been investigated to 
facilitate escape from the endosomes and achieve efficient transportation of genetic 
materials into the cytosol.126-131  In particular, imidazole-containing polymers have 
gained much attention recently, as they exhibit pKa ~ 6 and can undergo protonation in 
the acidic endosomal environment leading, eventually, to efficient endosomal 
disruption.130,131 
An intricate system that can electrostatically bind to nucleic acids, mediate 
cellular entry of the nanocomplexes and trigger mechanisms for endosomal lysis, either 
by interaction with the endosomal membrane or via the proton sponge effect, partially 
fulfills the design requirements for the cytoplasmic delivery of nucleic acids.128,132,133  
Some of these systems depend on incorporating two functional groups of low and high 
pKas, for example, poly(L-Lysine) as a segment with high pKa and poly[(3-
morpholinopropyl) aspartamide] as a low pKa polymer.  The high-pKa polymer interacts 
electrostatically with the nucleic acid at physiological pH, whereas the low-pKa polymer 
remains mostly non-ionized at this pH.  Protonation of the low-pKa polymer can buffer 
the endosomes and aid in pumping protons concurrently with chloride ions (i.e. 
endosomal burst via the proton sponge effect)134 or the additional positive charges 
(unbound to DNA/RNA) provide new sites for electrostatic interactions with the 
endosomal membrane.  Both effects may enhance the ability of the vector to escape from 
the endosomes and release their cargoes into the cytoplasm.135,136 
Our group has a long standing interest in designing novel polymeric systems and 
chemistries to engineer synthetic nanostructures, known as shell-crosslinked knedel-like  
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nanoparticles (SCKs) that have exhibited promise for a diverse set of biomedical 
applications, including nucleic acids delivery, due to their versatility in size, shape, and 
morphology, along with a synthetic approach that allows for ease of chemical 
modification, orthogonal functionalization and multivalency.7,9,15,20,31,137-140  SCKs are 
core-shell nanoparticles composed of amphiphilic block copolymers that self assemble 
in water, followed by selective crosslinking throughout adjacent chains in the 
hydrophilic shell layer, which allows SCKs to possess structural and kinetic stabilities.  
Cationic SCKs (cSCKs), with poly(acrylamidoethylamine) (PAEA) comprising the 
shells for electrostatic interaction with negatively-charged nucleic acids, have emerged 
as a promising class of nanomaterials for highly-efficient transfection of nucleic acids of 
various structures.83,110,141  In this study, a new class of cSCKs was designed by 
incorporating various amounts of histamines and primary amines (as low- and high-pKa 
functionalities) into their shells to achieve enhanced cell transfection with reduced 
toxicity, by absorbing protons at pH values between the physiological and endosomal pH 
range, resulting in disruption of endosomal membranes.  These cSCKs were 
electrostatically complexed with siRNA and investigated for their cellular uptake, 
cytotoxicity, immunogenicity and endosomal escape in RAW 264.7 mouse macrophages 
and OVCAR-3 cells. 
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4.2 Materials and Methods 
Polymerizations were performed on a double manifold with glassware and 
syringes that were dried in an oven (100 °C) for at least 1 h, and with syringes that were 
washed with N2 (3 ×), prior to use.  tert-Butyl acrylate (t-BA, 99%, Aldrich), styrene 
(99%, Aldrich), toluene (anhydrous, 99.8%, Aldrich), N,N,N′,N″,N″-
pentamethyldiethylenetriamine (PMDETA, 99% Aldrich),  copper (I) bromide (CuBr, 
99.99%, Aldrich), ethyl 2-bromopropionate (99%, Aldrich), trifluoroacetic acid (TFA, 
95%; Aldrich), 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide methiodide (EDCI, 
98%, Aldrich), hydroxybenzotriazole (HOBT, Aldrich), 2–(1H–benzotriazol–1–yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, Aldrich), N,N-
diisopropylethylamine (DIPEA, 99.5%, Aldrich).  The amphiphilic block copolymer of 
poly(acrylic acid)160-block-polystyrene30 (PAA160-b-PS30) was prepared using atom 
transfer radical polymerization (ATRP) of protected monomer precursors followed by 
deprotection, according to previously reported methods 142.  All other reagents were 
obtained from Sigma-Aldrich and used as received.  Spectra/Por membrane tubes were 
purchased from Spectrum Medical Industries, Inc. (Waltham, MA), and were used for 
dialysis.  Nanopure water (18 MΩ•cm) was acquired by means of a Barnstead Nanopure 
ultrapure water purification system (Thermo Scientific, Asheville, NC). 
1H NMR and 13C NMR spectra were recorded on an Inova 300 or Mercury 300 
MHz interfaced to a UNIX computer using VnmrJ software.  Samples were prepared as 
solutions in CDCl3, CD2Cl2, or DMF-d7 and solvent protons were used as internal 
standard.  Gel permeation chromatography (GPC) was conducted on a system equipped 
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with a Waters Chromatography, Inc. (Milford, MA) model 1515 isocratic pump and a 
model 2414 differential refractometer with a three-column set of Polymer Laboratories, 
Inc. (Amherst, MA) Styragel columns (PLgel 5µm Mixed C, 500 Å, and 10
4 Å, 300 x 7.5 
mm columns) and a guard column (PLgel 5µm, 50 x 7.5 mm).  The system was 
equilibrated at 40 °C in tetrahydrofuran (THF), which served as the polymer solvent and 
eluent (flow rate set to 1.00 mL min-1).  The differential refractometer was calibrated 
with Polymer Laboratories, Inc. polystyrene standards (300 to 467,000 Da).  Polymer 
solutions were prepared at a concentration of ca. 3 mg/mL with 0.05% (v/v) toluene as 
flow rate marker and an injection volume of 200 μL was used.  Data were analyzed 
using Empower Pro software from Waters Chromatography Inc.  IR spectra were 
recorded on an IR Prestige 21 system (Shimadzu Corp., Japan).  A small amount of 
sample was placed to cover the ATR crystal for IR measurements.  Data were analyzed 
using IRsolution software.  Thermogravimetric analysis was performed under N2 
atmosphere using a Mettler Toledo model TGA/DSC1 with a heating rate of 10 °C min-1.  
Measurements were analyzed using Mettler Toledo STARe software v.10.00.   
Samples for TEM were prepared by depositing 5 μL of sample to glow 
discharged carbon coated copper grids.  Excess sample was wicked off using filter paper 
and the grids were allowed to dry in air for 1 min.  The grids were then stained with 5 μL 
of 2% uranyl acetate and excess stain was wicked off using filter paper.  Specimens were 
observed on a JEOL 1200EX transmission electron microscope operating at 100 kV and 
micrographs were recorded at calibrated magnifications using an SIA-15C CCD camera. 
The final pixel size was 0.42 nm/pixel.  The number-average particle diameters (Dav) and 
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standard deviations were generated from the analysis of particles from at least two 
different micrographs (n = 100).  Dynamic light scattering (DLS) measurements were 
conducted using Delsa Nano C from Beckman Coulter, Inc. (Fullerton, CA) equipped 
with a laser diode operating at 658 nm.  Size measurements were made in water (n = 
1.3329,  = 0.890 cP at 25 ± 1 °C; n = 1.3293,  = 0.547 cP at 50 ± 1 °C; n = 1.3255,  
= 0.404 cP at 70 ± 1 °C).  Scattered light was detected at 165° angle and analyzed using 
a log correlator over 70 accumulations for a 0.5 mL of sample in a glass size cell (0.9 
mL capacity).  The photomultiplier aperture and the attenuator were automatically 
adjusted to obtain a photon counting rate of ca. 10 kcps.  The calculations of the particle 
size distribution and distribution averages were performed using CONTIN particle size 
distribution analysis routines.  Prior to analysis, the samples were filtered through a 0.45 
μm Whatman Nylon membrane filter (Whatman Inc., Piscataway, NJ).  The samples in 
the glass size cell were equilibrated at the desired temperature for 5 min before 
measurements were made.  The peak average of histograms from intensity, volume or 
number distributions out of ca. 70 accumulations was reported as the average diameter 
of the particles.  Absorption measurements were made using a UV-2550 system 
(Shimadzu Corp., Japan) using PMMA cuvettes.  Spectra were analyzed with UV-Probe 
2.33 software. 
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Synthesis of poly(acrylamidoethylamine)160-Boc-b-polystyrene30 (PAEA-Boc160-b-
PS30) (1) 
PAA160-b-PS30 (150 mg, 9.86 µmol) was allowed to dissolve in DMF (7.50 mL) 
for 30 min prior to the addition of HOBT (324 mg, 2.39 mmol) and HBTU (912 mg, 
2.39 mmol) in a DMF solution.  The reaction was allowed to stir for 30 min and 
diisopropylethylamine (180 mg, 1.34 mmol) was added along with N-boc-
ethylenediamine (389 mg, 2.39 mmol).  The reaction was allowed to stir overnight at 
room temperature for 24 h and dialyzed against 150 mM NaCl solution for 2 d, then 
against nanopure water for 5 d.  After dialysis, the solution was lyophilized to obtain a 
white powder (380 mg, 95.0% yield).  (Mn)NMR = 38.7 kDa.  (Mn)GPC = 47.0 kDa.  
(Mw)GPC = 60.1 kDa.  PDI= 1.27.  IR: 3630-3120, 2960, 2910, 1650, 1620, 1540, 1450, 
1380, 1260, 1180, 1030, 890, 830 cm-1.  1H-NMR (DMSO-d6) δ: 1.0 - 2.0 (br, polymer 
backbone, Boc), 2.2 ((br,-CHCH2-), 2.8-3.4 (br,-NCH2CH2N-) 6.2-7.3 (br, ArH) ppm.  
13C NMR (DMSO-d6) δ: 26.7, 31.6–41.0, 56.5, 80.2, 126.4–128.1, 145.5, 175.3 ppm.  
DSC: (Tg) = 28 °C, 106 °C.  Tonset = 132 °C, Tdecomposition:  [(132-239 °C) 29 % mass loss; 
(239-475 °C) 47% mass loss; 24% mass remaining]. 
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Synthesis of poly(acrylamidoethylamine-Boc)0.85-g-poly(acrylamide 
ethylimidazole)0.15-b-polystyrene30 ((PAEA-Boc0.85-g-PAEI0.15)160-b-PS30) (2) 
General procedure for incorporation of N-Boc ethylenediamine and histamine 
onto the polymer backbone:  PAA160-b-PS30 (150 mg, 9.9 µmol) was allowed to dissolve 
in DMF (7.50 mL) for 30 min prior to the addition of HOBT (324 mg, 2.39 mmol) and 
HBTU (912 mg, 2.39 mmol) in a DMF solution.  The reaction was stirred for 30 min and 
diisopropylethylamine (180 mg, 1.34 mmol) was added along with N-boc-
ethylenediamine (330 mg, 2.1 mmol) and histamine (40 mg, 0.2 mmol) from a stock 
solution in DMF.  The reaction was allowed to stir overnight at room temperature for 24 
h and dialyzed against 150 mM NaCl solution for 2 d, then against nanopure water for 5 
d.  After dialysis the solution was lyophilized to obtain a white powder (380 mg, 95.0% 
yield).  (Mn)NMR = 37.2 kDa.  IR: 3600-3000, 2965, 1700, 1650, 1538, 1498, 1380, 1288, 
1160 cm-1.  1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer backbone, Boc), 2.2 (br,-
CHCH2-), 2.8-3.4 (br,-NCH2CH2N- and -NCH2CH2C-) 6.2–8.5 (br, ArH, styrene and 
histamine) ppm.  13C NMR (DMSO-d6) δ: 28.2, 31.6-41.0, 77.6, 117.9, 126.4–128.1, 
134.7-136.4, 174.5 ppm.  Tonset = 186 °C, Tdecomposition:  [(186-255 °C) 22 % mass loss; 
(255-449 °C) 60% mass loss; 18% mass remaining].   
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Synthesis of poly(acrylamidoethylamine)0.50-boc-g-
poly(acrylamidoethylimidazole)0.50-b-polystyrene30 ((PAEA0.50-boc-g-PAEI0.50)160-b-
PS30) (3) 
Polymer 3 was synthesized according to the general procedure for preparation of 
graft copolymer as mentioned above.  (Mn)NMR = 34.4 kDa.  IR: 3600-3000, 2950, 1700, 
1640, 1545, 1460, 1375, 1250, 1160 cm-1..  
1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer 
backbone, boc), 2.2 ((br,-CHCH2-), 2.8-3.4 (br,-NCH2CH2N- and -NCH2CH2C-) 6.2–
8.5 (br, ArH, styrene and histamine) ppm.  13C NMR (DMSO-d6): δ: 28.2, 31.6–38.0, 
77.7, 117, 126.4–128.1, 134.6, 174.3 ppm.  Tonset = 183 °C, Tdecomposition:  [(183-237 °C) 6 
% mass loss; (237-263 °C) 20% mass loss; 74% mass remaining]. 
Synthesis of poly(acrylamidoethylimidazole)160-b-polystyrene31 (PAEI160-b-PS30) (4) 
PAA160-b-PS30 (150 mg, 9.86 µmol) was allowed to dissolve in DMF (7.50 mL) 
for 30 min prior to the addition of HOBT (324 mg, 2.39 mmol) and HBTU (912 mg, 
2.39 mmol) in a DMF solution.  The reaction was stirred for 30 min and 
diisopropylethylamine (180 mg, 1.34 mmol) was added along with histamine (270 mg, 
2.43 mmol) from a stock solution in DMF.  The reaction was allowed to stir overnight at 
room temperature for 24 h and dialyzed against 150 mM NaCl solution for 2 d, then 
against nanopure water for 5 d.  After dialysis the solution was lyophilized to obtain a 
white powder (380 mg, 95.0% yield).  (Mn)NMR = 30.5 kDa.  IR: 3650-3000, 2940, 1630, 
1540, 1440, 13750, 1250, 1125 cm-1.1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer 
backbone), 2.2 ((br,-CHCH2-), 2.8-3.4 (br, -NCH2CH2C-) 6.2-8.5 (br, ArH, styrene and 
histamine) ppm.  13C NMR (DMSO-d6): δ: 35-42.3, 117.9, 126.4-128.1, 134.7-136.4, 
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174.5 ppm.  Tonset = 108 °C, Tdecomposition:  [(108 - 283 °C) 11 % mass loss; (283-500 °C) 
48% mass loss; 41% mass remaining].   
Synthesis of poly(acrylamidoethylamine)-b-polystyrene30 (PAEA-160-b-PS30) (5) 
General procedure for the removal of Boc groups:  A white powder of 1 (153 mg, 
3.54 µmol) was allowed to dissolve in TFA (7.00 g, 61.4 mmol) and stirred at room 
temperature overnight.  The following day, TFA was removed under a stream of N2.  
The polymer was then dissolved in DMSO and dialyzed against 150 mM NaCl solution 
for 1 d followed by dialysis against nanopure water for 3 d.  The solution was then 
lyophilized to obtain the deprotected polymer.  (Mn)NMR = 22.1 kDa.  IR: 4000-2360, 
1670, 1560, 1470, 1190, 1130, 855, 810, 750 cm-1.  1H-NMR (DMSO-d6): δ 1.0-2.0 (br, 
polymer backbone), 2.2 (br,-CHCH2-), 2.8-3.4 (br,-NCH2CH2N-) 6.2-7.3 (br, ArH), 7.2-
8.4 (br, NH) ppm.  13C-NMR (DMSO-d6): δ: 26.7, 31.6-38.0, 40.5, 126.4-128.1, 145.5, 
175.0 ppm.  Tonset = 173 °C, Tdecomposition:  [(173 - 296 °C) 14 % mass loss; (296-484 °C) 
48% mass loss; 38% mass remaining].   
Synthesis of poly(acrylamidoethylamine)0.85-g-poly(acrylamidoethylimidazole)0.15-b-
polystyrene30 ((PAEA0.85-g-PAEI0.15)160-b-PS30) (6) 
Polymer 6 was prepared according to the general procedure for removal of Boc 
groups as mentioned above.  (Mn)NMR = 23.4 kDa.  IR: 3600-3000, 2940, 1640, 1538, 
1450, 1225 cm-1.1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer backbone), 2.2 ((br,-
CHCH2-), 2.8-3.4 (br,-NCH2CH2N- and -NCH2CH2C-) 6.2–9.5 (br, ArH, styrene and 
histamine, NH) ppm.  13C NMR (DMSO-d6): δ: 31.6–41.0, 117.9, 126.4–128.1, 134.7-
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136.4, 174.8 ppm.  Tonset = 193 °C, Tdecomposition:  [(193 - 469 °C) 70 % mass loss; 30% 
mass remaining].   
Synthesis of poly(acrylamidoethylamine)0.50-g-poly(acrylamidoethylimidazole)0.50-b-
polystyrene30 ((PAEA0.50-g-PAEI0.50)160-b-PS30) (7)  
Polymer 7 was synthesized according to the general procedure for removal of 
Boc groups as mentioned above.  (Mn)NMR = 26.3 kDa.  IR: 3600-3000, 2925, 1750, 
1625, 1525, 1450, 1375, 1250, 1160 cm-1. 1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer 
backbone), 2.2 ((br,-CHCH2-), 2.8-3.4 (br,-NCH2CH2N- and -NCH2CH2C-) 6.2-9.5 (br, 
ArH, styrene and histamine, NH) ppm.  13C NMR (DMSO-d6): δ: 31.6–38.0, 117, 
126.4–128.1, 134.6, 174.8 ppm.  Tonset = 188 °C, Tdecomposition:  [(188-294 °C) 27 % mass 
loss; (294-497 °C) 62% mass loss; 11% mass remaining].   
General procedure for micellization (8-11) 
Each polymer (5.0 mg) was directly dissolved in nanopure water (5.0 mL) and 
sonicated using a water bath sonicator for 10 min to obtain clear micellar solution at a 
concentration of 1 mg/mL.  The solution was then allowed to stir overnight at room 
temperature.  DLS and zeta-potential measurements are listed in the supporting 
information (S4-S7).   
Preparation of cSCKs of PAEA-160-b-PS30 (12) 
            General procedure for preparation of cSCKs:  To 8 (5.00 mL), sodium carbonate 
(20 µL of 1.0 M solution) was added to adjust the pH to ca. 8.0.  A diacid crosslinker, 
4,15-dioxo-8,11-dioxa-5,14-diazaoctadecane-1,18-dioic acid, (2.0 mg) was activated 
with HOBT (1.7 mg, 2.2 equiv. per COOH) and HBTU (4.8 mg, 2.2 equiv. per COOH) 
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in 300 µL of DMF for 30 min.  The activated crosslinker solution was slowly added to 
the micellar solution to crosslink ca. 5 % of the amines.  The reaction mixture was 
allowed to stir overnight, and then transferred to a dialysis tube (MWCO ca. 6000-8000 
Da) and dialyzed against nanopure water for 3 d to obtain clear cSCK solution at 0.88 
mg/mL.  (Dh)number (DLS) = 21 ± 6 nm; (Dh)volume (DLS) = 30 ± 18 nm; (Dh)intensity (DLS) 
= 106 ± 81 nm.  Zeta potential = 26 ± 2 mV (in nanopure water pH 5.5). 
Preparation of cSCKs of (PAEA0.85-g-PAEI0.15)160-b-PS30 (13) 
cSCKs of 13 were prepared from the micelles following the general procedure 
for crosslinking as listed above.  (Dh)number (DLS) = 14 ± 4 ; (Dh)volume (DLS) = 21 ± 4 
nm; (Dh)intensity (DLS) = 147 ± 61 nm nm.  Zeta potential = 35 ± 1 mV (pH 5.5). 
Preparation of cSCKs of (PAEA0.50-g-PAEI0.50)160-b-PS30 (14) 
cSCKs of 14 were prepared from the micelles following the general procedure 
for crosslinking as listed above.  (Dh)number (DLS) = 19 ± 5 nm; (Dh)volume (DLS) = 29 ± 
19 nm; (Dh)intensity (DLS) = 168 ± 163 nm.  Zeta potential = 50 ± 2 mV (pH 5.5).   
Potentiometric titration experiments 
The buffering capacities of the nanoparticles were determined by acid-base 
titration assays over pH range of 12.0-to-2.0, as reported previously 132.  Briefly, cSCKs 
(9.0 µmoles of amine) were dissolved in 15 mL NaOH (0.01 N with 150 mM NaCl) and 
then titrated with HCl (0.01 N with 150 mM NaCl).  The buffering capacity was 
measured as the volume of HCl needed to change pH from 5.1 to 7.4.   
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Cytotoxicity assays 
RAW 264.7 (2 x 104 cells/well) mouse macrophages were plated in 96-well plate 
in Dulbecco's Modified Eagle Medium (DMEM) (10% fetal bovine serum and 1% 
penicillin/streptomycin).  Cells were incubated at 37 C in a humidified atmosphere 
containing 5% CO2 for 24 h to adhere.  Then, the medium was replaced with a fresh 
medium 1-h prior to the addition of 20 L of the cSCKs and Lipofectamine to 100 L of 
the medium (final concentrations ranged from 0-to-100 µg/mL).  The cells were 
incubated with the formulations for 24 h and washed once with phosphate-buffered 
saline (PBS) and 100 μL of the complete media was added to the cells.  MTS combined 
reagent (20 μL) was added to each well (Cell Titer 96® Aqueous Non-Radioactive Cell 
Proliferation Assay, Promega Co., Madison, WI).  The cells were incubated with the 
reagent for 2 h at 37 C in a humidified atmosphere containing 5% CO2 protected from 
light.  Absorbance was measured at 490 nm using SpectraMax M5 (Molecular Devices 
Co., Sunnyvale, CA).  The cell viability was calculated based on the relative absorbance 
to the control-untreated cells.  The calculation of the IC50 values and the statistical 
analysis were performed using GraphPad Prism four-parameter fit, considering the 0% 
and 100% cell viabilities are for the control medium (no cells) and cells with no 
treatment, respectively. 
Multi-plex assay 
The RAW 264.7 cells were treated with medium (control), unmodified cSCKs 
and 15%-His-cSCKs (5 µg/mL) for 24 h.  The supernatants were then collected and 
centrifuged for 10 min at 13,000 rpm.  Serial dilutions of standards of cytokines were 
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also prepared in the same diluent utilized for the samples (i.e. cell-culture medium).  
Control, standards and nanoparticle-treated samples (50 µL) were incubated with 
antibody-conjugated magnetic beads for 30 min in the dark.  After washing, the 
detection antibody was added to the wells and incubated in the dark for 30 min under 
continuous shaking (300 rpm).  After washing, streptavidin-phycoerythrin was added to 
every well and incubated while protected from light for 10 min under the same shaking 
conditions.  Finally, after several washings and re-suspension in the assay buffer and 
shaking, the expression of the mouse cytokines, interleukin (IL)-1, IL-1β, IL-2, IL-3, 
IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (P40), IL-12 (P70), IL-13, IL-17, Eotaxin, 
Granulocyte-colony-stimulating factor (G-CSF), granulocyte macrophage-colony-
stimulating factor (GM-CSF), Interferon- (IFN-), keratinocyte-derived chemokine 
(KC), monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein 
(MIP)-1, MIP-1β, regulated upon activation normal T-cell expressed and presumably 
secreted (RANTES) and tumor necrosis factor-α (TNF-α) was measured immediately 
using Bio-plex 200 system with HTF and Pro II Wash station (Bio-Rad Laboratories, 
Inc., Hercules, CA) and the data were analyzed using the Bio-plex Data Pro software. 
Gel shift assay 
Agarose gels (1%) were prepared in Tris-acetate-EDTA buffer (Bio-Rad 
Laboratories, Inc., Hercules, CA).  The siRNA (5'-Cy3-(sense strand)-
GGCCACAUCGGAUUUCACU, Mw = 13814 g/mol, Dharmacon, Chicago, IL), either 
free or complexed to the various nanoparticle formulations at nitrogen (total 
concentrations of the primary amines and histamines)-to-phosphate (N/P) ratios ranging 
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from 0.25-to-6 (1.3 µg siRNA/25 µL/well), were mixed with glycerol (20% v/v) prior to 
the electrophoresis.  Gel electrophoresis was carried out using a horizontal apparatus at 
100 V for 30 min and fluorescence imaging of the separated siRNA bands was 
performed using a ChemiDoc XRS (Bio-Rad Laboratories, Inc.). 
Death-siRNA transfection assays 
RAW 264.7 mouse macrophages (2 x 104 cells/well) and human ovarian 
adenocarcinoma cells (OVCAR-3) (5 x 103 cells/well) were plated in a 96-well plate in 
DMEM and RPMI-1640 medium (10% and 20% fetal bovine serum, for the RAW 264.7 
and OVCAR-3, respectively and 1% penicillin/streptomycin).  Cells were incubated at 
37 C in a humidified atmosphere containing 5% CO2 for 24 h to adhere.  Then, the 
medium was replaced with a fresh medium 1-h prior to the addition of the siRNA-loaded 
cSCKs (100 nM final concentrations of AllStars death- or negative control-siRNA 
(Qiagen, Valencia, CA)) at N/P ratio of 5, unless otherwise indicated.  The cells were 
incubated with the various formulations for 24 h and washed extensively with PBS and 
the cell viability was measured 24 h later by measuring the relative cell viability of the 
cells treated with death-siRNA to the negative control-loaded cSCKs.  The cell 
viabilities were measured as described in the cytotoxicity section.  The Lipofectamine-
siRNA complexes were prepared according to the manufacturer instructions and the 
transfection efficiency was measured following the same procedures of the siRNA-
cSCKs complexes.  The effect of endosomal acidification on transfection efficiency was 
studied by incubating cells with 200 nM bafilomycin A1 (Sigma-Aldrich, St. Louis, 
MO) 30-min prior to the transfection and by adding the same concentration of 
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bafilomycin to the transfection medium.  The toxicity of siRNA complexes could be also 
measured by comparing the cell viability of the cells treated with the negative control-
siRNA complexes to that of the control-untreated cells. 
Laser scanning confocal microscopy (LSCM) 
RAW 264.7 mouse macrophages (1 x 105 cells/well) were plated in glass-bottom 
six-well plate (MatTek Co., Ashland, MA) in DMEM medium.  Cells were incubated at 
37 C in a humidified atmosphere containing 5% CO2 for 24 h to adhere.  Then, the 
medium was replaced with a fresh media 1-h prior to the addition of siRNA-loaded 
cSCKs or Lipofectamine (100 nM final concentration of the 5'-Cy3-siRNA).  The cells 
were incubated with the formulations for 3 h and washed extensively with PBS.  Then, 
DRAQ-5 (Biostatus Ltd., Shepshed, Leicestershire, UK) was utilized to stain the nucleus 
(30 min incubation, followed by extensive washing with PBS).  Cells were then fixed 
with 1% formaldehyde for 20 min, washed once with PBS.  The cells were then stored in 
1 mL PBS in the refrigerator and analyzed by laser scanning confocal microscopy (LSM 
510, Zeiss, Jena, Germany).  The images were collected under the same conditions (laser 
power, detector gain, etc.) for consistency, and λexcitation of 543 and 633 nm were utilized 
for the Cy3 and DRAQ-5, respectively. 
Statistical analysis 
Values are presented as mean ± SD of at least three independent experiments.  
Significance of the differences between two groups was evaluated by Student’s t test 
(unpaired) or between more than two groups by one-way ANOVA followed by Tukey’s 
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multiple comparison tests.  Differences between different groups were considered 
significant for p values less than 0.05. 
4.3 Results and Discussion 
Synthesis of polymers 
A library of cationic micelles (8-11) and shell crosslinked nanoparticles (cSCKs, 
12-14) was prepared from amphiphilic block copolymers (4-7) in a stepwise process, 
each of which was self-assembled into micelles followed by chemical crosslinking as 
illustrated in Figures 4.1 and 4.2.  Each of the amino- and/or histamine-functionalized 
amphiphilic block copolymers was derived from the same block copolymer precursor 
PAA160-b-PS30, which was prepared by a two-step ATRP process of tBA and styrene, 
followed by deprotection (S1-S3).  Chemical modification reactions onto the PAA 
backbone and selective acidolysis then introduced the amino and histamine side chain 
groups.  The acrylic acid repeat units were converted to acrylamides, each carrying a 
protected amino group (0%-His), imidazole (100%-His) or mixture of both at various 
ratios (85:15 (15%-His) and 50:50 (50%-His)), by using an excess of N-Boc ethylene 
diamine and/or histamine in the presence of HOBT, HBTU and DIPEA in DMF, 
yielding polymers 1, 2, 3 and 4.  In the final step, the Boc protecting groups were 
removed by direct dissolution of 1, 2 and 3 in TFA overnight, followed by removal of 
the TFA under a N2 stream, to obtain the block copolymers 5, 6 and 7.   
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Figure 4.1.  Schematic representation of incorporation of various amounts of primary amines and 
histamines onto a segment of an amphiphilic block copolymer backbone by a sequential two-step process 
of amidation followed by deprotection.  
 
 
 
  
 
Figure 4.2.  Self assembly of polymers with various amounts of primary amines and histamines (4-7) into 
micelles (8-11) followed by crosslinking selectively in the hydrophilic shell regions of (8-10) to obtain 
cSCKs (12-14).   
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Preparation and characterization of cSCKs 
cSCKs were prepared by the solution-state assembly of amphiphilic block 
copolymers in water followed by crosslinking selectively throughout the hydrophilic 
shell layer (Fig. 4.2).  Self assembly was induced by the direct dissolution of the 
amphiphilic block copolymer (5, 6, 7, and 4) at 1 mg mL-1 in molecular biology grade 
water to yield micelles 8, 9, 10 and 11, respectively (0%-His-, 15%-His-, 50%-His- and 
100%-His-micelles, respectively)(S4-S7).  The series of cSCKs 12, 13 and 14 (0%-His-, 
15%-His-, and 50%-His-cSCKs, respectively) was obtained by crosslinking 
approximately 5% of the amino groups along the hydrophilic segments of 8-10 by 
amidation with activated carboxylic acids (activated using 2.2 equiv. of both HOBT and 
HBTU relative to the COOH groups in the crosslinker in DMF) of the diacid crosslinker 
(4,15-dioxo-8,11-dioxa-5,14-diazaoctadecane-1,18-dioic acid) at pH ca. 8 (adjusted 
using 1.0 M Na2CO3 (aq.)).  The crosslinking reaction was allowed to proceed overnight, 
followed by extensive dialysis (MWCO 6-8 kDa) to remove the unreacted small 
molecule starting materials and reaction by-products.  The 100%-His-micelles did not 
have any crosslinking sites due to the complete incorporation of histamine groups onto 
the polymer backbone and, hence, were not converted to the corresponding cSCKs; 
further studies were continued with the micellar form.   
To understand the physicochemical properties of the cationic micelles and 
cSCKs, their sizes and zeta-potential values were determined.  Dynamic light scattering 
(DLS) analysis showed that the hydrodynamic diameters of the micelles and cSCKs 
decreased slightly with increasing amounts of histamines incorporated.  The number-
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averaged diameters of the nanoparticles were less than 20 nm in all cases (Fig. 4.3).  It 
was difficult to obtain high quality TEM images for all of the samples, but for those that 
gave adequate images, the core diameters were measured to be ca. 10 nm, consistent 
with the hydrodynamic DLS-measured overall diameter values (Fig. S2).  Zeta potential 
values of the micelles and cSCKs, each in nanopure water at pH 5.5 were determined 
initially, and found to be positive for 8-10 and 12-14, but negative for 11 having only 
histamines and no primary amino groups.  Given the pKa of histamine groups, typically 
6-6.5, the observation of a negative zeta potential at pH 5.5 was hypothesized to be due 
to the use of nanopure water without high salt content and/or the presence of only 
histamine groups and, therefore, was then followed by a full study of each of the 
micellar solutions 8-11 at pH 5.0, 6.0 and 7.4 (PBS buffer, 10 mM NaCl).  As the 
micelles 11 (100%-His) did not have any primary amines in the polymer backbone for 
crosslinking reaction, this study of zeta potential measurements at different pHs was 
performed only for the micellar solutions.  As expected, at pH 7.4, all of the samples 
were found to be positively charged except the 100%-His-micelles, which were 
negatively charged (Figure 4.4 A).  Generally, zeta-potential values were found to 
increase with the decrease in pH, which indicates higher protonation of polymers at 
acidic pH, corresponding to the endosomal environment.  Additionally, nanoparticles 
with the highest amount of histamine content showed the least zeta potential values at all 
pHs, and were confirmed to be positively-charged at and below pH 6.0.  At pH 7.4, the 
50% His-micelles were insoluble and 100% His-micelles exhibited low zeta-potential 
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values, whereas the 15%-His-micelles demonstrated similar behavior to the unmodified 
cSCKs. 
To determine the buffering capacities of each type of cationic nanostructures, 
potentiometric titration studies were conducted over a pH range of 12 to 2, with focus 
over the range of 7.4 to 5.1 of relevance to extracellular to endosomal/lysosomal 
transitions (Figure 4.4 B).  The nanoparticles were dissolved in NaOH(aq) and titrated by 
gradual addition of HCl.  The particles were found to require increasing amounts of HCl 
to change the pH from 7.4 to 5.1 (17 µmol to 41 µmol) with increasing histamine 
content (12 to 14 to 11, respectively).  cSCK nanoparticles with 0% histamines (12) 
required the least amount (1.7 mL) of HCl to change pH from 7.4 to 5.1, while micellar 
nanoparticles with the highest histamine content (100% His, 11) needed the highest 
amount (4.1 mL) of HCl to induce the same change.  In general, increasing histamine 
content directly correlated with the amount of acid needed, demonstrating the increased 
buffering capacities of nanoparticles with greater histamine content.  In comparison to 
PEI, which contains combinations of primary, secondary and tertiary amines, the 
primary amino-containing cSCKs, 12, and the cSCKs with few histamines, 13, gave 
lower buffering capacity, whereas each of the cSCK and micelles with 50% and 100% 
histamines gave higher buffering capacities.  Nanoparticles with higher buffering 
capacity are expected to buffer the endosomes to a greater extent and, hence, result in 
higher endosomal disruption.128,133,134 
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Figure 4.3.  DLS histograms from measurements of nanoparticles with various amounts of primary 
amines and histamines:  (A) 0%-His-cSCK (12), (B) 15%-His-cSCK (13), (C) 50%-His-cSCK (14) and 
(D) 100%-His-micelles (11). 
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Figure 4.4  (A) Zeta-potential measurements of micelles 8-11 with increasing histamine content, each at 
pH 5.0, 6.0 and 7.4.  (B) Relative buffering capacity of cSCK nanoparticles 12-14 and micelles 11 
containing various amounts of histamine obtained from potentiometric titration experiments, and 
comparison with PEI.  Each bar represents the amount of HCl (in mL) needed to change the pH of the 
nanoparticle solutions from pH 7.4 to 5.1.   
 
 
 
Toxicity and immunogenicity of cSCKs 
The cytotoxicity of nanoparticles containing various amounts of histamine and 
primary amine groups was evaluated in RAW 264.7 mouse macrophages, and compared 
to Lipofectamine (Table 4.1).  Increasing the histamine contents significantly increased 
the IC50 values of the nanoparticles from 16.3 µg/mL to 20.7 µg/mL (p < 0.05), for the 
cSCKs with 0% and 15% histamines, 12 and 13, respectively.  The IC50 values could not 
be determined for nanoparticles that contained 50% and 100% histamine at the tested 
concentrations (0-to-100 µg/mL), due to the high cell viability measured over this 
concentration range.  The IC50 value of the tested Lipofectamine was significantly higher 
than the cSCKs of 100% and 85% primary amines (12 and 13, respectively), but the cell 
viabilities were much lower than the cSCK (14) and micelles (11) with lower amine 
contents.  These results reveal that increasing the histamine content reduced the toxicity 
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of the nanoparticles, which is in accordance with previously published data from our 
group showing that reducing the amount of primary amines per polymer (by 
incorporating tertiary amines or carboxylic acids into the polymer structure), reduces the 
toxicity of the nanoparticles.7,83  With the higher cytotoxicities observed for the cSCKs 
having low histamine content, and because the nanoparticles with histamine content 
greater than 15% demonstrated low cellular uptake and transfection efficiency (vide 
infra), we decided to compare the immunotoxicities of the unmodified- and 15%-His-
modified cSCKs.  
 
 
 
Table 4.1  The cytotoxicity of Lipofectamine, cSCKs and micelles of various 
compositions (i.e. primary amine and histamine contents). 
 
Formulation IC50 (µg/mL) ± SD Significance (p < 0.05) 
Lipofectamine 31.4 ± 5.9 Lipofectamine has significantly higher IC50 
than 0%-His- and 15%-His-cSCKs 
0%-His-cSCKs 16.3 ± 3.2  
15%-His-cSCKs 20.7 ± 0.1 15%-His-cSCKs have significantly higher 
IC50 than 0%-His-cSCKs 
50%-His-cSCKs ----------  
100%-His-micelles ----------  
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The release of cytokines from cells treated with nanomaterials is usually utilized 
as an indication of possible immunotoxicity of nanoparticles and their 
immunomodulatory effects 143-146.  The structure and composition of nanoparticles can 
greatly impact their ability to interact with the various components of the immune 
system, where unintentional immunomodulation can be serious and cause severe adverse 
reactions and complications 147-149.  Cationic liposomes, for instance, are known to 
induce the secretion of proinflammatory cytokines (e.g. TNF-α, IFN- and IL-12) 148.  
Inorganic anionic zinc oxide nanoparticles also stimulated the release of IL-6 and TNF-α 
cytokines from dendritic cells treated with the nanoparticles 149. 
The immunotoxicities of the 0%- and 15%-His-cSCKs were studied by 
measuring the levels of 23 cytokines upon treatment of RAW 264.7 mouse macrophages 
with the nanoparticles for 24 h (Figure 4.5).  Generally, lower secretion of the cytokines 
was observed from cells treated with the histamine-modified cSCKs, 13, as compared to 
the cSCKs with 100% primary amines, 12.  A similar trend was observed for most of the 
tested cytokines, which indicate the potential immunotoxicity of the 0%-His-cSCKs as 
compared to the histamine modified ones.  The differences between the levels of the 
secreted cytokines were significant for 12 cytokines, IL-3, IL-6, IL-9, IL-10, IL-12(p40), 
IL-13, Eotaxin, RANTES, MCP-1, MIP-1β, KC and TNF-α (Figure 4.5).  The 
incorporation of histamine into the polymer precursor significantly reduced the toxicity 
of the nanoparticles and their ability to stimulate the cells and induce the secretions of 
cytokines, which might be due to the lower charge density, cell-binding affinity and 
cellular uptake, as will be discussed in the next sections. 
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Figure 4.5.  The expression of IL-3, IL-6, IL-9, IL-10, IL-12(p40), IL-13, Eotaxin, RANTES, MCP-1, 
MIP-1β, KC and TNF-α were particularly enhanced upon the treatment of Raw 264.7 mouse macrophages 
with the unmodified-cSCKs (0%-His-cSCKs) for 24 h, as compared to the 15%-His-cSCKs and the 
control-untreated cells. 
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Figure 4.5 continued 
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Nanocomplexes of siRNA-cSCKs for efficient gene-silencing 
The binding affinity of Cy3-labeled siRNA to the micelle and cSCK 
nanoparticles of various compositions was studied using agarose gel electrophoresis 
(Fig. 4.6).  Only the cSCKs with 0%- and 15%-histamine contents were able to 
efficiently bind siRNA at N/P ratios of 2 and 4, respectively.  The incorporation of 
histamine reduced the binding affinity of cSCKs and micelles to the siRNA.  In a 
previous study, the reduction of primary amine contents of cSCKs was also correlated 
with a reduced binding affinity to nucleic acids (plasmid DNA).83  Increasing the 
histamine contents reduces the amount of protonated primary amines available to 
electrostatically interact with the negatively-charged siRNA, and hence decreases the 
siRNA-binding affinity.  The cellular uptake and transfection experiments were then 
performed at N/P ratio of 5 to ensure the complete siRNA-binding for both kinds of 
nanoparticles, 12 and 13. 
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Figure 4.6  Gel-shift assay of Cy3-labeled siRNA, either naked (N/P = 0) or complexed to micelles or 
cSCKs of various composition at increasing N/P ratios from 0.25-to-6.  Complete binding is observed at 
N/P ratios of 2 and 4, for 0% and 15% histamine-modified cSCKs, whereas no binding was observed for 
cSCKs and micelles that contain 50% and 100% histamine-modified shells, respectively. 
 
 
 
The cellular uptake and transfection efficiency of cSCKs and Lipofectamine 
were studied using laser scanning confocal microscopy and siRNA-cell death assay 
using RAW 264.7 mouse macrophages and OVCAR-3 cancer cells (Figure 4.7 and 4.8).  
The siRNA-cell death assay was performed by measuring the relative viabilities of cells 
treated with nanoparticles-loaded with siRNA that induces cell death versus the cells-
treated with the same nanoparticles but loaded with a negative control siRNA.  No 
cellular uptake or transfection efficiency was observed in cells treated with the 50%-His-
cSCKs and 100%-His-micelles.  Higher cellular uptake was observed for the cells 
treated with the 0%-His-cSCKs than the cells treated with the 15%-His-cSCKs and 
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Lipofectamine as indicated by the confocal microscopy images (Fig. 4.7), probably due 
to the higher binding affinity of the nanoparticles that are fully functionalized with 
primary amines to the cell membrane as compared to the other nanoparticles.  However, 
the transfection efficiency of the 15%-histamine-modified cSCKs and the Lipofectamine 
was higher than the 0%-His-cSCKs.  The incorporation of histamine increased the 
buffering capacities of the nanoparticles, as shown by the potentiometric titration 
experiments (Fig. 4.4B), which is expected to have facilitated greater endosomal release 
of siRNA/nanoparticles into the cytoplasm and thus resulted in higher intracellular 
bioavailability.  The cellular uptake is not always correlated with transfection efficiency 
as it does not measure the ability of nanoparticles to reach their target sites into the 
cytoplasm/nucleus and additionally, does not differentiate between drug molecules that 
are being delivered into the cytoplasm or entrapped within endosomes/lysosomes.  
Elsabahy et al. 135 have observed higher transfection efficacy and Bcl-2 protein 
knockdown from antibody fragment-targeted poly(amidoamine)-based polyion complex 
micelles loaded with Bcl-2 siRNA than the corresponding non-targeted 
poly(amidoamine)/siRNA complexes, although the latter showed higher cellular uptake 
as measured by flow cytometric analysis and shown by confocal microscopy images. 
The effect of N/P ratio on the transfection efficiency was also measured using the 
same siRNA-cell death assay and showed a slight increase in transfection efficiency of 
the cSCKs by increasing the N/P ratio from 5 to 10 (Fig. 4.8B).  However, no observable 
transfection was observed for the 50%-His-cSCKs at both N/P ratios.  No toxicities were 
observed for the siRNA/cSCKs complexes at both N/P ratios (Fig. 4.8C).  The role of 
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endosomal acidification on the transfection of cSCKs was investigated by measuring the 
effect of bafilomycin A1 (an inhibitor of endosomal acidification) (Fig. 4.9) 134.  The 
pre-incubation of cells with bafilomycin had a slight effect on the transfection of 
Lipofectamine and 0%-His-cSCKs, but completely inhibited the transfection of the 15%-
His-cSCKs.  The non-acidified endosomes partially prevent the protonation of the 
histamine functionalities, which reduced their ability to destabilize the endosomes and to 
release a considerable amount of siRNA into the cytoplasm 135,150,151. 
 
 
 
 
 
Figure 4.7.  Laser scanning confocal microscopy analysis of the control-untreated RAW 264.7 mouse 
macrophages (A), cells treated with Cy3-siRNA (100 nM) complexed with Lipofectamine (B), 0%-His- 
(C), 15%-His- (D), 50%-His- (E) and 100%-His-nanoparticles (F) at N/P ratio of 5.  Two (left panel) and 
three (right panel)-dimensional images were collected for the cells (A-D), while only two-dimensional 
images were collected for E and F.  On the two-dimensional images, the nucleus were stained with 
DRAQ5 nuclear stain (blue panel), whereas Cy3-labeled siRNA appears in red.  The transmitted light-
images and merged images are also indicated. 
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A) 
 
B) 
 
C) 
 
 
Figure 4.8.  Transfection efficiency of death-siRNA complexed with Lipofectamine or cSCKs of varying 
primary amine and histamine ratios into OVCAR-3 cells and RAW 264.7 mouse macrophages at N/P 
ratios of 5 and 10.  (A) The transfection of the death-siRNA/cSCK complexes in the two different cell 
lines at a N/P ratio of 5.  (B) The effect of N/P ratio on the transfection efficiency in the OVCAR-3 cells, 
determined by comparison of death-siRNA/cSCKs vs. negative control-siRNA/cSCKs. (C) The effect of 
N/P ratio on the cytotoxicity of cSCKs in OVCAR-3 cells, determine by comparison of negative control-
siRNA/cSCKs vs. control, untreated cell assays.  
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Figure 4.9.  Transfection efficiency of death-siRNA (100 nM) complexed with Lipofectamine or cSCKs 
of varying compositions into OVCAR-3 cells, with and without pre-treatment with bafilomycin A1 (BA, 
200 nM for 30 min before the transfection and continued during the transfection). 
 
 
 
4.4 Conclusions 
In this study, a library of block copolymer micelles and cSCKs has been created 
with different percentages of primary amines and histamines incorporated into the 
nanoparticle shells.  The 50% and 100%-histamine-modified nanoparticles induced 
lower cytotoxicity as compared to Lipofectamine, whereas the cSCKs with 85% and 
100% primary amines (15% and 0% histamines) were more toxic than Lipofectamine.  
Treatment of mouse macrophages with the unmodified cSCKs resulted in the secretion 
of large amounts of several cytokines, as compared to the control-untreated cells and the 
cells-treated with histamine-modified nanoparticles.  Increasing the amount of 
histamines increased the buffering capacities of the nanoparticles at the expense of the 
siRNA-binding affinity, due to the reduced contents of primary amines.  Intermediate 
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primary amine and histamine levels resulted in higher intracellular concentrations of the 
complexed siRNA and higher gene silencing activity.  Histamine incorporation of 15% 
appeared to be a threshold for the series of samples tested, with cSCKs having higher 
histamine contents completely lost the ability to bind siRNA and to interact with cell 
membrane and induce gene silencing.  These nanoparticles are among the initial steps 
involved in the development of cSCKs for effective delivery of nucleic acids for clinical 
applications.  However, a further probing of histamine contents between 15% and 50% 
may better identify the optimum balance of siRNA binding, cellular uptake and 
buffering capacity.  Expansion of the chemical compositional heterogeneity and 
synthesis of degradable analogs of these cSCKs is currently underway for extended in 
vitro and in vivo studies toward development of novel polymeric materials for nucleic 
acids delivery. 
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4.6 Supporting Information 
Synthesis of poly(tert-butyl acrylate)160 (PtBA160) (S1) 
Bulk polymerization of tert-butyl acrylate by atom transfer radical 
polymerization:  To a flame-dried 100 mL Schlenk flask, tert-butyl acrylate (56.6 g, 44.2 
mmol) was added along with copper (I) bromide (0.41 g, 2.9 mmol). The reaction 
mixture was sealed and three freeze pump thaw cycles were performed with N2 
backfilling.  N,N,N’,N’,N’’-pentamethyldiethylenetriamine (0.49 g, 2.9 mmol) and 2-
ethylbromo propionate (0.40 g, 2.2 mmol) were added to the reaction mixture via a 
syringe and the reaction mixture was allowed to undergo two more freeze pump cycles.  
The reaction mixture was brought to room temperature and stirred to ensure 
homogeneity.  Following this, the Schlenk flask was immersed into a preheated oil bath 
at 50 °C.  Aliquots were taken at predetermined time interval and conversion was 
monitored via NMR and GPC.  After the expected conversion was reached, the 
polymerization was quenched by immersing the reaction flask into liquid nitrogen.  The 
reaction mixture was passed through a short alumina plug to remove copper and three 
consecutive precipitations were performed in methanol and ice (80:20).  After the final 
precipitation, removal of solvent and subsequent drying in vacuo, a white solid polymer 
was obtained (18.0 g, 50% yield).  (Mn)NMR = 21.2 kDa.  (Mn)GPC = 14.9 kDa.  (Mw)GPC = 
17.7 kDa.  PDI= 1.18.  IR: 3000-2750, 1710, 1500, 1370, 1220, 1150, 880, 810 cm-1.  
1H-NMR (CD2Cl2): δ 1.5 (s, (CH3)3COC-), 1.8, (br, -CHCH2-), 2.2 ((br, -CHCH2-), 4.1 
(CH3CH2OCO-) ppm.  
13C NMR (CD2Cl2): δ: 26.7, 31.6–38.0, 80.2, 174.6 ppm.  DSC: 
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(Tg) = 58 °C.  TGA:  Tonset = 118 °C; Tdecomposition:  [(118-248 °C) 31 % mass loss; (248-
457 °C) 43% mass loss; 26% mass remaining].   
Synthesis of poly(tert-butyl acrylate)160-b-poly(styrene)30 (PtBA160-b-PS30) (S2) 
The block copolymer poly(tert-butyl acrylate)160-b-poly(styrene)30 (PtBA160-b-
PS30) was prepared using atom transfer radical polymerization.  To a flame-dried 25 mL 
Schlenk flask, PtBA160 (8.00 g, 0.37 mmol) was added along with copper (I) bromide 
(108 mg, 0.75 mmol), styrene (1.96 g, 18.9 mmol) and anisole (8.00 g).  The reaction 
mixture was sealed and three freeze pump thaw cycles were performed with N2 
backfilling.  N,N,N’,N’,N’’-pentamethyldiethylenetriamine (130 mg, 0.75 mmol) was 
added to the reaction mixture via a syringe and the reaction mixture was treated by two 
more freeze pump thaw cycles.  The reaction mixture was brought to room temperature 
and stirred to ensure homogeneity.  Following this, the Schlenk flask was immersed into 
a preheated oil bath at 82 °C.  Aliquots were taken at predetermined time intervals and 
conversions were monitored via 1H-NMR spectroscopy and GPC.  After the expected 
conversion was reached, the polymerization was quenched by immersing the reaction 
flask into liquid nitrogen.  The reaction mixture was passed through a short alumina plug 
to remove copper and three consecutive precipitations were performed in methanol and 
ice (80:20).  After the final precipitation, removal of solvent and subsequent drying in 
vacuo, a white powder was obtained (6.08 g, 97% yield).  (Mn)NMR = 24.4 kDa.  (Mn)GPC 
= 23.4 kDa.  (Mw)GPC = 25.9 kDa.  PDI= 1.11.  IR: 3200-3050, 3000-2750, 1730, 1460, 
1380, 1280, 1150, 870, 770 cm-1.  1H-NMR (CD2Cl2): δ 1.5 (s, (CH3)3COC-), 1.8, (br, -
CHCH2-), 2.2 ((br, -CHCH2-), 4.1 (CH3CH2OCO-), 6.2-7.3 (br, ArH) ppm.  
13C NMR 
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(CD2Cl2): δ: 26.7, 31.6–38.0, 80.2, 126.4–128.1, 174.6 ppm.  DSC: (Tg)PtBA = 51 °C; 
(Tg)PS = not observed.  TGA:  Tonset = 136 °C; Tdecomposition:  [(136-245 °C) 36 % mass 
loss; (245-464 °C) 43% mass loss; 21% mass remaining].   
Synthesis of poly(acrylic acid)160-b-poly(styrene)30 (PAA160-b-PS30) (S3) 
Block copolymer S2 (2.1 g, 0.09 mmol) was dissolved in trifluoroacetic acid (70 
g, 0.6 mol) and stirred at room temperature for 16 h.  The next day, TFA was evaporated 
under a N2 stream, and the polymer was dissolved in THF and transferred to presoaked 
dialysis tubing (MWCO 6-8000 Da).  The mixture was extensively dialyzed for 4 days 
against nanopure water followed by lyophilization to obtain white fluffy polymer of 
PAA164-b-PS31 (1.0 g, yield = 78%).  (Mn)NMR = 15.2 kDa.  IR: 3700-2400, 1720, 1488, 
1280, 1205, 860 cm-1.  1H-NMR (DMSO-d6) δ: 1.0-2.0 (br, polymer backbone), 2.2 (br, -
CHCH2-), 4.1 (CH3CH2OCO-), 6.2 - 7.3 (br, ArH), 12.2 (br, COOH) ppm.  
13C NMR 
(DMSO-d6) δ: 31.6–38.0, 126.4–128.1, 175.6 ppm.  DSC: (Tg)PAA = 127 °C; (Tg)PS = not 
observed.  TGA:  Tonset = 154 °C; Tdecomposition:  [(154-289 °C) 6 % mass loss; (289-482 
°C) 40% mass loss; 40% mass remaining].   
Characterization of micelles of PAEA160-b-PS30 (S4) 
(Dh)num (DLS) = 28 ± 5 nm; (Dh)vol (DLS) = 36 ± 23 nm; (Dh)int (DLS) = 170 ± 
150 nm.  Zeta potential = 47 ± 5 mV (in nanopure water pH 5.5). 
Characterization of micelles of (PAEA0.85-g-PAEI0.15)160-b-PS30 (S5) 
(Dh)num (DLS) = 14 ± 4 nm; (Dh)vol (DLS) = 21 ± 4 nm; (Dh)int (DLS) = 150 ± 
160 nm.  Zeta potential = 57 ± 2 mV (in nanopure water pH 5.5). 
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Characterization of micelles of (PAEA0.50-g-PAEI0.50)160-b-PS30 (S6) 
(Dh)num (DLS) = 11 ± 3 nm; (Dh)vol (DLS) = 16 ± 12 nm; (Dh)int (DLS) = 160 ± 
170 nm.  Zeta potential = 38 ± 1 mV (in nanopure water pH 5.5). 
Characterization of micelles of PAEI160-b-PS30 (S7) 
(Dh)num (DLS) = 11 ± 3 nm; (Dh)vol (DLS) = 17 ± 11 nm; (Dh)int (DLS) = 100 ± 
100 nm.  Zeta potential = -34 ± 2 mV (in nanopure water pH 5.5).   
 
 
 
 
Figure 4.10.  GPC of PtBA160-b-PS30 (S2) and P(AEA-Boc)160-b-PS30 (1).  
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Figure 4.11.  TEM micrograph of cSCKs (12) composed of PAEA160-b-PS30.   
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CHAPTER V 
HIERARCHICALLY-ASSEMBLED THERANOSTIC NANOSTRUCTURES FOR 
SIRNA DELIVERY AND IMAGING APPLICATION 
 
5.1 Introduction 
Construction of sophisticated three-dimensional multifunctional nanostructures, 
such as viruses, in Nature by sequential hierarchical assembly of simpler lower order 
building blocks (i.e., amino acids to proteins to viral capsid assembly) provides broad 
inspiration,2,3,152 and has prompted us to expand our synthetic methodology for the 
preparation of nanoscopic discrete objects from molecular polymerization and 
macromolecular assembly to the next level of complexity, involving the hierarchical 
assembly of nanoscopic building blocks.  From a fundamental perspective, the 
development of strategies by which to construct unique objects in the laboratory setting 
from nanoscopic materials is of interest to explore advantages of their compositions, 
structures, overall shapes, and internal morphologies on their biological interactions and 
properties.  Ultimately, multiple levels and types of functional performance may be 
incorporated.  With recent advances in nanotechnologies, there is a high level of 
attention being directed toward the creation of polymeric nanodevices that can bring 
together multiple components, for instance to achieve coincident therapy and diagnosis 
in nanomedicine applications.   
Several nanomedical devices incorporate multiple functions within a single 
entity, where optimization for the integration of various functionalities into nanoparticles 
plays a critical role in their performance and biological behavior in vivo.  Current 
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methods for introduction of multi-functionalities involve manipulation of polymers that 
are the building blocks of the nanoparticles, which can be iterative and inefficient, as 
entirely new block copolymers must be synthesized to alter the composition of merely 
one element contributing to the multi-functionality.  Recently, the combination of 
multiple functions through several individual nanoscopic devices is receiving increased 
attention, due to the potential for simplification and individualized optimization.  As an 
example, Bhatia et al. recently reported the employment of two different nanoparticles in 
tandem, with each performing a different function to achieve increased drug delivery for 
the treatment of breast cancer.  Firstly, a gold nanorod ‘scout’ nanoparticle was 
administered - to accumulate at the tumor site and initiate a clotting cascade after being 
heated by infrared light irradiation.  The clotting process produced additional signals for 
attracting a second type of nanoparticle loaded with doxorubicin, which led to a 40-fold 
increase in the amount of drug delivered into the tumor, relative to control studies.153  
Such ‘division of labor’ allows versatility of each of the nanoparticles to be adjusted for 
their individual performance for a mutually enhanced function and behavior in vivo.   
In our continued interest to explore nanoscopic objects designed for various 
biomedical applications, shell crosslinked knedel-like nanoparticles (SCKs) with tunable 
size, shape and morphology have been extensively investigated.9,14,16,17,20,31,72,85,138,154  
These SCKs consist of a hydrophobic core and a hydrophilic shell domain, the latter of 
which can be modified to carry radionuclides, poly(ethylene glycol)s (PEGs), targeting 
moieties, fluorophore labels, and various payloads to serve as vehicles for combinational 
therapies.  Herein, we have adopted an intermediate approach to bring together 
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individual components with unique properties by hierarchical assembly of the 
independent units.  Hierarchical assembly of two different modules, one loaded with 
therapeutic cargo and the other with sites to carry imaging agents, was achieved by 
templating cationic SCKs (cSCKs) that can electrostatically bind negatively-charged 
siRNA, onto anionic shell crosslinked rods (SCRs), the core of which provides sites for 
radiolabeling.  These hierarchically hierarchically-assembled theranostic (HAT) 
nanostructures hold great potential as a platform that allows for merging individual 
components with independent domains for carrying payloads and radiolabels, optimized 
as agents for combined therapy and diagnosis.  Our initial focus is on the construction of 
multifunctional nanomaterials that present surface chemistries for transport of nucleic 
acids as therapeutic cargo into cells, while also possessing an overall shape that provides 
for long in vivo lifetimes.  In our laboratory, these have included spherical cSCKs, which 
have been shown to package negatively-charged nucleic acids via electrostatic 
interactions, protect them from enzymatic degradation and deliver them into cellular 
target sites.36,84   
However, many reports of the effects of nanoparticle structure on in vivo 
pharmacokinetics have shown that high aspect ratio nanoparticles provide for extended 
blood circulation lifetimes,155,156 while the cell internalization kinetics are dependent on 
the size, shape and also surface chemistry.159,160  Although those studies have focused on 
negatively-charged or neutral materials, examples of cylindrical or rod-shaped 
nanomaterials having cationic surface characteristics have been produced by 
engineering161 or block copolymer crystallization-driven162 supramolecular assembly 
 116 
 
approaches.  We have demonstrated that the cSCK property of cell transfection can be 
transferred onto nanocylinders upon co-assembly, and111 therefore, in our effort to 
extend those initial studies to fully functional high aspect ratio nanostructures capable of 
nucleic acids delivery with radiolabel tracking, we have explored as an alternative 
approach, hierarchical supramolecular assemblies of cSCKs, produced together with 
negatively-charged shell crosslinked rods (SCRs), which have sites for radiolabeling in 
the core.   
5.2 Materials and Methods 
Polymerizations were performed on a double manifold with glassware and 
syringes that were dried in an oven (100 °C) for at least 1 h, and with syringes that were 
washed with N2 (3 ×), prior to use.  tert-Butyl acrylate (t-BA, 99%, Aldrich), styrene 
(99%, Aldrich), toluene (anhydrous, 99.8%, Aldrich), N,N,N′,N″,N″-
pentamethyldiethylenetriamine (PMDETA, 99% Aldrich),  copper (I) bromide (CuBr, 
99.99%, Aldrich), ethyl 2-bromopropionate (99%, Aldrich), trifluoroacetic acid (TFA, 
95%; Aldrich), 1-(3′-dimethylaminopropyl)-3-ethylcarbodiimide methiodide (EDCI, 
98%, Aldrich), hydroxybenzotriazole (HOBT, Aldrich), 2–(1H–benzotriazol–1–yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, Aldrich), N,N-
diisopropylethylamine (DIPEA, 99.5%, Aldrich).  The amphiphilic block copolymer of 
poly(acrylic acid)160-block-polystyrene30 (PAA160-b-PS30) was prepared using atom 
transfer radical polymerization (ATRP) of protected monomer precursors followed by 
deprotection, according to previously reported methods 142.  All other reagents were 
obtained from Sigma-Aldrich and used as received.  Spectra/Por membrane tubes were 
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purchased from Spectrum Medical Industries, Inc. (Waltham, MA), and were used for 
dialysis.  Nanopure water (18 MΩ•cm) was acquired by means of a Barnstead Nanopure 
ultrapure water purification system (Thermo Scientific, Asheville, NC). 
1H NMR and 13C NMR spectra were recorded on an Inova 300 or Mercury 300 
MHz interfaced to a UNIX computer using VnmrJ software.  Samples were prepared as 
solutions in CDCl3, CD2Cl2, or DMF-d7 and solvent protons were used as internal 
standard.  Gel permeation chromatography (GPC) was conducted on a system equipped 
with a Waters Chromatography, Inc. (Milford, MA) model 1515 isocratic pump and a 
model 2414 differential refractometer with a three-column set of Polymer Laboratories, 
Inc. (Amherst, MA) Styragel columns (PLgel 5µm Mixed C, 500 Å, and 10
4 Å, 300 x 7.5 
mm columns) and a guard column (PLgel 5µm, 50 x 7.5 mm).  The system was 
equilibrated at 40 °C in tetrahydrofuran (THF), which served as the polymer solvent and 
eluent (flow rate set to 1.00 mL min-1).  The differential refractometer was calibrated 
with Polymer Laboratories, Inc. polystyrene standards (300 to 467,000 Da).  Polymer 
solutions were prepared at a concentration of ca. 3 mg/mL with 0.05% (v/v) toluene as 
flow rate marker and an injection volume of 200 μL was used.  Data were analyzed 
using Empower Pro software from Waters Chromatography Inc.  IR spectra were 
recorded on an IR Prestige 21 system (Shimadzu Corp., Japan).  A small amount of 
sample was placed to cover the ATR crystal for IR measurements.  Data were analyzed 
using IRsolution software.  Thermogravimetric analysis was performed under N2 
atmosphere using a Mettler Toledo model TGA/DSC1 with a heating rate of 10 °C min-1.  
Measurements were analyzed using Mettler Toledo STARe software v.10.00.   
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Samples for TEM were prepared by depositing 5 μL of sample to glow 
discharged carbon coated copper grids.  Excess sample was wicked off using filter paper 
and the grids were allowed to dry in air for 1 min.  The grids were then stained with 5 μL 
of 2% uranyl acetate and excess stain was wicked off using filter paper.  Specimens were 
observed on a JEOL 1200EX transmission electron microscope operating at 100 kV and 
micrographs were recorded at calibrated magnifications using an SIA-15C CCD camera. 
The final pixel size was 0.42 nm/pixel.  The number-average particle diameters (Dav) and 
standard deviations were generated from the analysis of particles from at least two 
different micrographs (n = 100).  Dynamic light scattering (DLS) measurements were 
conducted using Delsa Nano C from Beckman Coulter, Inc. (Fullerton, CA) equipped 
with a laser diode operating at 658 nm.  Size measurements were made in water (n = 
1.3329,  = 0.890 cP at 25 ± 1 °C; n = 1.3293,  = 0.547 cP at 50 ± 1 °C; n = 1.3255,  
= 0.404 cP at 70 ± 1 °C).  Scattered light was detected at 165° angle and analyzed using 
a log correlator over 70 accumulations for a 0.5 mL of sample in a glass size cell (0.9 
mL capacity).  The photomultiplier aperture and the attenuator were automatically 
adjusted to obtain a photon counting rate of ca. 10 kcps.  The calculations of the particle 
size distribution and distribution averages were performed using CONTIN particle size 
distribution analysis routines.  Prior to analysis, the samples were filtered through a 0.45 
μm Whatman Nylon membrane filter (Whatman Inc., Piscataway, NJ).  The samples in 
the glass size cell were equilibrated at the desired temperature for 5 min before 
measurements were made.  The peak average of histograms from intensity, volume or 
number distributions out of ca. 70 accumulations was reported as the average diameter 
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of the particles.  Absorption measurements were made using a UV-2550 system 
(Shimadzu Corp., Japan) using PMMA cuvettes.  Spectra were analyzed with UV-Probe 
2.33 software. 
Cytotoxicity assays 
RAW 264.7 (2 x 104 cells/well) mouse macrophages were plated in 96-well plate 
in Dulbecco's Modified Eagle Medium (DMEM) (10% fetal bovine serum and 1% 
penicillin/streptomycin).  Cells were incubated at 37 C in a humidified atmosphere 
containing 5% CO2 for 24 h to adhere.  Then, the medium was replaced with a fresh 
medium 1-h prior to the addition of 20 L of the cSCKs and Lipofectamine to 100 L of 
the medium (final concentrations ranged from 0-to-100 µg/mL).  The cells were 
incubated with the formulations for 24 h and washed once with phosphate-buffered 
saline (PBS) and 100 μL of the complete media was added to the cells.  MTS combined 
reagent (20 μL) was added to each well (Cell Titer 96® Aqueous Non-Radioactive Cell 
Proliferation Assay, Promega Co., Madison, WI).  The cells were incubated with the 
reagent for 2 h at 37 C in a humidified atmosphere containing 5% CO2 protected from 
light.  Absorbance was measured at 490 nm using SpectraMax M5 (Molecular Devices 
Co., Sunnyvale, CA).  The cell viability was calculated based on the relative absorbance 
to the control-untreated cells.  The calculation of the IC50 values and the statistical 
analysis were performed using GraphPad Prism four-parameter fit, considering the 0% 
and 100% cell viabilities are for the control medium (no cells) and cells with no 
treatment, respectively. 
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Gel shift assay 
Agarose gels (1%) were prepared in Tris-acetate-EDTA buffer (Bio-Rad 
Laboratories, Inc., Hercules, CA).  The siRNA (5'-Cy3-(sense strand)-
GGCCACAUCGGAUUUCACU, Mw = 13814 g/mol, Dharmacon, Chicago, IL), either 
free or complexed to the various nanoparticle formulations at nitrogen (total 
concentrations of the primary amines and histamines)-to-phosphate (N/P) ratios ranging 
from 0.25-to-6 (1.3 µg siRNA/25 µL/well), were mixed with glycerol (20% v/v) prior to 
the electrophoresis.  Gel electrophoresis was carried out using a horizontal apparatus at 
100 V for 30 min and fluorescence imaging of the separated siRNA bands was 
performed using a ChemiDoc XRS (Bio-Rad Laboratories, Inc.). 
Death-siRNA transfection assays 
RAW 264.7 mouse macrophages (2 x 104 cells/well) and human ovarian 
adenocarcinoma cells (OVCAR-3) (5 x 103 cells/well) were plated in a 96-well plate in 
DMEM and RPMI-1640 medium (10% and 20% fetal bovine serum, for the RAW 264.7 
and OVCAR-3, respectively and 1% penicillin/streptomycin).  Cells were incubated at 
37 C in a humidified atmosphere containing 5% CO2 for 24 h to adhere.  Then, the 
medium was replaced with a fresh medium 1-h prior to the addition of the siRNA-loaded 
cSCKs (100 nM final concentrations of AllStars death- or negative control-siRNA 
(Qiagen, Valencia, CA)) at N/P ratio of 5, unless otherwise indicated.  The cells were 
incubated with the various formulations for 24 h and washed extensively with PBS and 
the cell viability was measured 24 h later by measuring the relative cell viability of the 
cells treated with death-siRNA to the negative control-loaded cSCKs.  The cell 
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viabilities were measured as described in the cytotoxicity section.  The Lipofectamine-
siRNA complexes were prepared according to the manufacturer instructions and the 
transfection efficiency was measured following the same procedures of the siRNA-
cSCKs complexes.  The effect of endosomal acidification on transfection efficiency was 
studied by incubating cells with 200 nM bafilomycin A1 (Sigma-Aldrich, St. Louis, 
MO) 30-min prior to the transfection and by adding the same concentration of 
bafilomycin to the transfection medium.  The toxicity of siRNA complexes could be also 
measured by comparing the cell viability of the cells treated with the negative control-
siRNA complexes to that of the control-untreated cells. 
Laser scanning confocal microscopy (LSCM) 
RAW 264.7 mouse macrophages (1 x 105 cells/well) were plated in glass-bottom 
six-well plate (MatTek Co., Ashland, MA) in DMEM medium.  Cells were incubated at 
37 C in a humidified atmosphere containing 5% CO2 for 24 h to adhere.  Then, the 
medium was replaced with a fresh media 1-h prior to the addition of siRNA-loaded 
cSCKs or Lipofectamine (100 nM final concentration of the 5'-Cy3-siRNA).  The cells 
were incubated with the formulations for 3 h and washed extensively with PBS.  Then, 
DRAQ-5 (Biostatus Ltd., Shepshed, Leicestershire, UK) was utilized to stain the nucleus 
(30 min incubation, followed by extensive washing with PBS).  Cells were then fixed 
with 1% formaldehyde for 20 min, washed once with PBS.  The cells were then stored in 
1 mL PBS in the refrigerator and analyzed by laser scanning confocal microscopy (LSM 
510, Zeiss, Jena, Germany).  The images were collected under the same conditions (laser 
power, detector gain, etc.) for consistency, and λexcitation of 543 and 633 nm were utilized 
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for the Cy3 and DRAQ-5, respectively. 
5.3 Results and Discussion 
 
 
 
 
Figure 5.1.  Schematic representation of A) Preparation of cationic shell crosslinked nanostructures by 
directly dissolving polymers into water to obtain micelles followed by crosslinking selectively in the shell 
region to obtain cSCKs b) Preparation of anionic nanorods by direct dissolution of polymers followed by 
crosslinking in the shell region C) Hierarchical-assembly of cSCKs on SCRs via supramolecular assembly 
in aqueous medium.   
 
 
 
The cSCKs were prepared in a two-step process, first by direct dissolution of 
poly(acrylamidoethylamine)160-block-polystyrene30 (PAEA160-b-PS30) to obtain a 
micellar solution, followed by selectively crosslinking 5% of the amines within the 
hydrophilic shell domain by employing a diacid crosslinker, 4,15-dioxo-8,11-dioxa-
5,14-diazaoctadecane-1,18-dioic acid, (activated using O-benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexafluoro-phosphate (HBTU) and hydroxybenzotriazole (HOBT) 
in DMF) in aqueous medium (Fig. 5.1A,S1).  Dynamic light scattering (DLS) and 
transmission electron microscopy (TEM) were used to measure the sizes of the particles 
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in solution and dry state, and were determined to be ca. 20 nm and 15 nm (n = 100), 
respectively.  A zeta potential value of ca. 35 mV was determined by electrophoretic 
light scattering measurements, indicating that the surface of the cationic nanoparticles 
was positively charged.   
Similarly, anionic cylinders were prepared by aqueous self assembly and shell 
crosslinking of the amphiphilic block copolymer poly(acrylic acid)140-b-poly(para-
hydroxystyrene)50 (PAA140-b-PpHS50), as reported previously,
157 that consisted of PAA 
as the hydrophilic shell segments and PpHS as the hydrophobic core domain.  The 
cylindrical micelles were allowed to undergo crosslinking of approximately 10% of the 
acrylic acid residues by amidation with the amine groups of the crosslinker (2,2’-
ethylenedioxy)bis(ethylamine), in the presence of 1-ethyl-3-(3’-dimethylaminopropyl) 
carbodiimide methiodide) (EDCI) (Fig. 5.1 B, S2).  TEM images confirmed that these 
nanostructures were rod-like with diameters of ca. 10 nm and lengths of ca. 1.5 µm (n = 
100).  Zeta potential measurements were used to evaluate the surface charge of the 
nanorods and were found to be -30 mV, indicating that they were negatively charged.   
The individual cationic spherical and anionic cylindrical nanostructures were co-
assembled and further assessed for their performances in vitro.  The hierarchical 
assemblies were prepared by mixing cationic spheres with anionic cylinders in aqueous 
medium at amine-to-carboxylate (N/C) ratio of 10:1.  The surfaces of the nanorods were 
coated with the spheres, as demonstrated by TEM imaging (Fig. 5.1 C,Fig. 5.5).  Zeta 
potential measurements of the complexes were ca. 25 mV, indicating a decrease in the 
net charge of the spheres as a result of electrostatic complexation to the negatively-
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charged cylinders, although still maintaining a net positive charge.  The abilities of these 
supramolecular structures to complex siRNA onto the PAEA shell of the spheres and to 
carry 76Br radiolabels in the PpHS core of the cylinders were investigated. 
Binding of siRNA to the individual components, and to the HAT nanoassemblies 
was studied, followed by evaluating the transfection efficiencies of the siRNA 
nanocomplexes in two different cancer cell lines.  It has been demonstrated that the 
nanoparticle shapes, sizes and charges play a role in cellular internalization.  We have 
previously shown that hierarchical assemblies, as well as cSCKs can be taken up by 
cells.84,158  Cylindrical nanoparticles, cSCKs and HAT nanostructures were mixed with 
Cy3-labeled siRNA and their binding efficiencies were studied by agarose gel 
electrophoresis at various N/P ratios (Fig. 5.2).  Both the cSCKs and the assemblies were 
able to completely bind the siRNA at a N/P ratio of 2, indicating that the hierarchical 
assembly process did not adversely affect the electrostatic interactions between cSCKs 
and nucleic acids.  The percentages of free (non-complexed) siRNA at N/P ratios of 0.5 
and 1, were 66 vs. 62 and 39 vs. 20% of the control siRNA for the spherical cSCKs and 
HAT nanostructures, respectively (Figure 5.2 C and D).  These data indicate the ability 
of both cSCKs and HAT nanostructures to complex siRNA, with slightly higher 
efficiency for the HAT, probably due to the cooperative electrostatic interactions 
between the multiple spheres assembled on the surface of the cylinders, as compared to 
the individual spherical cSCKs.  On the contrary, the anionic cylinders were not able to 
complex the siRNA at a weight ratio up to 5 (cylinders to siRNA; because the anionic 
cylinders lack amino groups, except for the few that may be present due to incomplete 
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reaction of the crosslinker, a N/P ratio was not applicable), due to the lack of positively-
charged functionalities, which are required for siRNA complexation (Fig. 5.2 A).  Worth 
mentioning is that the amount of cylinders utilized at a weight ratio of 0.5 is higher than 
the amount of cylinders incorporated into the HAT at a N/P ratio of 5, indicating that the 
anionic cylinders did not contribute to the binding property of the HAT, but probably 
clustering of multiple cationic spheres on their surfaces enhanced the electrostatic 
binding efficiencies with siRNA.  In the case of Lipofectamine, complete binding was 
not observed even at 5-fold the amount recommended by the manufacturer, whereas 
complete binding of the same amount of siRNA was observed at a N/P ratio of 2 for the 
cSCKs and HAT (Fig. 5.2).  The latter demonstrates the advantage of using 
nanoparticles for the efficient complexation of nucleic acids, in particular for in vivo 
applications, where complete shielding from extra- and intracellular nucleases is 
essential for increasing the delivery of intact siRNA to the target sites or intracellularly.  
For further studies, the nanocomplexes were prepared at N/P ratio of 5.   
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Figure 5.2.  Gel-shift assay of Cy3-labeled siRNA, either naked (N/P = 0), mixed with the cylinders (A), 
Lipofectamine (B) or complexed to cSCKs (C) or HAT (D) at increasing N/P ratios.  For cylinders, the 
weight ratio was used, whereas, for Lipofectamine, the optimal ratio was set according to the manufacturer 
instructions.   
 
 
 
The cellular uptake and transfection efficiencies of the Cy3-labeled siRNA as 
mixtures/complexes with cylinders, cSCKs, HAT assemblies and Lipofectamine was 
studied by laser scanning confocal microscopy in human ovarian adenocarcinoma 
(OVCAR-3) cells (Fig. 5.3).  Both cSCKs and assemblies showed comparable cellular 
uptake (Figure 3A, A4 and A5) that was higher than Lipofectamine (Figure 5.3A, 
5.3A3), as indicated by the visual fluorescence intensities and the apparent number of 
fluorescent cells in the images.  No uptake was observed in the control-untreated cells or 
cells treated with a mixture of siRNA/cylinders (Figure 5.3  A, A1 and A2), which is in 
agreement with the gel-shift assay results (Fig. 5.2).  siRNA-cell death assay was then 
performed using OVCAR-3 cancer cells and RAW 264.7 mouse macrophages (Fig. 5.3 
B), by measuring the relative viabilities of cells treated with nanoparticles-loaded with 
siRNA that induces cell death vs. the cells-treated with the same nanoparticles but loaded 
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with a negative control siRNA.  The nanoparticles showed lower transfection efficiency 
than Lipofectamine.  Our group and others have shown that cellular uptake is not always 
correlated with transfection efficiency.163,164  The lower transfection of nanoparticles 
might be related to the higher stability of the complexes that partially retard the release 
of siRNA intracellularly.  For instance, Leroux and coworkers have found that amine 
functionalized poly(glycerol methacrylate) linear polymer induced higher bcl-2 
oncoprotein knockdown as compared to the star-shaped analogue, although the latter 
demonstrated higher antisense oligonucleotide binding efficiency.164  In both cell lines, 
HAT assemblies induced higher cell-death (transfection), as compared to the cSCKs, 
and, as expected, no transfection was found for the death-siRNA mixed with the 
cylinders.  The difference in transfection between the cSCKs and the HAT might be 
related to the multivalent binding of the HAT structures to the cell surface which allowed 
longer contact period for the intracellular delivery of siRNA.  Further studies of the 
intracellular delivery mechanisms of the cSCKs and assemblies are currently underway. 
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Figure 5.3.  (A) Laser scanning confocal microscopy images of OVCAR-3 cells that were either untreated 
(A1), or treated with Cy3-labeled siRNA (200 nM) mixed with cylinders (A2), or complexed with 
Lipofectamine (A3), spherical cSCKs (A4) or HAT (A5) for 3 h.  The Cy3-siRNA and the nucleus stained 
with DRAQ-5 appear in the red (upper left) and blue (lower left) panels, respectively.  The light 
transmitted images (upper right) and merged images (lower right) are also presented.  (B) Transfection 
efficiency of the cell-death siRNA (100 nM) mixed with the cylinders, or complexed to Lipofectamine, 
spherical cSCKs or HAT nanostructures.  The complexes were incubated with cells for 24 h and the 
transfection efficiencies were calculated based on the relative cell viabilities of the cells treated with the 
nanocomplexes versus the cells treated with the same complexes, but prepared with negative control 
siRNA. 
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To further evaluate their potential as theranostic candidates, these nanoparticles 
were radiolabeled with 76Br.  cSCKs, HAT nanostructures and SCRs were incubated 
with 130 µCi 76Br in phosphate-buffered saline (PBS) with the addition of 
bromoperoxidase (BPO, 0.6 units) in hydrogen peroxide (2.65 pmol) for 1 h at 0 °C 
(S4).  The radiochemical purities of 76Br-radiolabeled nanoparticles were monitored by 
radio instant thin layer chromatography.  Among the three nanoparticles, SCRs had the 
highest radiolabeling yield (94%) and specific activity (SA = 6.06 µCi/µg) (Fig. 4), 
which was comparable to the SA of other phenolic-containing nanostructures.12  
Hierarchical assembly by surrounding the anionic SCRs with cSCKs diminished the 
radiolabeling capability only slightly, giving a radiolabeling yield of 72% and SA of 
4.69 µCi/µg.  As expected, the PS core-containing cSCKs gave the lowest radiolabeling 
yield, 30% and SA of 2.01 µCi/µg.  Additionally, the chloramine-T method was also 
used for radiobromination of the three types of nanoparticles and the labeling results 
were similar to those obtained by the BPO method (Fig 5.4).   
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Figure 5.4.  Radiolabeling of nanostructures using 76Br.  The nanostructures were incubated with 130 µCi 
76Br in 1x PBS with the addition of bromoperoxidase (BPO, 0.6 units) in hydrogen peroxide (2.65 pmol) 
for 1 h at 0 °C and chloramine-T (219.6 nmol) at room temperature for 1 h.  The radiochemical purity of 
76Br-radiolabeled nanoparticles was monitored by radio instant thin layer chromatography.   
 
 
 
5.4 Conclusions 
In summary, we have prepared HAT nanostructures where cationic spheres, for 
complexation of siRNA as a therapeutic cargo, were templated around anionic cylinders 
with sites for radiolabeling in their hydrophobic cores.  These complex nanostructures 
were able to efficiently complex siRNA and deliver it intracellularly.  The HAT 
structures showed superior siRNA binding affinity and transfection efficiency, in 
comparison to the individual cationic spheres and anionic cylinders.  Additionally, they 
were radiolabeled with 76Br and exhibited superior radiolabeling efficiency, as compared 
to the cSCK samples.  The HAT nanostructures constitute the first steps toward the 
development of novel materials that can take advantage of individual components and 
serve as the next generation of theranostic agents.   
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5.6 Supporting Information 
Preparation of cSCKs 
The cSCKs were prepared in a two-step process; firstly amphiphilic block 
copolymer of PAEA160-b-PS30 (5.0 mg) was directly dissolved in nanopure water (5.0 
mL) and sonicated using a water bath sonicator for 10 min to obtain clear micellar 
solution at a concentration of 1 mg/mL.  The solution was then allowed to stir overnight 
at room temperature.  To the micellar solution (5.0 mL), sodium carbonate (20 µL of 1.0 
M solution) was added to adjust the pH to ca. 8.0.  A diacid crosslinker, 4,15-dioxo-
8,11-dioxa-5,14-diazaoctadecane-1,18-dioic acid, (2.0 mg) was activated with HOBT 
(1.7 mg, 2.2 equiv. per COOH) and HBTU (4.8 mg, 2.2 equiv. per COOH) in 300 µL of 
DMF for 30 min.  The activated crosslinker solution was slowly added to the micellar 
solution to crosslink ca. 5 % of the amines.  The reaction mixture was allowed to stir 
overnight, and then transferred to a dialysis tubing (MWCO ca. 6000-8000 Da) and 
dialyzed against nanopure water for 3 d to obtain clear cSCK solution at 0.88 mg/mL.  
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(Dh)number (DLS) = 21 ± 6 nm; (Dh)volume (DLS) = 48 ± 22 nm; (Dh)intensity (DLS) = 101 ± 
59 nm. Dav (TEM) = 15 ± 3 nm.  Zeta potential = 35 ± 2 mV (nanopure water, pH 5.5). 
Preparation of SCRs 
Anionic cylinders were prepared by aqueous self assembly of amphiphilic block 
copolymer of PAA140-b-PpHS50, as reported previously.
157  To a 100 mL round bottom 
flask, equipped with a magnetic stir bar, PAA140-b-PpHS50 (25 mg) was added followed 
by nanopure water (25 mL) to achieve a polymer concentration of 1 mg/mL.  The 
mixture was allowed to stir at room temperature for 2 h followed by addition of 
nanopure water (60 mL) to achieve a final polymer concentration of ca 0.3 mg/mL.  The 
solution was then allowed to stir at room temperature.  The following day, cylindrical 
micelles were allowed to undergo crosslinking of approximately 10% of the acrylic acid 
segments via amidation.  To a 50 mL round bottom flask equipped with a magnet stir 
bar, a solution of cylindrical micelles (25 mL) was added.  To this solution, a diamine 
crosslinker 2, 2’-ethylenedioxy)bis(ethylamine) (1 mg, 1.1 equiv. per COOH) was added 
from a stock solution in nanopure water and the reaction mixture was allowed to stir.  
After 30 min, 1-ethyl-3-(3-dimethylaminopropyl carbodiimide methiodide) (2.4 mg, 1.3 
equiv. per COOH) was slowly added over a period of 2 min from a stock solution in 
nanopure water.  The reaction mixture was allowed to stir overnight, and then transferred 
to a dialysis tubing (MWCO ca. 6000-8000 Da) and dialyzed against nanopure water for 
3 d to obtain SCR solution at 0.28 mg/mL.  Zeta potential = -30 ± 2 mV (nanopure 
water, pH 5.5). 
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Preparation of hierarchical assemblies  
Hierarchical assemblies were prepared by mixing cSCKs (600 µL) with SCRs 
(150 µL) to achieve an amine: carboxylate (N/C) ratio of 10:1.  Zeta potential = 25 ± 2 
mV (nanopure water, pH 5.5). 
 
 
 
 
Figure 5.5.  TEM micrographs of hierarchically-assembled nanoparticles 
 
 
 
Radiolabeling of nanostructures 
Bromine-76 (t1/2 = 16.2 h, β+ = 57%, EC = 43%) was produced on the 
Washington University Medical School CS-15 cyclotron by the 76Se (p,n) 76Br nuclear 
reaction.2  Hierarchically-assembled HAT nanoparticles, cSCKs, and SCRs (20 µg) were 
each incubated with 130 µCi 76Br in 1x PBS buffer with the addition of bromoperoxidase 
(BPO, 0.6 units) in hydrogen peroxide (2.65 pmol) for 1 h at 0 °C.  The radiochemical 
purity of 76Br-radiolabeled nanoparticles was monitored by radio instant thin layer 
chromatography (radio-ITLC, Bioscan, Washington, DC).  Additionally, chloramines-T 
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method was also employed for 76Br radiolabeling following a previously published 
procedure. 
 135 
 
CHAPTER VI 
CONCLUSIONS 
 
This dissertation has focused on the design and development of multifunctional 
bio-synthetic hybrid nanostructures as theranostic agents for the delivery of nucleic acids 
toward the treatment of various diseases such as acute lung injury and brain tumor.  The 
main emphasis of this study has been on optimization of nanoparticles to overcome 
biological barriers toward the efficient delivery of nucleic acids (e.g. PNAs and siRNAs) 
into the cells.  We have successfully demonstrated preparation of multifunctional 
nanoparticle that fulfills the design requirements for imaging and diagnosis.  These 
SCKs consisted of DOTA-lysine to provide sites for chelation of 64Cu for radiolabeling, 
PEG for prolonged circulation and enhanced biocompatibility in vivo and chemical 
functionalities at the terminus of PEG for tethering targeting ligands (F3 peptide, cell 
penetrating peptides) or therapeutics cargoes (e.g. PNAs) such that they are presented at 
the outermost surface of the nanostructures.  Confirmation of the ability of the PNAs to 
bind selectively to the target iNOS mRNAs when tethered to the SCK nanoparticles was 
determined by in vitro competition experiments.  When attached to the SCKs having a 
hydrodynamic diameter of 60 ± 16 nm, the Kd values of the PNAs were ca. an order of 
magnitude greater than the free PNAs, while the mismatched PNA showed no significant 
binding.  However, these nanoparticles consisted of PAA as the shell resulting in a net 
negative charge that potentially could undergo repulsion with the bilayer of the cells 
hindering its uptake.   
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Chapters 3 borrowed from the lessons learnt in Chapter 2 to make modification 
on SCKs for enhanced cellular uptake.  In this chapter, facile preparation of cationic 
SCKs with positive charge on the surface that facilitates cellular entry and enhances 
binding of nucleic acids for enhancing transfection in vitro is discussed.  cSCKS were 
conjugated with a tumor-homing F3 peptide and later complexed with nucleolin 
targeting siRNA to create a biosynthetic hybrid nanocomplex for improved cellular 
uptake and knockdown of nucleolin.  In vitro studies demonstrated an enhanced uptake 
of cSCKs tethered to F3 peptide compared to the scrambled peptide control nanoparticle 
sample.  Additionally, cSCKs showed effective binding to plasmid DNA and were 
delivered into the cells for efficient knockdown of nucleolin as demonstrated by 
immunoblot assays.   
Chapter 4 further extends this study to prepare cSCKs optimized for endosomal 
escape by incorporation of various amounts (0%, 15%, 50% and 100%) of histamine 
moieties into the polymer precursor of the nanoparticles to afford cSCKs with tunable 
buffering capacities.  The tunable pKa obtained by conjugation of histamine moieties 
improved the cytotoxicities of the nanoparticles while also improving the delivery of 
nucleic acids into the cytosol, as seen by in vitro experiments.  Histamine incorporation 
of 15% appeared to be a threshold for the series of samples tested, with cSCKs having 
higher histamine contents completely lost the ability to bind siRNA and to interact with 
cell membrane and induce gene silencing.  Incorporation of histamine moieties indeed 
enhanced the cellular delivery of nucleic acids into the cytosol.  However, a further 
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probing of histamine contents between 15% and 50% may better identify the optimum 
balance of siRNA binding, cellular uptake and buffering capacity. 
In Chapter 5, hierarchically-assembled structures were prepared by templating 
cationic spheres that can electrostatically bind nucleic acid onto anionic cylinders that 
can be radiolabeled in the hydrophobic core for imaging.  This study is an extension to 
the earlier studies, where only one type of structure was employed for performing 
multiple functions (radiolabeling, nucleic acid delivery, PEGylation).  This system 
provided an overall advantage over individual nanobjects, as the hierarchically 
assembled nanostructures exhibited improved siRNA delivery and radiolabeling 
collectively, compared to the individual nanoparticles which could each only perform 
one of the separate functions.  This provides a facile method to bring together multiple 
components by simple iterative process to create multifunctional theranostic agents that 
exhibit great potential as the next generation of theranostic agents.   
Nanomedicine is a very promising field that holds a great potential in 
development of innovative diagnosis and treatment strategies, novel drug candidates and 
state-of-the-art technologies to revolutionize the fields of healthcare and medicine.  
However, application of nanotechnology for development of safer and effective 
medicine and technologies that can be translated from a mere academic curiosity to real-
life applications in clinical settings has many hurdles that have to be addressed and 
overcome.  An ideal candidate for biomedical applications in vivo has several design 
requirements ranging from tunability in their sizes, shapes, morphologies, ability to 
circulate for a pre-determined period of time by mimicking stealth characteristics to 
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minimize protein adsorption, integration of imaging agents, high loading capacities for 
drugs followed by competence to release them at a specific sites, either by active or 
passive targeting strategies, programmed degradability of the nanoparticles by inflicting 
minimal toxicities, amongst many others.  The recent advances in polymer chemistry 
and nanotechnology has enabled researchers around the world to develop nanoentities 
that can fulfill one or more of the listed design requirements, however amalgamation of 
all the components to make an ultimate theranostic agent, known as the “magic bullet” 
still remains the holy grail of nanomedicine.   
This particular study has contributed in advancing the understanding of cellular 
uptake of nanoparticles complexed with nucleic acids and delivery into cells for 
theranostics.  Efficient delivery into the cytosol is a critical factor that governs the 
availability of cargo for binding with mRNAs for achieving binding with targeted 
mRNA for gene suppression.  In addition to the current system under investigation, 
degradable analogues of nanoparticles that can undergo triggered delivery and enhanced 
clearance in vivo will make potential candidates for further studies.  It will be important 
to study the effects of nanoparticles on biological systems in vitro and in vivo along with 
the extent, rates and conditions of degradation of the nanoparticles and their degradation 
products.  Furthermore, endosomolytic peptides can be covalently conjugated to the 
nanoparticles to induce lysis of the endosomal membrane for successful transfection.  
One of the major challenges in these studies is the ability to quantify the amount of 
nucleic acids that is delivered into the cells, available in the cytoplasm and those that are 
available for participating in the binding event in vitro and in vivo.  Determination of the 
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amount of nucleic acids available is significant in precise quantification and optimization 
of transfection efficiencies.  Novel assays and analytical methods have to be developed 
for accurate determination nucleic acid available at each stage of investigation that will 
allow for better understanding of the binding events for development of improved 
transfection agents.   
Nanotechnology is a comparatively new field of study that has been growing by 
leaps and bounds in the last two decades.  Realization of the challenges in the field has 
opened opportunities for researchers to strive forward toward development of novel 
therapeutics.  The current evolution in physical, biological and analytical sciences will 
provide opportunities to improve the design, facilitate preparation and extensive 
characterization of nanomaterials along with an in depth understanding of biological 
interactions of nanostructures and their ultimate fate in vitro and in vivo to translate them 
from bench-to-bedside.  There is still “plenty of room at the bottom.”.5,6 
 
 140 
 
REFERENCES 
 
 (1) Miyata, K.; Nishiyama, N.; Kataoka, K. Chem. Soc. Rev. 2012, 41, 2562-
2574. 
 (2) Whitesides, G. M.; Grzybowski, B. Science 2002, 295, 2418-2421. 
 (3) Dobon, C. M. Nature 2003, 426, 884-890. 
 (4) Miyata, K.; Nishiyama, N.; Kataoka, K. Chem. Soc. Rev. 2012, 41, 2562-
2574. 
 (5) Feyman, R. P. Eng. Sci. 1960, 23, 22-36. 
 (6) Kamaly, N.; Xiao, Z.; Valencia, P. M.; Radovic-Moreno, A. F.; 
Farokhzad, O. C. Chem. Soc. Rev. 2012, 41, 2971-3010. 
 (7) Elsabahy, M.; Wooley, K. L. Chem. Soc. Rev. 2012, 41, 2545-2561. 
 (8) Elsabahy, M.; Wooley, K. L. J. Polym. Sci. Poly. Chem. 2012, 50, 1869-
1880. 
 (9) Nystrom, A. M.; Wooley, K. L. Accounts Chem. Res. 2011, 44, 969-978. 
 (10) Petros, R. A.; DeSimone, J. M. Nat. Rev. Drug. Discov. 2010, 9, 615-627. 
 (11) Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, 
R. Nat.Nanotechnol. 2007, 2, 751-760. 
 (12) Mehnert, W.; Mader, K. Adv. Drug. Deliv. Rev. 2001, 47, 165-196. 
 (13) Han, G.; Ghosh, P.; Rotello, V. M. Nanomedicine -UK 2007, 2, 113-123. 
 (14) Sun, X. K.; Rossin, R.; Turner, J. L.; Becker, M. L.; Joralemon, M. J.; 
Welch, M. J.; Wooley, K. L. Biomacromolecules 2005, 6, 2541-2554. 
 141 
 
 (15) Sun, G.; Xu, J.; Hagooly, A.; Rossin, R.; Li, Z.; Moore, D. A.; Hawker, 
C. J.; Welch, M. J.; Wooley, K. L. Adv Mater 2007, 19, 3157-3162. 
 (16) Nystrom, A. M.; Wooley, K. L. Tetrahedron 2008, 64, 8543-8552. 
 (17) Wooley, K. L.; Lin, L. Y.; Lee, N. S.; Zhu, J. H.; Nystrom, A. M.; 
Pochan, D. J.; Dorshow, R. B. J Control Release 2011, 152, 37-48. 
 (18) Samarajeewa, S.; Shrestha, R.; Li, Y. L.; Wooley, K. L. J. Am. Chem. 
Soc. 2012, 134, 1235-1242. 
 (19) Shrestha, R.; Shen, Y. F.; Pollack, K. A.; Taylor, J. S. A.; Wooley, K. L. 
Bioconjugate. Chem. 2012, 23, 574-585. 
 (20) Sorrells, J. L.; Shrestha, R.; Neumann, W. L.; Wooley, K. L. J. Mater. 
Chem. 2011, 21, 8983-8986. 
 (21) Sun, G.; Hagooly, A.; Xu, J.; Nystrom, A. M.; Li, Z. C.; Rossin, R.; 
Moore, D. A.; Welch, M. J.; Wooley, K. L. Biomacromolecules 2008, 9, 1997-2006. 
 (22) Hawker, C. J.; Wooley, K. L. Science 2005, 309, 1200-1205. 
 (23) Braunecker, W. A.; Matyjaszewski, K. Prog. Polym. Sci. 2007, 32, 93-
146. 
 (24) Cui, H. G.; Chen, Z. Y.; Zhong, S.; Wooley, K. L.; Pochan, D. J. Science 
2007, 317, 647-650. 
 (25) Zhong, S.; Cui, H. G.; Chen, Z. Y.; Wooley, K. L.; Pochan, D. J. Soft 
Matter 2008, 4, 90-93. 
 (26) Zhu, J. H.; Zhang, K.; Wooley, K. L.; Miesch, C.; Emrick, T.; Pochan, D. 
J. Soft Matter 2011, 7, 2500-2506. 
 142 
 
 (27) Cui, H. G.; Chen, Z. Y.; Wooley, K. L.; Pochan, D. J. Soft Matter 2009, 
5, 1269-1278. 
 (28) Chen, Z. Y.; Cui, H. G.; Hales, K.; Qi, K.; Wooley, K. L.; Pochan, D. J. 
Science 2004, 306, 94-97. 
 (29) Cui, H. G.; Chen, Z. Y.; Zhong, S.; Pochan, D. J.; Wooley, K. L. Science 
2007, 317, 647-650. 
 (30) Samarajeewa, S.; Shrestha, R.; Li, Y. L.; Wooley, K. L. J. Am. Chem. 
Soc. 2012, 134, 1235-1242. 
 (31) Shrestha, R.; Shen, Y. F.; Pollack, K. A.; Taylor, J. S. A.; Wooley, K. L. 
Bioconjugate Chem. 2012, 23, 574-585. 
 (32) Zhang, K.; Rossin, R.; Hagooly, A.; Chen, Z.; Welch, M. J.; Wooley, K. 
L. J. Polym. Sci. Poly. Chem. 2008, 46, 7578-7583. 
 (33) Fang, H.; Zhang, K.; Shen, G.; Wooley, K. L.; Taylor, J. S. Mol. Pharm. 
2009, 6, 615-626. 
 (34) Rossin, R.; Sun, X.; Fang, H.; Turner, J. L.; Li, X.; Wooley, K. L.; 
Taylor, J. S.; Welch, M. J. J. Labelled. Compd. Rad. 2005, 48, S35-S35. 
 (35) Sun, G.; Xu, J.; Hagooly, A.; Rossin, R.; Li, Z.; Moore, D. A.; Hawker, 
C. J.; Welch, M. J.; Wooley, K. L. Adv. Mat. 2007, 19, 3157-3162.   
 (36) Zhang, K.; Fang, H. F.; Wang, Z. H.; Li, Z.; Taylor, J. S. A.; Wooley, K. 
L. Biomaterials 2010, 31, 1805-1813. 
 (37) Nyström, A. M.; Wooley, K. L. Tetrahedron 2008, 64, 8543-8552. 
 143 
 
 (38) Whitehead, K. A.; Langer, R.; Anderson, D. G. Nat. Rev. Drug Discov. 
2009, 8, 129-138. 
 (39) Pack, D. W.; Hoffman, A. S.; Pun, S.; Stayton, P. S. Nat. Rev. Drug 
Discov. 2005, 4, 581-593. 
 (40) Rubenfeld, G. D.; Caldwell, E.; Peabody, E.; Weaver, J.; Martin, D. P.; 
Neff, M.; Stern, E. J.; Hudson, L. D. N. Engl. J.  Med. 2005, 353, 1685-1693. 
 (41) Goodman, R. B.; Pugin, J.; Lee, J. S.; Matthay, M. A. Cytokine Grow. 
Fac. Rev. 2003, 14, 523-535. 
 (42) Hemmrich, K.; Kröncke, K.-D.; Suschek, C. V.; Kolb-Bachofen, V. 
Nitric Oxide 2005, 12, 183-199. 
 (43) Guo, F. H.; Deraeve, H. R.; Rice, T. W.; Stuehr, D. J.; Thunnissen, F. B. 
J. M.; Erzurum, S. C. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7809-7813. 
 (44) Hosogi, S.; Iwasaki, Y.; Yamada, T.; Komatani-Tamiya, N.; Hiramatsu, 
A.; Kohno, Y.; Ueda, M.; Arimoto, T.; Marunaka, Y. Biomed Res-Tokyo 2008, 29, 257-
266. 
 (45) Mehta, S. Vasc. Pharmacol. 2005, 43, 390-403. 
 (46) Zhang, J.; McCarthy, T. J.; Moore, W. M.; Currie, M. G.; Welch, M. J. J 
Med Chem 1996, 39, 5110-5118. 
 (47) Panda, K.; Chawla-Sarkar, M.; Santos, C.; Koeck, T.; Erzurum, S. C.; 
Parkinson, J. F.; Stuehr, D. J. P Natl Acad Sci USA 2005, 102, 10117-10122. 
 144 
 
 (48) Towner, R. A.; Smith, N.; Doblas, S.; Garteiser, P.; Watanabe, Y.; He, T.; 
Saunders, D.; Herlea, O.; Silasi-Mansat, R.; Lupu, F. Free Rad. Bio. Med. 2010, 48, 691-
703. 
 (49) Hesslinger, C.; Strub, A.; Boer, R.; Ulrich, W. R.; Lehner, M. D.; Braun, 
C. Biochem. Soc. Trans. 2009, 37, 886-891. 
 (50) Lim, M. H.; Xu, D.; Lippard, S. J. Nat. Chem. Biol. 2006, 2, 375-380. 
 (51) Ouyang, J.; Hong, H.; Zhao, Y.; Shen, H.; Shen, C.; Zhang, C.; Zhang, J. 
Nitric Oxide 2008, 19, 42-49. 
 (52) Zhou, D.; Lee, H.; Rothfuss, J. M.; Chen, D. L.; Ponde, D. E.; Welch, M. 
J.; Mach, R. H. J. Med. Chem. 2009, 52, 2443-2453. 
 (53) Koppelhus, U.; Nielsen, P. E. Adv. Drug Deliv.Rev. 2003, 55, 267-280. 
 (54) Nielsen, P. E.; Egholm, M.; Berg, R. H.; Buchardt, O. Science 1991, 254, 
1497-1500. 
 (55) Nielsen, P. E. Mol. Biotechnol. 2004, 26, 233-248. 
 (56) Lundin, K. E.; Good, L.; Stromberg, R.; Graslund, A.; Smith, C. I. Adv. 
Genet. 2006, 56, 1-51. 
 (57) Nielsen, P. E. Curr. Pharm. Des. 2010, 16, 3118-3123. 
 (58) Shi, N.; Boado, R. J.; Pardridge, W. M. Proc. Natl. Acad. Sci. USA 2000, 
97, 14709-14714. 
 (59) Rao, P. S.; Tian, X.; Qin, W.; Aruva, M. R.; Sauter, E. R.; Thakur, M. L.; 
Wickstrom, E. Nucl. Med. Commun. 2003, 24, 857-863. 
 145 
 
 (60) Sun, X.; Fang, H.; Li, X.; Rossin, R.; Welch, M. J.; Taylor, J. S. 
Bioconjugate Chem. 2005, 16, 294-305. 
 (61) Santangelo, P.; Nitin, N.; Bao, G. Ann. Biomed. Eng. 2006, 34, 39-50. 
 (62) Jia, F.; Figueroa, S. D.; Gallazzi, F.; Balaji, B. S.; Hannink, M.; Lever, S. 
Z.; Hoffman, T. J.; Lewis, M. R. J. Nucl. Med. 2008, 49, 430-438. 
 (63) Lendvai, G.; Estrada, S.; Bergstrom, M. Curr. Med. Chem. 2009, 16, 
4445-4461. 
 (64) Iyer, A. K.; He, J. Curr. Org. Synth. 2011, 8, 604-614. 
 (65) Zhilina, Z. V.; Ziemba, A. J.; Ebbinghaus, S. W. Curr. Top. Med. Chem. 
2005, 5, 1119-1131. 
 (66) Abes, R.; Arzumanov, A. A.; Moulton, H. M.; Abes, S.; Ivanova, G. D.; 
Iversen, P. L.; Gait, M. J.; Lebleu, B. Biochem. Soc. Trans. 2007, 35, 775-779. 
 (67) Thurmond, K. B.; Kowalewski, T.; Wooley, K. L. J. Am. Chem. Soc. 
1997, 119, 6656-6665. 
 (68) Thurmond, K. B.; Huang, H. Y.; Clark, C. G.; Kowalewski, T.; Wooley, 
K. L. Colloid Surface B 1999, 16, 45-54. 
 (69) Remsen, E. E.; Thurmond, K. B.; Wooley, K. L. Macromolecules 1999, 
32, 3685-3689. 
 (70) Thurmond, K. B.; Kowalewski, T.; Wooley, K. L. J. Am. Chem. Soc. 
1996, 118, 7239-7240. 
 (71) Samarajeewa, S.; Shrestha, R.; Li, Y.; Wooley, K. L. J. Am. Chem. Soc. 
2012, 134, 1235-1242. 
 146 
 
 (72) Cui, H. G.; Chen, Z. Y.; Zhong, S.; Wooley, K. L.; Pochan, D. J. Science 
2007, 317, 647-650. 
 (73) Becker, M. L.; Bailey, L. O.; Wooley, K. L. Bioconjugate Chem. 2004, 
15, 710-717. 
 (74) Becker, M. L.; Remsen, E. E.; Pan, D.; Wooley, K. L. Bioconjugate 
Chem. 2004, 15, 699-709. 
 (75) Joralemon, M. J.; Murthy, K. S.; Remsen, E. E.; Becker, M. L.; Wooley, 
K. L. Biomacromolecules 2004, 5, 903-913. 
 (76) Joralemon, M. J.; Smith, N. L.; Holowka, D.; Baird, B.; Wooley, K. L. 
Bioconjugate Chem. 2005, 16, 1246-1256. 
 (77) Lin, L. Y.; Lee, N. S.; Zhu, J.; Nystrom, A. M.; Pochan, D. J.; Dorshow, 
R. B.; Wooley, K. L. J. Control. Release 2011, 152, 37-48. 
 (78) Nystrom, A. M.; Xu, Z. Q.; Xu, J. Q.; Taylor, S.; Nittis, T.; Stewart, S. 
A.; Leonard, J.; Wooley, K. L. Chem Commun 2008, 3579-3581. 
 (79) Zhang, S.; Li, Z.; Samarajeewa, S.; Sun, G.; Yang, C.; Wooley, K. L. J. 
Am. Chem. Soc. 2011, 133, 11046-11049. 
 (80) Pan, D.; Turner, J. L.; Wooley, K. L. Chem. Commun. 2003, 2400-2401. 
 (81) Zhang, K.; Fang, H. F.; Chen, Z. Y.; Taylor, J. S. A.; Wooley, K. L. 
Bioconjugate Chem. 2008, 19, 1880-1887. 
 (82) Turner, J. L.; Becker, M. L.; Li, X. X.; Taylor, J. S. A.; Wooley, K. L. 
Soft Matter 2005, 1, 69-78. 
 147 
 
 (83) Zhang, K.; Fang, H.; Wang, Z.; Li, Z.; Taylor, J. S.; Wooley, K. L. 
Biomaterials 2010, 31, 1805-1813. 
 (84) Zhang, K.; Fang, H.; Wang, Z.; Taylor, J. S.; Wooley, K. L. Biomaterials 
2009, 30, 968-977. 
 (85) Nystrom, A. M.; Wooley, K. L. Soft Matter 2008, 4, 849-858. 
 (86) O'Connor, R. D.; Zhang, Q.; Wooley, K. L.; Schaefer, J. Helv. Chim. 
Acta. 2002, 85, 3219-3224. 
 (87) Zhang, Q.; Clark, C. G.; Wang, M.; Remsen, E. E.; Wooley, K. L. Nano 
Lett. 2002, 2, 1051-1054. 
 (88) Zhang, Q.; Wang, M.; Wooley, K. L. Curr Org Chem 2005, 9, 1053-
1066. 
 (89) Lai, J. T.; Filla, D.; Shea, R. Macromolecules 2002, 35, 6754-6756. 
 (90) Liu, J.; Zhang, Q.; Remsen, E. E.; Wooley, K. L. Biomacromolecules 
2001, 2, 362-368. 
 (91) Zhang, K.; Fang, H.; Chen, Z.; Taylor, J.-S. A.; Wooley, K. L. 
Bioconjugate Chem. 2008, 19, 1880-1887. 
 (92) Pack, D. W.; Hoffman, A. S.; Pun, S.; Stayton, P. S. Nat. Rev. Drug 
Discov. 2005, 4, 581-593. 
 (93) Rossin, R.; Pan, D. P. J.; Qi, K.; Turner, J. L.; Sun, X. K.; Wooley, K. L.; 
Welch, M. J. J. Nucl. Med. 2005, 46, 1210-1218. 
 (94) Fang, H.; Shen, Y.; Taylor, J. S. RNA 2010, 16, 1429-1435. 
 148 
 
 (95) Fang, H.; Yue, X.; Li, X.; Taylor, J. S. Nucleic Acids Res. 2005, 33, 
6700-6711. 
 (96) Rich, J. N.; Bigner, D. D. Nature Rev. Drug Discov. 2004, 3, 430-446. 
 (97) Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; 
Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, 
J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; 
Eisenhauer, E.; Mirimanoff, R. O.N. Engl. J. Med. 2005, 352, 987-996. 
 (98) Tokatlian, T.; Segura, T. Nanomed. and Nanobiotechnol. 2010, 2, 305-
315. 
 (99) Dowdy, S. F.; Eguchi, A.; Meade, B. R.; Chang, Y. C.; Fredrickson, C. 
T.; Willert, K.; Puri, N. Nature Biotechnol. 2009, 27, 567-571. 
 (100) Bhatia, S.; Agrawal, A.; Min, D. H.; Singh, N.; Zhu, H. H.; Birjiniuk, A.; 
von Maltzahn, G.; Harris, T. J.; Xing, D. Y.; Woolfenden, S. D.; Sharp, P. A.; Charest, 
A. ACS Nano 2009, 3, 2495-2504. 
 (101) Akerman, M. E.; Chan, W. C.; Laakkonen, P.; Bhatia, S. N.; Ruoslahti, E. 
Proc. Natl. Acad. Sci. U S A 2002, 99, 12617-12621. 
 (102) Torchilin, V. P. Nat. Rev. Drug Discov. 2005, 4, 145-160. 
 (103) Weissleder, R.; Kelly, K.; Sun, E. Y.; Shtatland, T.; Josephson, L. Nature 
Biotechnol. 2005, 23, 1418-1423. 
 (104) Bao, G.; Nitin, N. Bioconjugate Chem. 2008, 19, 2205-2211. 
 (105) Bao, G.; Nitin, N.; Santangelo, P. J.; Kim, G.; Nie, S. M. Nucleic Acids 
Res. 2004, 32-39. 
 149 
 
 (106) Thurmond Ii, K. B.; Huang, H.; Clark Jr, C. G.; Kowalewski, T.; Wooley, 
K. L. Colloids and Surface B: 1999, 16, 45-54. 
 (107) Hawker, C. J.; Fukukawa, K. I.; Rossin, R.; Hagooly, A.; Pressly, E. D.; 
Hunt, J. N.; Messmore, B. W.; Wooley, K. L.; Welch, M. J. Biomacromolecules 2008, 9, 
1329-1339. 
 (108) Elsabahy, M.; Wooley, K. L. J. Polym. Chem. Poly. Sci. 2012, 50, 1869-
1880. 
 (109) Nystrom, A. M.; Xu, Z. Q.; Xu, J. Q.; Taylor, S.; Nittis, T.; Stewart, S. 
A.; Leonard, J.; Wooley, K. L. Chem. Commun. 2008, 3579-3581. 
 (110) Zhang, K.; Fang, H.; Wang, Z.; Taylor, J.-S. A.; Wooley, K. L. 
Biomaterials 2009, 30, 968-977. 
 (111) Zhang, K.; Fang, H.; Li, Z.; Ma, J.; Hohlbauch, S. V.; Taylor, J. S. A.; 
Wooley, K. L. Soft Matter 2009, 5, 3585-3589. 
 (112) Christian, S.; Pilch, J.; Akerman, M. E.; Porkka, K.; Laakkonen, P.; 
Ruoslahti, E. J. Cell. Biol. 2003, 163, 871-878. 
 (113) Reddy, G. R.; Bhojani, M. S.; McConville, P.; Moody, J.; Moffat, B. A.; 
Hall, D. E.; Kim, G.; Koo, Y. E. L.; Woolliscroft, M. J.; Sugai, J. V.; Johnson, T. D.; 
Philbert, M. A.; Kopelman, R.; Rehemtulla, A.; Ross, B. D. Clin. Cancer. Res. 2006, 12, 
6677-6686. 
 (114) Park, J. H.; von Maltzahn, G.; Zhang, L. L.; Derfus, A. M.; Simberg, D.; 
Harris, T. J.; Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. Small 2009, 5, 694-700. 
 (115) Ruoslahti, E.; Bhatia, S. N.; Sailor, M. J. J. Cell Biol. 2010, 188, 759-768. 
 150 
 
 (116) Orringer, D. A.; Koo, Y. E. L.; Chen, T.; Kim, G.; Hah, H. J.; Xu, H.; 
Wang, S. Y.; Keep, R.; Philbert, M. A.; Kopelman, R.; Sagher, O. Neurosurgery 2009, 
64, 965-971. 
 (117) Orringer, D. A.; Koo, Y. E.; Chen, T.; Kopelman, R.; Sagher, O.; 
Philbert, M. A. Clin. Pharmacol. Ther. 2009, 85, 531-534. 
 (118) Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D. W. Y. Nat. Chem. 
Biol. 2006, 2, 711-719. 
 (119) Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; 
Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Nature 2010, 464, 1067-1070. 
 (120) Ferrari, M. Nat. Rev. Clin. Oncol. 2010, 7, 485-486. 
 (121) Nishikawa, M.; Huang, L. Hum. Gene. Ther. 2001, 12, 861-870. 
 (122) Mastrobattista, E.; Hennink, W. E. Nat. Mater. 2012, 11, 10-12. 
 (123) Suma, T.; Miyata, K.; Ishii, T.; Uchida, S.; Uchida, H.; Itaka, K.; 
Nishiyama, N.; Kataoka, K. Biomaterials 2012, 33, 2770-2779. 
 (124) Takemoto, H.; Ishii, A.; Miyata, K.; Nakanishi, M.; Oba, M.; Ishii, T.; 
Yamasaki, Y.; Nishiyama, N.; Kataoka, K. Biomaterials 2010, 31, 8097-8105. 
 (125) Li, W. J.; Szoka, F. C. Pharm. Res. 2007, 24, 438-449. 
 (126) Murthy, N.; Robichaud, J. R.; Tirrell, D. A.; Stayton, P. S.; Hoffman, A. 
S. J. Control Release. 1999, 61, 137-143. 
 (127) Chen, T.; McIntosh, D.; He, Y.; Kim, J.; Tirrell, D. A.; Scherrer, P.; 
Fenske, D. B.; Sandhu, A. P.; Cullis, P. R. Mol.Membr.Biol. 2004, 21, 385-393. 
 151 
 
 (128) Itaka, K.; Kanayama, N.; Nishiyama, N.; Jang, W. D.; Yamasaki, Y.; 
Nakamura, K.; Kawaguchi, H.; Kataoka, K. J. Am. Chem. Soc. 2004, 126, 13612-13613. 
 (129) Cho, Y. W.; Kim, J. D.; Park, K. J. Pharm. Pharmacol. 2003, 55, 721-
734. 
 (130) Putnam, D.; Gentry, C. A.; Pack, D. W.; Langer, R. Proc. Natl. Acad. Sci. 
USA. 2001, 98, 1200-1205. 
 (131) Luo, S. B.; Cheng, R.; Meng, F. H.; Park, T. G.; Zhong, Z. Y. J. Polym. 
Sci. Pol. Chem. 2011, 49, 3366-3373. 
 (132) Kanayama, N.; Fukushima, S.; Nishiyama, N.; Itaka, K.; Jang, W. D.; 
Miyata, K.; Yamasaki, Y.; Chung, U. I.; Kataoka, K. Chem. Med. Chem. 2006, 1, 439-
444. 
 (133) Fukushima, S.; Miyata, K.; Nishiyama, N.; Kanayama, N.; Yamasaki, Y.; 
Kataoka, K. J. Am. Chem. Soc. 2005, 127, 2810-2811. 
 (134) Akinc, A.; Thomas, M.; Klibanov, A. M.; Langer, R. J. Gene. Med. 2005, 
7, 657-663. 
 (135) Elsabahy, M.; Wazen, N.; Bayo-Puxan, N.; Deleavey, G.; Servant, M.; 
Damha, M. J.; Leroux, J. C. Adv. Funct. Mater. 2009, 19, 3862-3867. 
 (136) Elsabahy M; Dufresne M-H; J-C, L. Handbook of Materials for 
Nanomedicine 2012, 169-227. 
 (137) Elsabahy, M.; Wooley, K. L. J. Polym. Sci. Pol. Chem. 2012, 50, 1869-
1880. 
 152 
 
 (138) Samarajeewa, S.; Shrestha, R.; Li, Y. L.; Wooley, K. L. J. Am. Chem. 
Soc. 2012, 134, 1235-1242. 
 (139) Welch, M. J.; Pressly, E. D.; Rossin, R.; Hagooly, A.; Fukukawa, K. I.; 
Messmore, B. W.; Wooley, K. L.; Lamm, M. S.; Hule, R. A.; Pochan, D. J.; Hawker, C. 
J. Biomacromolecules 2007, 8, 3126-3134. 
 (140) Thurmond, K. B.; Huang, H.; Clark Jr, C. G.; Kowalewski, T.; Wooley, 
K. L. Colloids and Surface B 1999, 16, 45-54. 
 (141) Zhang, K.; Fang, H.; Shen, G.; Taylor, J. S.; Wooley, K. L. Proc. Am. 
Thorac. Soc. 2009, 6, 450-457. 
 (142) Ma, Q. G.; Wooley, K. L. J. Polym. Sci. Pol. Chem. 2000, 38, 4805-4820. 
 (143) Heng, B. C.; Zhao, X.; Tan, E. C.; Khamis, N.; Assodani, A.; Xiong, S.; 
Ruedl, C.; Ng, K. W.; Loo, J. S. Arch Toxicol 2011, 85, 1517-1528. 
 (144) Hussain, S.; Boland, S.; Baeza-Squiban, A.; Hamel, R.; Thomassen, L. 
C.; Martens, J. A.; Billon-Galland, M. A.; Fleury-Feith, J.; Moisan, F.; Pairon, J. C.; 
Marano, F. Toxicology 2009, 260, 142-149. 
 (145) Rettig, L.; Haen, S. P.; Bittermann, A. G.; von Boehmer, L.; Curioni, A.; 
Kramer, S. D.; Knuth, A.; Pascolo, S. Blood 2010, 115, 4533-4541. 
 (146) Poland, C. A.; Duffin, R.; Kinloch, I.; Maynard, A.; Wallace, W. A. H.; 
Seaton, A.; Stone, V.; Brown, S.; MacNee, W.; Donaldson, K. Nat. Nanotechnol. 2008, 
3, 423-428. 
 (147) Tao, W. K.; Mao, X. Z.; Davide, J. P.; Ng, B.; Cai, M. M.; Burke, P. A.; 
Sachs, A. B.; Sepp-Lorenzino, L. Mol. Ther. 2011, 19, 567-575. 
 153 
 
 (148) Cui, Z. R.; Han, S. J.; Vangasseri, D. P.; Huang, L. Mol. Pharm. 2005, 2, 
22-28. 
 (149) Heng, B. C.; Zhao, X. X.; Tan, E. C.; Khamis, N.; Assodani, A.; Xiong, 
S. J.; Ruedl, C.; Ng, K. W.; Loo, J. S. C. Arch. Toxicol. 2011, 85, 1517-1528. 
 (150) Dufes, C.; Uchegbu, I. F.; Schatzlein, A. G. Adv. Drug Deliver. Rev. 
2005, 57, 2177-2202. 
 (151) Hong, S. P.; Leroueil, P. R.; Janus, E. K.; Peters, J. L.; Kober, M. M.; 
Islam, M. T.; Orr, B. G.; Baker, J. R.; Holl, M. M. B. Bioconjugate Chem. 2006, 17, 
728-734. 
 (152) Zhang, S. G. Nat. Nanotechnol. 2006, 1, 169-170. 
 (153) Maltzahn, G. V.; Park, J.-H.; Lin, K. Y.; Singh, N.; Schwoppe, C.; 
Mesters, R.; Berdel, W. E.; Ruoslahti, E.; Sailor, M. J.; Bhatia, S. N. Nat. Mater. 2011, 
10, 545-552. 
 (154) Welch, M. J.; Rossin, R.; Pan, D. P. J.; Qi, K.; Turner, J. L.; Sun, X. K.; 
Wooley, K. L. J. Nucl. Med. 2005, 46, 1210-1218. 
 (155) Geng, Y.; Dalhaimer, P.; Cai, S. S.; Tsai, R.; Tewari, M.; Minko, T.; 
Discher, D. E. Nat. Nanotechnol. 2007, 2, 249-255. 
 (156) Decuzzi, P.; Godin, B.; Tanaka, T.; Lee, S. Y.; Chiappini, C.; Liu, X.; 
Ferrari, M. J. Control. Release 2010, 141, 320-327. 
 (157) Lee, N. S.; Lin, L. Y.; Neumann, W. L.; Freskos, J. N.; Karwa, A.; Shieh, 
J. J.; Dorshow, R. B.; Wooley, K. L. Small 2011, 7, 1998-2003. 
 154 
 
 (158) Zhang, K.; Fang, H. F.; Li, Z.; Ma, J.; Hohlbauch, S. V.; Taylor, J. S. A.; 
Wooley, K. L. Soft Matter 2009, 5, 5045-5045. 
 (159) Zhang, K.; Rossin, R.; Hagooly, A.; Chen, Z.; Welch, M. J.; Wooley, K. L. 
J.  Polym.Sci. Poly. Chem. 2008, 46, 7578-7583. 
 (161) Doshi, N.; Mitragotri, S. Interface 2010, 7, 403-410. 
 (162) Petzetakis, N.; Dove, A. P.; O'Reilly, R. K. Chem Sci 2011, 2, 955-960. 
 (163) Nam, H. Y.; Nam, K.; Hahn, H. J.; Kim, B. H.; Lim, H. J.; Kim, H. J.; 
Choi, J. S.; Park, J. S. Biomaterials 2009, 30, 665-670. 
 (164) Gao, H.; Elsabahy, M.; Giger, E. V.; Li, D. K.; Prud'homme, R. E.; 
Leroux, J. C. Biomacromolecules 2010, 11, 889-895. 
 (165) Almutairi, A.; Rossin, R.; Shokeen, M.; Hagooly, A.; Ananth, A.; 
Capoccia, B.; Guillaudeu, S.; Abendschein, D.; Anderson, C. J.; Welch, M. J.; Frechet, J. 
M. Proc Natl Acad Sci U S A 2009, 106, 685-690. 
 
  
 155 
 
APPENDIX A 
HIGHLY SPECIFIC IN VIVO TARGETING OF INOS MRNA AND ENHANCED 
CELLULAR UPTAKE OF ANTISENSE PNAS MEDIATED BY CATIONIC SHELL 
CROSSLINKED NANOPARTICLES* 
 
Acute lung injury (ALI) is a complex lung disease characterized by the up-
regulation of inflammatory mediators in the host followed by dyspnea, hypoxemia and 
pulmonary edema.  Over expression of inducible nitric oxide synthase (iNOS) results in 
production of high levels of nitric oxide, which in turn plays a crucial role in mediating 
acute lung injury.  Thus, there is a great interest in developing probes for sensitive and 
specific imaging of iNOS expression toward diagnosis of ALI.  In this study, we employ 
peptide nucleic acids (PNAs) as a candidate, which have several advantages including in 
vivo stability and superior binding affinity that make them an ideal platform for 
development of antisense theranostic agents.  However, their membrane impermeability 
that results in poor cellular uptake limits their biological applications.  Herein, we report 
the preparation of an iNOS imaging probe through electrostatic complexation between a 
PNA-oligodeoxynucleotide (ODN) hybrid and cationic shell-crosslinked knedel-like 
nanoparticle (cSCK) that allows for enhanced cellular uptake of PNA.   
____________ 
*In collaboration with Yuefei Shen†, Aida Ibricevic§, Sean P. Gunsten§, Michael J. 
Welch#, Steven L. Brody§,#, John-Stephen A. Taylor*,† and Yongjian Liu*,# †Department 
of Chemistry, Washington University in Saint Louis, § Department of Medicine, 
Washington University in Saint Louis, # Department of Radiology, Washington 
University in Saint Louis. 
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We found complete binding of cSCK amine to ODN phosphate (ratio of cSCK 
nitrogen to ODN phosphate, N/P) was achieved at 8:1 ratio as shown by gel retardation 
assay.  PNA-ODN-cSCK nanocomplexes showed efficient cellular entry in RAW 264.7 
cell line, compared to naked PNA.  Additionally, to determine the specific targeting of 
iNOS  
mRNA, antisense or scramble PNAs radiolabeled with 123I were complexed with 
cSCKs.  123I-PNAantisense-ODN-cSCK nanocomplexes demonstrated significantly higher 
retention in iNOS-induced RAW cell model when compared to 123I-PNAscramble-ODN-
cSCK.  Moreover, increased retention of radiolabeled PNAantisense-ODN-cSCK was also 
observed in vivo in iNOS-induced mouse lung after intratracheal administration of 
nanocomplexes.  This work shows specific and sensitive in vitro and in vivo detection of 
iNOS mRNA with radiolabeled nanocomplexes and their potential in early diagnosis of 
ALI.   
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APPENDIX B 
PEGYLATION OF CATIONIC, SHELL-CROSSLINKED-KNEDEL-LIKE 
NANOPARTICLES MODULATES INFLAMMATION AND ENHANCES 
CELLULAR UPTAKE IN THE LUNG * 
 
The airway provides a major route for delivery of nanoparticles bearing 
therapeutic or diagnostic payloads with advantages for local and systemic applications, 
however optimizing a nanoplatform for this application remains challenging. 
Poly(ethylene glycol) (PEG) surface modification is commonly used to improve the 
performance of intravenously-administered nanoparticles but less is known about the 
behavior of PEGylated nanoparticles delivered to the airway, where complex 
interactions with innate immune and barrier functions must be considered. We assess the 
behavior of a library of cationic, shell crosslinked knedel-like nanoparticles (cSCKs), 
constructed with varying amounts of primary and tertiary amines or PEG (1.5 kDa PEG 
with 2, 5 or 10 molecules/polymer arms) on the outer shell. Following delivery of cSCK 
to the lung via the trachea, the acute inflammatory response and nanoparticle fate were 
studied.  
____________ 
*In collaboration with Aida Ibricevic§, Sean P. Gunsten§, Ke Zhang, Jing Yi Sun, 
Michael J. Welch#, Yongjian Liu# and Steven L. Brody§,#,* § Department of Medicine, 
Washington University in Saint Louis, # Department of Radiology, Washington 
University in Saint Louis. 
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Assay of immune cells and cytokines recovered in bronchoalveolar lavage after 
24 h showed that non-PEGylated cSCKs with any modification induced marked 
inflammation, whereas PEGylation of particles resulted in significantly less 
inflammation, in a PEG dose-dependent manner. PEGylation also enhanced the entry of 
cSCKs in lung alveolar epithelial cells and improved penetration through surfactant and 
mucosal barriers. Endocytosis inhibitor studies showed that PEGylation altered the 
mechanism of uptake in lung epithelial cells. Non-PEGylated cSCKs used clathrin- and 
dynamin-dependent pathways, whereas PEGylated cSCKs utilized predominantly non-
clathrin, dynamin-independent routes of endocytosis. These results indicate that 
PEGylation favorably affect the in vivo properties of nanoparticles and enhanced the 
performance following airway delivery. 
 
 
